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The aim of this project is to express various transgenic tools in adult mouse primary afferent 
neurons in vivo and use them to study various aspects of physiology and anatomy of primary 
afferent neurons. In order to achieve expression, we used non-pathogenic adeno-associated 
virus serotype 9 (AAV9). Our first aim was to establish an AAV delivery method that achieves 
high transduction in vivo in adult mouse primary afferents. We used AAV9 containing eGFP 
transgene in order to identify and characterise transduced neurons. We designed a new 
intrathecal delivery method that produces reliable and reproducible transduction in the 
majority of the L4 DRG neurons. After that, we investigated the impact various experimental 
parameters, such as viral titre and time post injection, have on the transduction pattern. 
 After a successful delivery method was established, our next aim was to deliver functional 
transgenes to primary afferent neurons, such as GCaMP6s, in order to study activity of these 
neurons in vivo and in vitro. We assessed the performance of GCaMP6s in primary afferent 
cultures and attempted to establish an in vitro sensitisation model for calcium imaging that 
uses electrical stimulation as an activity trigger. Finally, we explored the use of our method of 
transgene delivery to express other transgenic tools in vivo, including Cre recombinase for the 
control of gene expression and an engineered glutamate-gated chloride channel for neuronal 
silencing. 
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Chapter 1: General Introduction 
1.1 The nervous system and pain 
The nervous system (NS) is one of the most complex parts of an organism, comprising of 
billions of  neurons and glial cells and significantly more numerous connections between them 
(Andrade-Moraes et al., 2013; von Bartheld, Bahney and Herculano-Houzel, 2016). One of the 
main functions of the NS is to gather and process information about the changing external and 
internal organismal environment (Ringkamp et al., 2013). This environment is continuously 
monitored by the sensory division of the peripheral nervous system (PNS) (Frings, 2012). 
Primary afferent neurons are the PNS neurons responsible for detecting various stimuli, such 
as thermal (skin warming in the sun) and mechanical stimuli (gentle touch or muscle stretch) 
(Ringkamp et al., 2013). The cell bodies of these primary afferent neurons are located in the 
dorsal root ganglia (DRG) and trigeminal ganglia (TG) (Purves et al., 2018). Their axons 
bifurcate, with one branch innervating a target, such as skin or muscle, and the other 
projecting into the central nervous system (CNS) (Todd and Koerber, 2013). When a stimulus is 
detected by the sensory afferent in the periphery, it is converted into an electrical signal and 
passed along the axon into the CNS. There, it is integrated and processed, leading to 
generation of a sensation that reflects the nature of the stimulus (Purves et al., 2018). 
One of the most important sensations is pain. Pain is defined by the International Association 
for the Study of Pain as “an unpleasant sensory and emotional experience associated with 
actual or potential tissue damage, or described in terms of such damage“ (IASP Task Force on 
Taxonomy, 1994). Pain serves a protective role, as it signals the threat of injury or its 
occurrence, and promotes protective behaviour that facilitates healing  (Woolf, 2004). Pain 
sensation can be elicited following detection of a noxious (injurious or potentially injurious) 
stimulus by the PNS and its processing in the CNS (Ringkamp et al., 2013). Neural encoding of a 
noxious stimulus is known as nociception  (IASP Task Force on Taxonomy, 1994; Baliki and 
Apkarian, 2015). Several distinct parts of the neural circuitry contribute to nociception and 
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pain. First, primary nociceptive neurons are activated in the periphery by a noxious mechanical, 
thermal or chemical stimulus (Kelleher, Tewari and McMahon, 2017). These neurons project to 
the dorsal horn of the spinal cord, where they pass on the signal to second-order neurons 
(Schaible, 2006). This signal then undergoes partial processing in interneuron circuits before 
being passed onto ascending projection neurons that carry the signal to the targets in the 
brainstem and thalamus (Todd, 2010). From there, the information is passed to many cortical 
areas and the sensation of pain is elicited (Apkarian et al., 2005; Basbaum et al., 2009) . In 
addition, there are descending pathways, mostly originating from nucleus raphe magnus and 
locus coeruleus, that project to the dorsal horn of the spinal cord and are capable of 
modulating nociceptive input (Todd, 2010; West et al., 2015). 
1.2 Primary afferents and nociception 
Primary afferent neurons that detect only high-intensity noxious stimuli are classified as 
nociceptors (Basbaum and Jessell, 2000). These neurons are a crucial part of the pain circuitry, 
as they are responsible for sensing damage or the threat of damage and triggering the cascade 
leading to pain sensation.  Nociceptors can be divided into two broad categories, A-fibre and C-
fibre nociceptors (Basbaum et al., 2009). A-fibre nociceptors include medium diameter thinly 
myelinated afferent (Aδ fibres). These neurons have superior conduction velocities compared 
to C-fibre afferents and are mostly responsible for evoking acute, sharp, fast pain upon injury 
(Slugg, Meyer and Campbell, 2000; Basbaum et al., 2009; Ringkamp et al., 2013). They can be 
further sub-divided into two types: type I and type II. Most of the type I A-fibre nociceptors are 
polymodal, capable of detecting noxious thermal, mechanical and chemical stimuli, and have a 
high heat response threshold and a relatively slow response to intense heat (Treede et al., 
1998; Ringkamp et al., 2013). Type II A-fibre nociceptors have a much faster response to 
intense heat and a lower threshold of activation with thermal stimuli, but have a very high 
mechanical threshold (Treede et al., 1998; Basbaum et al., 2009). In contrast, C-fibre 
nociceptors are small diameter, unmyelinated fibres with slower conduction speeds compared 
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to A-fibres (Ringkamp et al., 2013). Most of these fibres are also polymodal, responding 
robustly to mechanical and heat stimuli, and to a smaller extent, chemical stimuli  (Davis, 
Meyer and Campbell, 1993; Schmidt et al., 1995). In addition, some of C-fibre nociceptors are 
mechanically-insensitive, but can develop mechanosensitivity after exposure to chemicals 
released upon tissue injury (Schmidt et al., 1995; Basbaum et al., 2009). 
Peripheral projections of nociceptors do not innervate any specialised structures, and instead 
terminate in the target area as free nerve endings (Caterina, Gold and Meyer, 2005). These 
nerve endings contain all the machinery required for the transduction of a noxious chemical, 
thermal and mechanical stimuli into electrical signals (Gold, 2013). Noxious stimuli, detected 
by their respective specialised receptors in the free nerve endings, trigger generator potentials, 
which in turn give rise to action potentials and propagation of a signal (Gold, 2013). A large 
number of proteins have been shown to play a role in detecting noxious stimuli, including 
transient receptor potential vanilloid 1 (TRPV1) receptor for noxious heat (Caterina et al., 
1997; Tominaga et al., 1998), transient receptor potential ankyrin 1 (TRPA1) for noxious cold 
and several noxious chemicals like mustard oil and formalin (Story et al., 2003; Jordt et al., 
2004; Karashima et al., 2007, 2009; McNamara et al., 2007), acid-sensing ion channels (ASICs)  
for protons and low pH (Lingueglia, 2007), and Piezo2 for noxious mechanical stimuli, although 
the role of this channel is still under investigation (Coste et al., 2010). 
Central projections of the DRG neurons terminate in the dorsal horn of the spinal cord. Most 
projections from nociceptive A- and C-fibres terminate in the lamina I and lamina II of the 
dorsal horn (Todd, 2010). Here, they synapse onto excitatory and inhibitory interneurons, as 
well as projection neurons (Todd, 2010). The interneuron circuitry is complex and plays a 
crucial role in modulating the signal carried by the primary nociceptive neurons before passing 
it on to projection neurons (Todd and Koerber, 2013; West et al., 2015). However, some 
nociceptors can synapse directly onto the projection neurons, for example peptidergic C-fibre 
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nociceptors can synapse onto neurokinin 1 receptor-expressing projection neurons in lamina I 
(Todd et al., 2002).  
One of the core features of nociceptors is that they can exhibit the phenomenon of 
hyperalgesia (Ringkamp et al., 2013).  Nociceptors that exhibit hyperalgesia show greatly 
augmented responses to stimuli that would normally trigger only moderate activity. For 
instance, responses of A- and C-fibre rat nociceptors to suprathreshold mechanical stimuli 
were much more intense after the induction of hyperalgesia by Complete Freund’s Adjuvant 
(CFA)-induced inflammation (Andrew and Greenspan, 1999). A similar increase in neuronal 
discharge is evident in human A-fibres responses to a suprathreshold heat stimulus after a 
burn injury (Meyer and Campbell, 1981). This potentiation of nociceptor responses is caused 
by the action of various inflammatory mediators that are released after injury (Basbaum et al., 
2009). Binding of inflammatory mediators to their respective receptors on the nociceptor’s 
peripheral terminals can initiate a secondary-messenger cascade that triggers modification of 
the receptors responsible for detecting noxious stimuli (Dawes et al., 2013). For instance, 
activation of bradykinin B1 or B2 receptors by bradykinin leads to a secondary messenger 
cascade involving phospholipase C (PLC) and protein kinase C (PKC), which results in 
phosphorylation of TRPV1 and potentiation of neuronal responses to heat and capsaicin 
(Chuang et al., 2001; Vellani et al., 2001; Bhave et al., 2003; Vellani, Zachrisson and 
McNaughton, 2004).  In addition to sensitising nociceptors to noxious stimuli, inflammatory 
mediators have been shown to lower the threshold of activation for the nociceptors to such a 
degree that non-noxious stimuli are capable of activating nociceptors and eliciting pain 
behaviour (Martin et al., 1987; Ahlgren, Wang and Levine, 1996; Bishop et al., 2010; Lennertz 
et al., 2012; Weinkauf et al., 2013). This process of peripheral sensitisation serves to promote 
protective behaviour, forcing the individual to take care not to damage the injury site further 
and to promote rest and healing (Ringkamp et al., 2013). 
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1.3 Pain disorders and nociceptors 
The importance of correct functioning of the nociceptive circuitry is best highlighted by its 
disorders. For instance, genetic conditions, such as congenital insensitivity to pain, can result in 
the inability to feel pain. This leads to a severely reduced life expectancy and quality of life 
(Goldberg et al., 2007), since patients experience serious or life threatening injuries without 
noticing them. They do not realise when a bone is fractured and cannot  protect the affected 
limb, preventing it from healing (Schon, Parker and Woods, 2018). On the other end of the 
pain disorders spectrum are individuals that have a gain-of-function mutation, e.g. in the 
SCN9A gene which encodes the voltage-gated sodium channel Nav1.7 (Yang et al., 2004; Dib-
Hajj et al., 2005). These mutations cause patients to experience extreme pain in the absence of 
noxious stimuli, which dramatically reduces quality of life (Fischer and Waxman, 2010; Bennett 
and Woods, 2014).  
These genetic disorders, although severe, are not common in the general population (Bennett 
and Woods, 2014).  Conversely, chronic pain generally affects approximately 20% of the 
population, and has severe socio-economic and quality of life implications (Breivik et al., 2006; 
Treede et al., 2015). Chronic pain is defined as a persistent or recurrent pain lasting longer 
than 3 months, and can be divided into different types based on the cause (Treede et al., 2015). 
These include chronic inflammatory pain after prolonged inflammation, and neuropathic pain 
following a nerve injury (Treede et al., 2015). Often, the sensation of pain is disproportionate 
to the severity of the initial injury and this extends beyond the time of injury resolution and is 
associated with functional disability and emotional distress (Van Hecke, Torrance and Smith, 
2013; Treede et al., 2015). Critically, our capability of managing chronic pain disorders is 
limited, with many individuals responding poorly to the current available treatments (Garland, 
2014; Rajapakse, Liossi and Howard, 2014). 
Several core mechanisms that underlie this disorder have been uncovered, one of which is 
dysfunction of primary afferent nociceptors (Basbaum et al., 2009).For instance, persistent 
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inflammation, such as that seen in arthritis, causes permanent changes in peripheral 
nociceptors (Schaible, 2012; Nassini et al., 2014). These include a change in the expression of 
certain ion channels. The overexpression of the hyperpolarization-activated cyclic nucleotide-
gated (HCN) channel 2 in chronic inflammatory pain causes an increased Ih current, which leads 
to membrane depolarisation toward the action potential threshold (Weng et al., 2012). 
Changes in membrane receptors also take place, for example upregulation of TRPA1 causes 
increased activity of nociceptors (Obata et al., 2005; Nassini et al., 2014). Similar changes are 
also seen in neuropathic pain, with reports of altered expression of sodium and potassium ion 
channels, as well as membrane receptors (Persson et al., 2009; Hammer et al., 2010; Devor, 
2013). Their upregulation causes increased activity of nociceptors that is independent of the 
initial injury, for example nerve injury can cause ectopic firing in primary afferents, leading to 
the sensation of pain (Woolf, 2004; Devor, 2013). In chronic inflammatory pain, a persistent 
state of sensitisation primes nociceptors to respond to noxious stimuli with a greatly 
exaggerated activity, rendering even mild noxious as well as non-noxious stimuli painful 
(Fornasari, 2012; Lolignier, Eijkelkamp and Wood, 2014). In addition, the central terminals of 
the nociceptors can also exhibit physiological alterations, such as loss of inhibition and 
sensitisation of glutamate receptors (Basbaum et al., 2009). Finally, therapies that target 
primary afferent neurons, such as lidocaine-induced silencing, have been shown to be 
successful in alleviating chronic pain (Gammaitoni, Alvarez and Galer, 2003; Argoff et al., 2004). 
This highlights the importance of continuing to study all aspects of primary afferent neurons, 
from their anatomy to their physiology and activity patterns, to better understand the 
pathology associated with chronic pain, and to identify new targets that can be used to 
develop better therapies.  
1.4 Approaches to study DRG neurons 
There are a large number of experimental approaches and techniques that can be used to 
study DRG neurons, both in in the healthy state and under pathological conditions, such as 
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chronic pain. These approaches can be roughly split into two different types. The first focuses 
on monitoring aspects of the physiology of primary afferents, for example electrophysiological 
recordings of neuronal activity (Wickenden, 2014). The second approach is to actively interfere 
with cellular processes in primary afferents using methods such as overexpression or knock out 
of genes of interest to study the effect this has on both neuronal physiology as well as on the 
whole animal, for example the knockout of the TRPV1 gene (Caterina et al., 2000). However, 
these techniques are rarely used in isolation, and studies often utilise techniques that combine 
both observational and modulational approaches. Below I provide an overview of a few of 
these approaches, as well as examples of the tools and techniques used. 
As previously described, the pain circuit is an incredibly complex network of various types of 
neurons with a precise pattern of neuronal connections. Therefore, understanding the way 
that different parts of the pain circuit wire together is pivotal to gaining insight into their 
functions. The most common method for studying the morphology and anatomy of neurons is 
through the use of neuronal tracers (Vercelli et al., 2000; Basbaum and Bráz, 2010). Tracers 
have been used to study neuronal anatomy since the late 20th century, and there are 
numerous types of dyes available for a range of applications (Köbbert et al., 2000). For 
instance, a chemical fluorescent retrograde tracer Fluoro-gold (Ju, Han and Fan, 1989) has 
been used to study the nociceptor population that innervates the knee joint (Ivanavicius et al., 
2004), wrist joint (Kuniyoshi et al., 2007) and the mandibular incisor (Mosconi, Snider and 
Jacquin, 2001), as well as the central circuitry involved in nociception (Ding et al., 1995; 
Taguchi et al., 2007). Anterograde tracers, such as biotinylated dextran (BDA), have been used 
to study the projection targets of neurons in the pain circuit, for example primary nociceptor 
projections to the bladder (Spencer et al., 2018), and projections from the dorsal reticular 
nucleus in the medulla, which are  involved in the descending modulation of the nociceptive 
circuitry (Leite-Almeida, Valle-Fernandes and Almeida, 2006). Furthermore, a combined 
approach of tracer application and immunohistochemical analysis of tissue has been used to 
interrogate both the anatomical projections and the identity of the synaptic targets of neurons 
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involved in nociception, for example to study spinal cord targets of non-peptidergic VGluT2 
positive mouse primary afferents (Clarke et al., 2011).  
Tracer studies have contributed immensely to our understanding of the pain circuitry; however, 
the use of tracers also has some drawbacks. Dye injection into the tissue will result in all cells 
in the injection site taking up the dye, including those that are not the focus of the study. For 
example, injection into the dorsal horn will label interneurons as well as projection neurons 
(Basbaum and Bráz, 2010). This can be circumvented by tracer delivery via an intracellular 
injection, but this is a complex procedure and only labels one neuron per injection (Mason, 
Larkman and Eldridge, 1988). Alternatively, transgenic mouse lines expressing fluorescent 
proteins controlled by a specific promoter of interest can be used to visualise neurons of a 
particular population. For instance, this approach can be used when studying various classes of 
dorsal horn interneurons (Boyle et al., 2017; Gutierrez-Mecinas et al., 2018) or non-peptidergic 
Mas-related gene product receptor D (MRGPRD) - positive nociceptors (Olson et al., 2017). 
Transgenic mice have been developed that express the trans-synaptic neuronal tracer wheat 
germ agglutinin under a specific promoter or Cre-recombinase control (Yoshihara et al., 1999; 
Braz, Rico and Basbaum, 2002). However, most of the transgenic lines available are limited to 
mice, and the correct transgenic line for a particular neuronal population may not be available. 
Neuroanatomy is only one aspect of the physiology of neurons involved in the pain circuit. It is 
equally important to understand the way in which these neurons communicate with each 
other, what kind of stimuli they respond to, and what their activity patterns are. The main 
technique for studying neuronal activity in nociceptors is electrophysiology (Carter and Shieh, 
2015). There is a multitude of different electrophysiological techniques that makes it possible 
to extensively study many aspects of the activity patterns in nociceptors and related circuitry 
(Vertes and Stackman, 2011). It is beyond the scope of this thesis to compare them all, so only 
a few examples of their use for studying nociceptors are listed below. Intracellular and patch-
clamp recording of neuronal activity allows analysis of a single cell activity with unmatched 
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temporal precision (Carter and Shieh, 2015; Rubaiy, 2017). Both intracellular and patch-clamp 
techniques have been used to study various aspects of nociceptor physiology (Koerber, 
Druzinsky and Mendell, 1988; Traub and Mendell, 1988; Ritter and Mendell, 1992; Gee et al., 
1999), and their responses to various stimuli such as heat or capsaicin (Koplas, Rosenberg and 
Oxford, 1997; Davis et al., 2000; Woodbury et al., 2004). It is also possible to record the activity 
of a single neuron using a teased-nerve preparation. This technique does not require access to 
cell soma and leaves the circuitry predominantly intact, making it possible to record responses 
following application of stimuli to the innervation target of the neuron (Fleischer, Handwerker 
and Joukhadar, 1983; Lewin and McMahon, 1991; Kress et al., 1992; Koltzenburg, Stucky and 
Lewin, 1997). Furthermore, using a teased-nerve technique in vitro in conjunction with the 
nerve innervation target, such as skin, allows tight control over experimental variables such as 
the effective concentrations of applied compounds and their precise pattern of spread in the 
tissue (Reeh, 1986; Kress et al., 1992). This approach has been used to investigate nociceptor 
responses to stimuli such as heat and inflammatory mediators applied to the skin (Liang, Haake 
and Reeh, 2004; Derow et al., 2007).  
In summary, electrophysiological techniques are a powerful tool for studying neuronal activity, 
providing unmatched temporal resolution and sensitivity (Carter and Shieh, 2015). However, 
they also have some disadvantages, such as the necessity for physical contact with the tissue 
and the challenges associated with recording activity in more than a handful of neurons at the 
same time (Anderson, Zheng and Dong, 2018). Another technique for recording neuronal 
activity that circumvents these drawbacks is calcium imaging. This technique uses calcium-
sensitive dyes that change their visual properties based on the level of intracellular calcium 
(Paredes et al., 2008). In neurons, a sharp rise in intracellular calcium is observed during an 
action potential (Clapham, 2007). Calcium dyes provide the visual read-out for this increase, 
which in turn is used as a proxy for neuronal activity (Anderson, Zheng and Dong, 2018). 
Traditionally, chemical dyes such as Fura-2 AM have been extensively used to study responses 
of DRG neurons to various stimuli such as heat, capsaicin and inflammatory mediators (Kano et 
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al., 1994; Paredes et al., 2008; Wooten et al., 2014), however genetically-encoded calcium 
indicators (GECI) such as GCaMP are becoming more and more popular. GECI can be used to 
visualise activity in a specific subset of neurons using cell-specific promoters, in addition to 
circumventing some of the difficulties associated with loading of traditional chemical dyes 
(Tian, Hires and Looger, 2012; Pérez Koldenkova and Nagai, 2013; Lin and Schnitzer, 2016). A 
much more detailed description of the calcium imaging technique and its variations, is 
provided in the introduction to chapter 3. 
One final approach to studying nociceptors that I would like to mention in this overview is 
using tools that allow manipulation of cellular gene expression profiles. Neurons express 
thousands of genes throughout their lifetime, and this plays an important part in defining their 
physiology (F. C. Yang et al., 2013; Smith et al., 2013; Usoskin et al., 2015). The pattern of gene 
expression can change in response to changes in their environment, for instance nociceptors 
have been shown to alter their gene expression pattern in pathological conditions such as 
neuropathic pain (Smith et al., 2015; Cobos et al., 2018). By studying changes in genes 
expression in neurons within the pain circuit it may be possible to find ways to reverse, or at 
least attenuate, the pathology of these conditions (Mogil, Max and Belfer, 2013). This can be 
done using transgenic mouse lines. For example, deletion of the TRPV1 gene in a transgenic 
mouse line helped to elucidate the importance of TRPV1 for nociception (Caterina et al., 2000). 
Alternatively, several transgenic tools, such as Cre recombinase, CRISPR and zinc finger 
nucleases (ZFN) can be used to alter gene expression (Lewandoski, 2001; Gavériaux-Ruff and 
Kieffer, 2007; Urnov et al., 2010; Sander and Joung, 2014). These tools can be used to 
selectively knock out genes of interest and can be controlled both spatially (e.g. by using cell-
specific promoters for their expression, such as the Nav1.8 promoter for nociceptors (Stirling et 
al., 2005)) and temporally (e.g. an inducible Cre recombinase fused with a mutated oestrogen 
receptor T2 (Feil et al., 1996; Indra et al., 1999; Feil, Valtcheva and Feil, 2009)). A more 
extensive discussion of the use of Cre recombinase for modulation of gene expression is 
provided in chapter 4. 
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Listed above are just a few examples of different experimental approaches used to study the 
neurons involved in nociception and pain sensation. Importantly, they all have something in 
common: all these approaches can take advantage of transgenic tools. There is a multitude of 
transgenic tools available for almost every experimental approach to studying nociceptors, 
from visualising parts of a neuron with targeted fluorescent proteins (e.g. visualising 
presynaptic terminal by using GFP fused to Vesicle-associated membrane protein 2 (VAMP2) 
(D’Acunzo et al., 2014)) to controlling neuronal activity with optogenetics (Zhou, Pan and Lin, 
2015). However, all these tools have to be expressed by the cells of interest in order to be 
utilised, which is often achieved by using transgenic mouse lines that may not always be 
available. An alternative way of delivering transgenic tools to cells of interest that is quicker 
and does not require transgenic animals is the use of viral vectors. 
1.5 Viral vectors for transgene delivery 
Viral vectors are modified viral particles that can be used to deliver various genetic sequences 
into cells (Kantor et al., 2014). All viral vectors are derived from wild-type viruses. However, 
they are rendered incapable of replication within the host cell by removing most of the wild-
type viral genome and replacing it with the gene of interest (Lentz, Gray and Samulski, 2012). 
Usually, the part of the viral genome removed encodes proteins necessary for the correct 
assembly of the viral capsid and/or envelope, so it has to be supplied externally during viral 
vector production (Kantor et al., 2014). Most commonly, viral vectors are produced by 
transfecting an immortalised mammalian cell line, like HEK-293, with the plasmid that contains 
the gene of interest (expression cassette) and the plasmids that encode the viral machinery 
needed for vector production, as well as those encoding proteins for capsid and/or envelope 
assembly (packaging cassette) (Aponte-Ubillus et al., 2018; Penaud-Budloo et al., 2018; Sharon 
and Kamen, 2018). 
Many types of viral vectors exist, each with their own unique properties. They can be used for 
a large number of applications for studying the nervous system, including the delivery of gene 
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sequences to correct pathology and delivery of transgenic tools such as GECI, 
channelrhodopsin and Cre recombinase (Lentz, Gray and Samulski, 2012; Woodward and Pava, 
2012; Shimano et al., 2013; Gierut, Jacks and Haigis, 2014; Sengupta et al., 2017; Le Duigou et 
al., 2018). Below, I will describe some of the most popular viral vectors used for transgene 
delivery in the nervous system. These include lentiviral (LV) vectors, herpes simplex viral (HSV) 
vectors, adenoviral (AV) vectors and adeno-associated viral (AAV) vectors (Lentz, Gray and 
Samulski, 2012). 
1.5.1 Lentiviral vectors 
One of the most widely used viral vectors in the nervous system are lentiviral (LV) vectors. 
These vectors are based on the human immunodeficiency virus type I (HIV-I) (Naldini et al. 
1996). LV vectors have a single-stranded RNA genome and their cloning capacity is around 8 kb 
(Jakobsson and Lundberg, 2006). They were first used to transduce adult neurons in the rat 
brain in the 1996 (Naldini, Blomer, et al., 1996). Since then, LVs have undergone a number of 
rounds of optimisation and modification, and have been used extensively for gene delivery in 
the nervous system (Parr-Brownlie et al., 2015).  
Initially, only two plasmids were used for LV vector production, one encoding the gene of 
interest and another encoding all the required viral genes: gag (viral matrix and capsid), pol 
(enzymes necessary for viral genome processing), and env (envelope glycoprotein), as well as 
regulatory genes rev and tat and accessory genes (nef, vif, vpr, and vpu) (Naldini, Blomer, et al., 
1996; Coffin, Hughes and Varmus, 1997).  However, the use of only two plasmids for LV vector 
production often yielded LVs that were replication-competent, making them cytotoxic. 
Therefore, the packaging cassette was soon altered to delete the unnecessary accessory 
proteins and split into two separate plasmids (Zufferey et al., 1997; Dull et al., 1998). These 
alterations reduced the chances of generating replication-competent viruses without lowering 
the yield or the transduction efficiency (Kantor et al., 2014).  
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Another example of LV vector modification is pseudotyping. LV vectors have the ability to 
incorporate envelope proteins from different viruses (Kantor et al., 2014). The envelope of the 
virus is crucial in determining  its tropism, so by introducing specific proteins (often from other 
viruses) into the viral envelope (pseudotyping) it is possible to restrict the cell types that can 
be transduced with the LV vector (Bischof and Cornetta, 2010). There are a number of 
different envelopes available for pseudotyping, including those with broad transduction 
patterns like Vesicular stomatitis virus G-protein, and those with tropism for neurons like 
Rabies-G envelope (Schlegel et al., 1983; Reiser et al., 1996; Cronin, Zhang and Reiser, 2005; 
Rahim et al., 2009).  
LV vectors are powerful tools that can effectively transduce a large variety of cells and result in 
strong and stable transgene expression (Parr-Brownlie et al., 2015). However, there are some 
disadvantages to using LV vectors. The stability of transgene expression observed with LV 
vectors is due to integration of the vector genome into the host DNA (Escors and Breckpot, 
2010). This can be problematic, as the integration of the LV genome can disrupt the host’s 
genome and cause tumorigenesis (Themis et al., 2005). Several methods of overcoming this 
drawback have been designed, mostly focusing on the generation of non-integrating LV 
vectors, whose genomes exist in the nucleus as episomes within the transduced cell. This can 
be done by introducing a mutation into the Int gene that encodes the integrase, so that it is 
rendered non-functional (Bayer et al., 2008; Kantor et al., 2009). Alternatively, it is possible to 
mutate the integrase attachment sites on the viral DNA so that the integrase cannot interact 
with it (Apolonia et al., 2007). These non-integrating LV have been shown to have a very low 
incidence of integration into the host genome, however the transgene expression levels are 
lower than those of an integrating LV vector (Bayer et al., 2008; Kantor et al., 2014). Also, LV 
vectors are relatively large particles (~100 nm), which limits the spread of the LV vectors in the 
extracellular space, leading to the transduction only in cells close to the injection epicentre in 




1.5.2 Herpes simplex viral vectors 
Vectors derived from Herpes Simplex virus (HSV) are large particles (~186 nm), and can have a 
packaging capacity of up to ~150 kb (Lentz, Gray and Samulski, 2012). These vectors consist of 
a nucleocapsid harbouring double-stranded DNA genome, and a viral envelope with specific 
glycoproteins that are required for cell transduction (Lentz, Gray and Samulski, 2012). Between 
the nucleocapsid and the envelope is the tegument containing structural proteins and enzymes 
that are important for DNA replication and cell infection (Lentz, Gray and Samulski, 2012; 
Kantor et al., 2014). Upon infection, the wild-type HSV genome persists as an episome in the 
nucleus and is capable of remaining latent with little detrimental effect on the host for a long 
period of time. However, the wild-type HSV genome can also initiate a lytic pathway by the 
sequential expression of immediate-early proteins encoding transcription regulatory proteins, 
early proteins encoding the viral DNA polymerase and late proteins that mostly encode 
structural proteins (Lachmann, 2004; Kantor et al., 2014). There are three kinds of viral vectors 
that have been derived from HSV: replication-competent, replication-defective and amplicon 
vectors (Marconi et al., 2009). These vectors are suitable for use in the nervous system since 
the HSV is capable of retrograde transport and its envelope exhibits neuronal tropism (Lentz, 
Gray and Samulski, 2012). 
Replication-competent HSV vectors have an incomplete viral genome, lacking certain genes 
like thymidine kinase and ICP34.5 that are responsible for virulence and pathogenicity of the 
HSV (Todo, 2008). These mutations make it impossible for these vectors to initiate a lytic 
pathway in non-dividing cells. However, a lytic infection is still triggered in dividing cells 
present in tumours, as these vectors can take advantage of the physiological changes in 
tumour cells, that allow them to replicate and lyse these cells (Todo, 2008). Although not 
suitable for transgene delivery to healthy cells, replication-competent HSV vectors have been 
used for cancer therapy (Post et al., 2004). 
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Replication-deficient HSV vectors were created by deleting the genes encoding the proteins 
necessary for triggering the lytic pathway (Wu et al., 1996; Samaniego, Neiderhiser and DeLuca, 
1998). This significantly reduces their toxicity, making them suitable for transgene delivery to 
cells of interest (Kaplitt and Makimura, 1997; Krisky et al., 1998). These vectors have been 
used to deliver a wide variety of transgenes to neurons, for example pathology-correcting 
hexosaminidase in a model of Tay-Sachs disease (Martino et al., 2005), and short hairpin RNA 
to inhibit accumulation of amyloid-β in a mouse model of Alzheimer’s disease (Hong et al., 
2006). They have also been used in the field of pain research, for instance to investigate the 
protective role of NGF and neurotophin-3 in sensory neuropathy (Goss et al., 2002; 
Chattopadhyay et al., 2005), or the antinociceptive effect of enkephalin expression in the DRG 
neurons (Braz et al., 2001; Goss et al., 2001). 
Finally, amplicon vectors consist of a bacterial plasmid carrying an HSV origin of replication site 
and packaging signal, but no other viral genes (Spaete and Frenkel, 1982). Co-transfection with 
the helper HSV plasmid during production creates vectors that are identical to HSV, except for 
replacement of viral DNA with a bacterial plasmid (Epstein, 2005). This dramatically reduces 
toxicity of these vectors, as well as allowing more space for the insertion of the desired DNA 
sequence (up to 150 kb) (Epstein, 2009). It has been used in various studies of the nervous 
system, including those investigating the effect of NGF and NMDA receptors on learning and 
memory (Brooks et al., 2000; Adrover et al., 2003). 
HSV vectors are well-suited for gene delivery in the nervous system, as they possess an innate 
ability to target neurons and are capable of retrograde transport. In addition, they have a large 
packaging capacity. However, production of HSV vectors is not trivial, and sometimes results in 
production of cytotoxic replication-competent vectors alongside the desired viral vectors 
(Lentz, Gray and Samulski, 2012; Kantor et al., 2014). 
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1.5.3 Adenoviral vectors 
Adenoviral (AV) vectors are derived from adenoviruses, non-enveloped icosahedral viruses 
containing ~26-40 kb double stranded DNA (Campos and Barry, 2008). Initial research into the 
use of adenoviruses as viral vectors resulted in first-generation AV vectors derived from AV 
serotypes 2 and 5 that lacked the genes necessary for triggering DNA synthesis and viral 
replication (Graham et al., 1977). Upon infection, viral DNA did not integrate within the host’s 
DNA and was maintained as a nuclear episome (Lentz, Gray and Samulski, 2012). However, 
these first-generation AV vectors still elicited low-level expression of viral antigens in the host 
cell membrane, which lead to detection and elimination of the transduced cells by the host 
immune system, resulting in only transient expression of the transgene in vivo (McConnell and 
Imperiale, 2004). Further development of AV vectors resulted in generation of helper-
dependent “gutless” AV vectors, in which most of the viral genes have been removed and only 
the elements required for genome replication and encapsidation remain, increasing the 
packaging capacity to around 35 kb and reducing the host immune response (Palmer and Ng, 
2005). However, a significant degree of immune response still persists that can cause serious 
side-effects (Lehrman, 1999; Bessis, GarciaCozar and Boissier, 2004; Muruve, 2004).  
 AV vectors have been used extensively for gene delivery in a large number of research fields, 
including pain. For example, AV vectors have been used to study the physiology of endogenous 
analgesia via expression of a potassium channel on descending noradrenergic neurons, thus 
inhibiting their activity and causing hyperalgesia in rats (Howorth et al., 2009). AV vectors have 
also been used to express GDNF in DRG neurons after chronic constriction injury, which 
resulted in an improved myelination profile and attenuation of nocifensive behaviour (Shi et al., 
2011). 
The large packaging capacity and retrograde transport capabilities, as well as neuronal tropism, 
have made AV vectors popular tools for studying the nervous system (Kantor et al., 2014). 
However, AV vectors have some disadvantages, the major one being the high probability of 
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eliciting an immune response to the vector particles, and therefore only transient expression in 
vivo due to cell clearance by the immune cells (Lentz, Gray and Samulski, 2012). 
1.5.4 Adeno-associated viral vectors 
Adeno-associated viral (AAV) vectors are derived from adeno-associated viruses, which are a 
type of dependoviruses. AAV viral particles are only ~20 nm in diameter and do not have a viral 
envelope. Their genome is ~4.7 kb of singe-stranded DNA that has two Inverted Terminal 
Repeat (ITR) sequences, and encodes four replication proteins (rep) and three structural 
proteins (cap) (Kantor et al., 2014). Upon infection, the viral genome can stably integrate into 
the host’s DNA or persist as an episome (Samulski et al., 1991; Duan et al., 1998). As the wild-
type AAV genome does not encode all the proteins needed for replication, co-infection with a 
helper virus, such as an adenovirus, is required for AAVs to replicate (Murlidharan, Samulski 
and Asokan, 2014).  
In AAV vectors, only the ITR sequences are retained, while the rest of the genome is replaced 
with the transgene and an appropriate promoter (Xiao et al., 1997). This results in the 
packaging capacity very close to that of the wild-type vector, ~4.7 kb (Dong, Fan and Frizzell, 
1996). For manufacturing, the rep and cap genes are expressed using a separate packaging 
AAV plasmid, while the essential non-AAV genes are expressed using a helper plasmid (Xiao, Li 
and Samulski, 1998). This plasmid separation prevents the formation of wild-type AAV, 
therefore dramatically reducing the frequency of integration into the host DNA (Lentz, Gray 
and Samulski, 2012; Kantor et al., 2014). In addition, AAV vectors have been shown to induce 
little to no innate immune response (Zaiss et al., 2002; Bessis, GarciaCozar and Boissier, 2004). 
There are many AAV serotypes, each with a different capsid composition, primary receptor for 
infection and tropism (Wu, Asokan and Samulski, 2006). The desired expression plasmid can be 
packaged into any of them, and the serotype selection will influence the AAV vector’s cell 
specificity, which is highly beneficial for targeting transduction to a particular cell type 
(Rabinowitz et al., 2002). For instance, IV injection of AAV vector serotypes 1 - 9 encoding the 
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same luciferase has been shown to result in different transduction patterns and cell specificity 
for every serotype (Zincarelli et al., 2008). Furthermore, artificial modification of capsid can be 
achieved through rational design, directed and unbiased mutagenesis and peptide insertion 
(Kantor et al., 2014). Rational design aims to enhance or alter the properties of the AAV based 
on the current knowledge of capsid protein structure and interactions, for example using 
amino acid sequences from two or more serotypes to enhance targeting (Bowles et al., 2012). 
On the other hand, development of new capsids through unbiased mutagenesis involves 
randomly mutating and shuffling cap sequences from several serotypes before screening the 
products for the desired properties (Schaffer and Maheshri, 2004; Maheshri et al., 2006), for 
example the ability to cross a seizure-compromised blood-brain barrier (BBB) (Gray et al., 
2010). Finally, it is also possible to insert non-viral peptides into the capsid to alter its 
selectivity, for example insertion of NMDAR agonist-derived peptide and a dynein motif into 
the capsid greatly enhanced transduction and retrograde transport of AAV2 in the CNS (Xu et 
al., 2005). 
Another significant breakthrough in the AAV vector field was the development of self-
complimentary AAV (scAAV) vectors. The single stranded DNA of these vectors has two 
complimentary copies of the desired transgene separated by a mutated resolution sequence. 
This allows spontaneous re-annealing of the DNA, therefore eliminating the need for second 
strand synthesis in the infected cell (McCarty, Monahan and Samulski, 2001). This makes the 
onset of expression of the transgene much faster, and also increases transduction efficiency  
10- to 100-fold (McCarty, Monahan and Samulski, 2001; Kantor et al., 2014). However, by 
introducing a second copy of the transgene, the packaging capacity of scAAV vectors is 
reduced to ~2.2 kb (Kantor et al., 2014). 
Ease of production, low immunogenicity, high transduction efficiency, long-lasting transgene 
expression, availability of a large number of serotypes and advancements in vector design have 
made AAV vectors one of the most popular viral vectors for experimental and gene therapy 
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applications in the nervous system (Gray, Woodard and Samulski, 2010; Lentz, Gray and 
Samulski, 2012; Gray, 2013). AAV vectors have been used to deliver pathology-correcting 
transgenes in a variety of disease modes, including spinal muscular atrophy (Foust et al., 2010), 
glycogen storage disease type I (Koeberl et al., 2008), Krabbe’s disease (Marshall et al., 2018) 
and stroke (Yu et al., 2013). In the context of pain research, AAV vectors have been used to 
target many parts of the pain circuitry (Guedon et al., 2015; Zheng et al., 2018), including 
primary afferent neurons (Fischer et al., 2014; Chen et al., 2018), and the spinal cord circuitry 
(Gutierrez-Mecinas et al., 2018). However, it is important to note that despite low 
immunogenicity, some inflammatory responses may still be present after injection of the AAV 
(Ciesielska et al., 2013; Chew et al., 2016; Yang et al., 2016; Colella, Ronzitti and Mingozzi, 
2018). Interestingly, the responses are often caused by the vector product and not the AAV 
vector itself (Ciesielska et al., 2013; Chew et al., 2016). Therefore, it is important to control for 
these side-effects when using AAV vectors. 
Overall, AAV vectors seem to be well suited for studying primary afferent neurons, and have 
several advantages over other available vectors, including low immunogenicity, neuronal 
tropism, efficient transduction and low cell toxicity (Lentz, Gray and Samulski, 2012; Kantor et 
al., 2014). Therefore, in this study we decided to use AAV vectors as delivery tools to 
interrogate various aspects of the anatomy and physiology of primary afferent nociceptors. 
1.6 Project hypothesis and aim 
This project’s hypothesis is as follows: 
“AAV vectors, in particular AAV9, can be used to achieve high transduction in the primary 
afferent neurons following intrathecal and other delivery methods, and this approach can be 
used to to deliver functional transgenic tools that are then used to interrogate various aspects 
of neuronal physiology, including neuronal activity and gene expression.” 
The aim of this project is to express various transgenic tools in adult mouse primary afferent 
neurons in vivo and use them to study the various aspects of physiology and anatomy of 
35 
 
primary afferent neurons. In order to achieve expression of transgenes, we use non-
pathogenic adeno-associated virus serotype 9 (AAV9). Our first aim is to establish an AAV 
delivery method that achieves high transduction in vivo in adult mouse primary afferents. We 
use an AAV9 expressing an eGFP transgene to identify and characterise the transduction 
pattern in DRG neurons. Secondly, we aim to deliver functional transgenes to primary afferent 
neurons, such as GCaMP6s, to study activity of these neurons in vitro and in vivo. Before 
transitioning into in vivo GCaMP6s applications, we first assess the performance of GCaMP6s in 
primary afferents in vitro. To do that, we aim to establish an in vitro sensitisation model for 
calcium imaging that uses electrical stimulation as an activity trigger, and then use it in 
conjunction with virally-delivered GECI GCaMP6s to image neuronal activity. Finally, we 
explore the use of our intrathecal AAV9 delivery method to assess the functionality of other 
transgenic tools in vivo, including GCaMP6s for neuronal activity visualisation, Cre recombinase 
for the control of gene expression, and chemogenetic neuronal silencing using engineered 




Chapter 2: Transduction of DRG neurons following intrathecal 
delivery of AAV9 
2.1 Introduction 
As discussed in the previous chapter, transgenic tools are invaluable assets to studying pain 
physiology and pathology. One of the most popular methods for gene expression is to 
transduce cells with viral vectors. AAV vectors are one of the most widely used types of vectors 
due to their low pathogenicity (Lentz, Gray and Samulski, 2012). There are also a large number 
of AAV serotypes available, each with its own specific transduction properties (Zheng et al., 
2018). Furthermore, administration of the same AAV via different delivery routes can produce 
transduction patterns that are drastically different. Therefore, it important that the correct 
combination of serotype and delivery route is used to effectively target the specific cell 
type/structure that is being studied. Given our interest in pain physiology, with a particular 
focus on the primary afferent neurons, we sought to find a way of transducing large numbers 
of DRG neurons with AAV vectors in adult mice.  
2.1.1 Factors influencing AAV transduction 
AAV transduction efficiency can be influenced by a number of factors, including serotype 
tropism, receptor availability, and delivery route. Since the initial discovery of AAV2 in 1965 by 
Atchison et al, many AAV serotypes have been isolated (Atchison, Casto and Hammon, 1965). 
Transduction capabilities of these serotypes are affected by the expression of specific AAV 
receptors by the target cells. The presence of some receptors, such as the recently identified 
AAV receptor (AAVR), are a common requirement among many AAV serotypes, where knock-
out of its gene renders the cell lines or whole animals resistant to AAV infection with all 
serotypes (Pillay et al., 2016). Several serotypes require an additional receptor to be present to 
achieve successful transfection, for instance AAV9 requires a specific surface glycan, N-linked 
galactose, for successful transduction (Shen et al., 2011). Sialic acid linkages that obscure N-
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terminal galactose can be removed with neuraminidase, which in turn can facilitate 
transduction in cells that are normally resistant to AAV9, such as airway epithelial cells  (Bell et 
al., 2011). Some receptors are shared between several AAV serotypes, like the laminin 
receptor for AAV 2,3,8 and 9 or sialic acid for AAV1,4,5 and 6 (Kaludov et al., 2001; Wu et al., 
2006). Overexpression of laminin receptor (LamR) can boost transduction, while 
administration of an anti-LamR antibody reduces transduction efficiency in mice in vivo 
(Akache et al., 2006). Furthermore, pathology that alters the availability of the AAV receptor, 
such as masking it with sialic acid in lysosomal storage disease, can impair transduction with 
any AAV serotype that uses that receptor (Y. H. Chen et al., 2012). These studies show that 
receptor availability in the target cell type is one of the main factors that determines 
transduction efficiency. However, it is important to note that most cell types express multiple 
AAV receptors, so receptor availability alone may not be sufficient to determine a suitable AAV 
serotype  (Srivastava, 2016). 
There are numerous AAV serotypes that have been isolated from living organisms, as well as 
those of synthetic origin (Lentz, Gray and Samulski, 2012). All these AAV serotypes differ not 
only in their respective receptors required for transduction, but also in their tissue tropism and 
transduction efficiency (Murlidharan, Samulski and Asokan, 2014; Srivastava, 2016). Therefore, 
it is important to examine these properties together in order to choose the correct serotype 
for a specific study.  
Moreover, it is important to note that the delivery route also has a major impact on 
transduction properties of AAV serotypes. There is a large body of literature that details the 
use of AAV vectors to study almost all aspects of the nervous system, using a broad range of 
serotypes and delivery routes.  As the main aim of this project is to use AAVs to study primary 
sensory neurons involved in nociception and related pain circuitry, it is important to choose a 
serotype and delivery route that results in high transduction efficiency in the DRGs (where the 
cell bodies are located) and/or dorsal spinal cord (where their projections terminate). Below, 
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possible delivery routes for transduction of the nervous system in conjunction with 
transduction efficiency for various serotypes are described, together their advantages and 
disadvantages. 
2.1.2 AAV delivery routes to the nervous system 
2.1.2.1 Direct injection into the parenchyma of the brain or spinal cord 
Direct administration of AAVs into the brain or spinal cord parenchyma is one of the more 
popular routes of delivery to the central nervous system in pre-clinical studies, first used in 
mammals in 1994 (Kaplitt et al., 1994). Typically, direct brain injection of AAV results in a high 
level of transduction at the injection epicentre, and therefore can be used to target specific 
regions of the brain (Murlidharan, Samulski and Asokan, 2014). Burger et al tested how well 
injection of AAV1, 2 or 5 transduced different parts of the adult rat CNS, including the 
hippocampus, striatum, cortex and spinal cord. They found that all three vectors almost 
exclusively target neurons. AAV1 and 5 performed much better than AAV2, having greater 
spread, evidence of retrograde labelling and higher transgene expression in all parts of the CNS 
(Burger et al., 2004). Similar results were seen in the mouse brain, where AAV serotype 2 
performed worse than AAV serotypes 1,5,7 and 8 (Davidson, 2000; Taymans et al., 2007).  
In other studies, AAV serotypes 9 and rh10 were found to produce superior labelling when 
compared to most other serotypes (AAV1-8), with AAV9 also showing retrograde transport 
capabilities  (Cearley and Wolfe, 2006; Klein et al., 2008; Aschauer, Kreuz and Rumpel, 2013; 
Vincent, Gao and Jacobson, 2014). However, most robust retrograde transport in the CNS has 
been found for the AAV2.retro serotype, specifically designed for maximum retrograde 
capabilities (Tervo et al., 2016; Haenraets et al., 2017).  
Although direct brain injections of AAVs mostly target neurons, several studies report that 
several AAV serotypes, including 8, 9 and rh10, also transduce astrocytes and oligodendrocytes 
both in the brain and in spinal cord (Aschauer, Kreuz and Rumpel, 2013; Ciesielska et al., 2013; 
Löw, Aebischer and Schneider, 2013; Haenraets et al., 2017).  
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Interestingly, driving transgene expression with a cytomegalovirus (CMV) promoter was found 
to be less efficient than chicken β-actin (CBA) in the CNS (Klein et al., 2008). However, after 
injection into the spinal cord AAV9 under the CBA promoter showed poor labelling of motor 
neurons, while the CMV promoter achieved higher levels of transgene expression in motor 
neurons (Snyder et al., 2011). 
To summarise, direct parenchyma injection has the advantage of avoiding the blood-brain 
barrier, which would otherwise severely limit viral access to the CNS. However, each injection 
only targets a small area of the CNS, so multiple injections are required for targeting larger 
regions. Overall, this delivery route would be applicable in our project to study CNS nociceptive 
pathways, but it does not enable labelling of primary sensory neurons.  
2.1.2.2 Direct injection into DRGs 
AAV injections of a small volume into the DRG can be used to target primary sensory neurons. 
Mason et al compared AAV serotypes 1-6 and 8 to assess the efficiency of DRG transduction 
after intraganglionic injection. They found that AAV serotype 5 performed best, with ~48% 
neurons transduced per DRG after 2 weeks, and ~75% after 4 weeks. Out of these neurons, a 
large proportion were small diameter, with 33% calcitonin gene-related peptide (CGRP)-
positive, and 48% isolectin B4 (IB4)-positive neurons (Mason et al., 2010). A different study 
showed that intraganglionic injection of AAV9 results in transduction in ~40% of L4 DRG 
neurons (Haenraets et al., 2017). 
However, AAV targeting of neuronal sub-populations has been shown to differ depending on 
the serotype and promoter used. AAV8, for example, has been shown to prefer large-diameter 
neurons following intrganglionic injection (Jacques et al., 2012). On the other hand, 
intraganglionic injection of AAV9 with transgene under the control of the human synapsin 
promoter resulted in low transduction of IB4 positive neurons (Haenraets et al., 2017).  
Although direct DRG injection of AAV typically produces good levels of transduction among the 
primary sensory neurons, it is a difficult and invasive procedure that can have some 
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undesirable side effects on the animal. Rats injected with AAV8 into the L4 and L5 DRGs 
showed transient mechanical allodynia and thermal hyperalgesia, as well as declining rotarod 
motor performance (Fischer et al., 2011). DRG injection is an even more technically challenging 
procedure in mice, with a potential for greater side-effects due to the small size of the DRG 
itself. An alternative to using direct injections into the DRG or CNS parenchyma is to infuse the 
AAV into the cerebrospinal fluid (CSF) via cerebral ventricles, cisterna magna or lumbar 
puncture. 
2.1.2.3 Infusion of AAV into CSF via cerebral ventricles 
CSF is vital for the correct functioning of the brain, spinal cord and DRGs, as it provides 
nutrients and clears solutes from the brain and spinal cord (Sakka, Coll and Chazal, 2011). Most 
of the CSF is produced by the choroid plexus in the cerebral ventricles (Sakka, Coll and Chazal, 
2011). Since the CSF is in close contact with the brain, spinal cord and DRGs, it can serve as a 
medium for delivery of AAVs to a large proportion of the nervous system. One of the methods 
used to infuse the vectors into the CSF is by injection into cerebral ventricles. Interestingly, 
Intracecrebroventricular (ICV) administration of AAV2,4 or 5 in adult mice results in almost 
exclusive transduction of ependymal cells, with limited neuronal transduction (Davidson, 2000). 
AAV9, on the other hand, has shown promising results by producing extensive neuronal 
labelling in the brain and spinal cord 6 weeks after ICV delivery, but it was only tested in a 
single rat (Jackson et al., 2016).  
The transduction profile in neonates is drastically different from that in adults. ICV delivery of 
AAV straight after birth (P1) results in widespread transduction throughout brain parenchyma 
(Passini and Wolfe, 2001; Spampanato et al., 2011; Glascock et al., 2012). This has been 
observed with several serotypes, including AAV1, 2, 5, 7, 8 and 9, however, serotypes 8 and 9 
achieved best transduction (Chakrabarty et al., 2013; J.-Y. Kim et al., 2014; Hammond et al., 
2017). Interestingly, transduction throughout the brain was greatly diminished when viral 
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injection was done at P2 or P3, suggesting that the timing of injection is crucial. (Chakrabarty 
et al., 2013) 
Overall, ICV injection is effective in transducing a large proportion of brain parenchyma, but 
only if the AAV is delivered at P1. There is evidence that AAV9 is capable of transducing spinal 
cord neurons in adults, but it is too unspecific for studying pain circuitry and there is no 
evidence of DRG transduction (Donsante et al., 2016). However, delivery into the CSF at lower 
spinal regions may produce a different transduction profile. 
2.1.2.4 Infusion into CSF via the Cisterna Magna 
An alternative way of accessing the CSF is via infusion into the cisterna magna (CM) through 
the atlanto-occipital membrane. While ICV CSF delivery requires a craniotomy and the needle 
to be advanced through the brain parenchyma in order to target the ventricles, infusion into 
the CM is less invasive. It requires only the removal of muscle overlaying the atlanto-occipital 
membranes.  
CM Delivery of scAAV2 has been shown to transduce the adult brain and spinal cord all the 
way to the lumbar level (Fu et al., 2003). Furthermore, intravenous (IV) infusion of mannitol 
prior to CM delivery further increased the transduction efficiency (Fu et al., 2003). CM 
injection of AAVrh10 results in extensive transduction throughout the whole of the spinal cord, 
including interneurons, ascending projections and motor neurons (Hordeaux et al., 2015). In 
addition, DRG transduction was present in both adults and neonates (Hordeaux et al., 2015). In 
neonates, CM delivery of AAV8 and 9 results in efficient transduction in the brain and spinal 
cord parenchyma (Ayers et al., 2015). Moreover, AAV9 has been shown to transduce the spinal 
cord and brain after CM delivery both in neonates and adults (Lukashchuk et al., 2016; Sinnett 
et al., 2017).  
Although CM delivery transduces spinal cord neurons and DRGs, transduction diminishes with 
increasing distance from the injection point. This is a disadvantage for the pain research, since 
it often focuses on the lower limbs and their associated pathways. Therefore, achieving high 
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transduction in the lumbar DRGs and spinal cord is essential. By shifting the point of injection 
to the lower regions using methods such as lumbar puncture it might be possible to target 
these regions preferentially. 
2.1.2.5 Infusion into CSF via Lumbar Puncture 
Lumbar puncture (LP) delivery to CSF is a simpler procedure compared to CM delivery and may 
produce higher transduction in the lumbar regions. Adult mice injected with AAV6 via LP show 
the highest level of transduction in the L4 DRG neurons, with >50% of neurons transduced 
after a single injection. Moreover, labelling of the lumbar spinal cord was confined to laminae I 
and II possibly indicating preference for labelling nociceptive pathways (Towne et al., 2009). 
Similar results were seen with AAV5 and AAV8, although DRG labelling was not as extensive 
(Vulchanova et al., 2010). Interestingly, transgene levels in the spinal cord were significantly 
diminished in injected animals after dorsal rhizotomy. This suggests that most of the transgene 
expression observed in the spinal cord is located in primary afferent projections (Vulchanova 
et al., 2010). In a study by Homs et al intrathecal injection of AAV2 or 8 produced sparse 
labelling. AAVrh10, on the other hand, labelled the majority of L4 DRG neurons, 60% of which 
were CGRP or IB4 positive, suggesting a preference for nociceptors (Homs et al., 2014). 
Intrathecal delivery of AAVrh10 also produced extensive labelling in the spinal cord (Guo et al., 
2016). Greatest DRG transduction, however, was achieved with intrathecal administration of 
AAV9, with transgene expression in over 70% of L4 DRG neurons, around 60% of which were 
small-diameter (Schuster et al., 2014). Transgene labelling in the spinal cord was also extensive, 
both in the dorsal and ventral horns (Schuster et al. 2014; Bey et al. 2017).  
Of note, the possible labelling of the deep spinal cord may be dependent on the injection 
technique. In mice, injections of AAV9 under pia mater produced extensive labelling 
throughout spinal cord, however in animals receiving intrathecal injection of AAV9, without 
damaging the pia, labelling was confined to the dorsal horn and dorsal funiculus (Miyanohara 
et al. 2016).  
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Overall, intrathecal injection via LP is an efficient method for transduction in the lumbar DRGs 
and dorsal spinal cord. However, it is important to consider other delivery methods, like 
peripheral injections and intravenous delivery. 
2.1.2.6 Peripheral and intravenous injections 
Labelling of specific sensory neurons innervating peripheral anatomical structures of interest 
may be possible by injecting AAV directly into these structures.  AAV can then be taken up by 
the peripheral terminals of sensory neurons and transported retrogradely to the DRG. The 
sensory neurons labelled by peripheral injection will be confined to DRG levels that send 
projections to that structure. 
For instance, delivery of AAV6 by direct injection into the sciatic nerve labels DRG neurons in 
L4 (Towne et al., 2009). However, subcutaneous and intramuscular delivery did not label any 
neurons, which may be due to limited AAV6 retrograde transport capabilities. In another study, 
Pleticha et al showed that direct administration of AAVrh20 into the sciatic nerve produces 
labelling in L4 and L5 DRGs (Pleticha et al., 2014). 
Another peripheral delivery method to transduce sensory neurons and the CNS is intravenous 
infusion (IV). This delivery method is minimally invasive, and can potentially achieve good 
spread with a single injection (Murlidharan, Samulski and Asokan, 2014). However, 
intravenous delivery has a greater chance for off-target transduction, especially in tissues that 
all AAVs have tropism for, such as liver and heart (Zincarelli et al., 2008). The greatest 
drawback, however, is that many AAV serotypes have difficulties crossing the blood-brain 
barrier (BBB), making it difficult for IV injections to transduce the spinal cord and possibly DRG 
neurons (Towne et al., 2008; Foust et al., 2009). Indeed, AAV9 IV injection in adult mice results 
in limited neuronal transduction, but widespread transduction in the astrocytes, whose 
endfeet surround capillary endothelial cells (Foust et al., 2009). However, there is evidence 
that some AAV serotypes can cross the adult BBB. For instance, IV delivery of scAAV9 resulted 
in extensive transduction in the spinal cord and brain (Duque et al., 2009; Foust et al., 2009; 
44 
 
Gray, Foti, et al., 2011; Yang et al., 2014). Interestingly, extensive neuronal transduction was 
not observed with ssAAV9 (Foust et al., 2009; Schuster et al., 2014). Futhermore, when Yang et 
al compared transduction in the mouse adult brain and the spinal cord after IV injection of 
several AAV serotype, they found that AAV8, AAV9 and AAV.rh10 result in extensive 
transduction in the CNS neurons, while other serotypes did not produce such as strong 
expression, suggesting that these serotypes are more efficient at crossing an adult BBB  (Yang 
et al., 2014).  
Another way of circumventing the problem of crossing the BBB is pre-treatment with mannitol, 
that can temporarily disrupt the BBB (Pan, Liu and Liu, 2000). Mannitol pre-treatment has 
enabled scAAV2 to transduce neurons and glia in the brain after IV injection (Fu et al., 2003). 
Widespread brain transduction after mannitol treatment has also been seen with AAVrh.10 
(Foley et al., 2014). Of note, precise timing of mannitol administration is crucial, with the best 
AAV2 transduction in the CNS achieved when virus was administered 8 minutes after the 
mannitol treatment (McCarty et al., 2009). 
The more popular way of achieving high CNS transduction with IV-delivered AAVs is to 
administer them shortly after birth, when the BBB is not yet mature (Engelhardt and Liebner, 
2014). Many serotypes that do not efficiently transduce adult CNS after IV delivery show 
increased efficiency when administered in P1 (Zhang et al., 2011).  IV delivery of AAV9 to 
neonatal rats and mice resulted in extensive transduction in the brain and spinal cord (Foust et 
al., 2009, 2010; Wang et al., 2010).. 
Although IV administration produces widespread labelling, it does not transduce DRG neurons 
and spinal cord transduction is too widespread to be of use to this project. Additionally, all 
cited studies reported off-target transduction in liver or heart. Overall, IV injection is useful 
















AAV1 + + ++ - ++ + 
AAV2 + + + + - + 
AAV4 - + - NA NA - 
AAV5 ++ ++ 
  + - + - 
AAV6 + ++ + NA ++ + 
AAV7 + NA + NA NA ++ 
AAV8 ++ + ++ + + + 
AAV9 +++ ++ +++ ++ +++ ++ 
AAVrh10 ++ NA NA +++ ++ ++ 
AAV2.retro ++ NA NA NA NA NA 
 
Table 2.1 – Comparison of transduction for different AAV serotypes and different delivery 
methods. Relative performance of different AAV serotypes in different delivery scenarios in 
mouse neurons. The arbitrary scale form minus to three plusses represents “little to no 
transduction” to “strong and extensive transduction”. Table compiled with data from 
(Davidson, 2000; Passini and Wolfe, 2001; Fu et al., 2003; Burger et al., 2004; Cearley and 
Wolfe, 2006; Taymans et al., 2007; Klein et al., 2008; Iwamoto et al., 2009; McCarty et al., 
2009; Towne et al., 2009; Mason et al., 2010; Vulchanova et al., 2010; Gray, Matagne, et al., 
2011; Spampanato et al., 2011; Zhang et al., 2011; Glascock et al., 2012; Aschauer, Kreuz and 
Rumpel, 2013; Chakrabarty et al., 2013; Homs et al., 2014; Schuster et al., 2014; Vincent, Gao 
and Jacobson, 2014; Yang et al., 2014; Dirren et al., 2014; Ayers et al., 2015; Hordeaux et al., 
2015; Jackson et al., 2016; Lukashchuk et al., 2016; Tervo et al., 2016; Bey et al., 2017; 
Sinnett et al., 2017). 
After reviewing the available AAV serotypes and delivery methods (Table 2.1), we decided to 
use serotype 9, as it showed the greatest neuronal transduction when delivered via various 
routes, including direct parenchymal injection (Cearley and Wolfe, 2006), direct DRG injection 
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(Yu, Fischer and Hogan, 2016), ICV infusion (Chakrabarty et al., 2013), intrathecal infusion 
(Schuster et al., 2014), and peripheral injections (Foust et al., 2009). Additionally, to achieve 
greatest DRG transduction possible, we decided to use the lumbar puncture method to deliver 
AAV9 into the CSF. This method produced the highest level of transduction in the DRG neurons 
of all the review methods (Schuster et al., 2014). Furthermore, intrathecal delivery of AAV via 
the lumbar puncture is a relatively quick and simple procedure that is not very invasive, 
compared to intraparenchymal, ICV and intraganglionic injections. 
The aim of this chapter is to determine the transduction pattern that lumbar puncture delivery 
of AAV9 produces in DRG neurons and the spinal cord. Further, we will investigate the effect 
on transduction pattern and efficiency of factors like time post injection and virus titre. Finally, 
we will use peripheral injections into anatomical structures to achieve retrograde labelling in 






All procedures were in accordance with the UK Home Office guidelines and Animals (Scientific 
Procedures) Act 1986. C57Bl/6J mice were obtained from Charles River. Both males and 
females 3-6 months of age were used for intrathecal and peripheral vector delivery 
experiments. For in vitro experiments, 2-3 month old males and females were used. 
2.2.2 Viral Vectors 
All adeno-associated virus (AAV) vectors were obtained from UPENN Vector Core and were 
store d at -80 °C. Construct information and titres can be found in Table 2.2 
Vector Name In-text name Serotype Transgene Titer (GC/ml) 





AAV9.CB7.CI.mCherry.WPRE.rBG AAV9-mCherry AAV9 mCherry 1.49x1013  
AAV9.CAG.GCaMP6s.WPRE.SV40 AAV9-GCaMP6s AAV9 GCaMP6s 1.69x1013 
AAV9.CMV.PI.Cre.rBG AAV9-Cre AAV9 Cre 3.29x1013 
AAV8.CB7.CI.eGFP.WPRE.rBG AAV8-eGFP AAV8 eGFP 1.78x1013 
AAV9 - GluClβ AAV9-GluClβ AAV9 GluClβ 2.4x1013 
AAV9 - GluClα AAV9-GluCl AAV9 GluClα 1.5x1013 
 
Table 2.2 – Viral vectors used in this project 
2.2.3 Lumbar puncture AAV injections 
The procedure was executed by Clive Gentry. Mice were restrained in a cardboard tube. 
Vertebrae L3 and L4 were identified percutaneously. A gauge 26 needle attached to a Hamilton 
syringe was then carefully inserted at an angle between these two vertebrae, and 5 µl of virus 
was injected. The needle was then left in place for 10 seconds before its removal. Animal 
weight was monitored after the procedure for up to 7 days. 
2.2.4 Catheter mediated intrathecal injections 
First, the catheters were prepared by inserting 1.5cm of small diameter tubing (0.2 mm OD, 
Braintree Scientific, SUBL 080) into 15-20 cm of large diameter tubing (0.64 mm OD, VWR, 60-
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011-01) and secured using Epoxy glue, to form a long catheter with a short thin end. Glue was 
left to dry overnight, and the catheters were sterilised using UV light. 
On the day of the surgery, one catheter was attached to a 300 µl insulin syringe that was 
linked to a syringe pump. The syringe and large tubing was filled with sterile saline, then the 
virus was loaded after an air bubble was created to separate the virus from the saline. This was 
done to minimise pressure fluctuations and to ensure steady infusion of the virus. A mark was 
made on the large tubing at 6.6 cm from the junction with the small cannula to denote 5 µl 
volume of the large tubing. This length of the catheter has the volume of 5 µl, and the mark 
was used as a guide for virus loading.  
The mouse was then anaesthetised in the induction chamber with 5% Isofluorane (Henry 
Schein, 900-8931), and kept at 2-2.5% Isofluorane throughout the procedure. The mouse was 
given 50 µl 0.5% v/v carprieve (Norbrook) diluted in saline and 100 µl sterile saline 
subcutaneously before being shaved and the incision area disinfected with iodine. 
The animal was then transferred to the surgery area equipped with a heat mat, covered with a 
sterile drape containing a surgery window, and Viscotears were applied to the eyes to prevent 
their drying. Before proceeding, the absence of hindpaw pinch withdrawal reflexes were 
checked to ensure surgical anaesthesia depth, and were monitored throughout the procedure 
After that a 2cm skin incision was made on top of the vertebral column at the lumbar level. 
Region between vertebrae T12 and T13 was located and muscle between these vertebrae 
carefully removed using fine Rongeurs (Item 16221-14, Fins Scientific Tools). The vertebral 
column was stabilised using a “third hand” tool, and the mouse was slightly rotated towards 
the surgeon for easier access. Leftover muscle was cleaned up with no.5 forceps to expose the 
intervertebral ligament, which was then removed using no.5 forceps to expose the dura.  
Solution of 0.1% w/v Methylene Blue (Sigma, 66719) in sterile saline was applied on top of 
dura to visualise it, and then removed using a cotton bud. Dura was carefully lifted using fine 
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forceps (Item 11413-11, Fine Scientific tools), and a small hole was made with a gauge 30 
needle. 
Using fine forceps, dura was lifted caudally to the hole to allow easier intrathecal access. The 
thin end of the cannula was then inserted 1.2 cm into the caudal direction, to allow virus 
delivery at the L4 DRG level. After the cannula was fully inserted, 5 µl of virus was infused at a 
rate of around 1.2 µl per minute. 
After the infusion, cannula was left in place for 2 minutes to minimise backflow caused by 
cannula retraction. After cannula removal, mouse was unclamped, the incision washed with 
sterile saline and skin was closed using metal clips. Animal was then allowed to recover in the 
incubator at 32°C and monitored for any impairments. Weight was monitored until it returned 
to the pre-surgery value and clips were removed 7-10 days after surgery. 
2.2.5 Peripheral injections 
Intraneural injections 
Mice were anaesthetised using 5% isofluorane, they received 50 µl 0.5% v/v carprieve 
subcutaneously and their left hind limb was shaved. Mice were then placed on a heat mat, 
eyes covered with Viscotears and covered with a sterile drape. Anaesthesia was maintained 
with 2-2.5% isofluorane. Before proceeding, the absence of hindpaw pinch withdrawal reflexes 
were checked to ensure surgical anaesthesia depth and were monitored throughout the 
procedure. A skin incision was made to expose the sciatic nerve. The nerve was stabilised with 
no.5 forceps and 1 µl of virus was injected into the nerve at a rate of 0.25 µl/min using a 
microinjector. After injection, the glass needle was left in place for 2 minutes to minimise 
backflow. The needle was retracted, and skin closed using metal clips. Mice were left to 
recover in the incubator at 32°C and monitored for weight loss and impairments. Clips were 





Mice were anaesthetised using 5% isofluorane and given 50 µl 0.5% v/v carprive 
subcutaneously. Mice were placed on a heatmat, eyes covered with Viscotears and sterile 
drape put over the mouse. Hindpaw was extended and 5 µl of virus was injected into the 
plantar surface of the paw using an insulin syringe. Needle was left in place to minimise 
backflow. Mice were left to recover in the incubator at 32°C and monitored for weight loss and 
impairments. 
Intraarticular injection 
Injection technique adapted from (Salo and Tatton, 1993).  Mice were anaesthetised using 5% 
isofluorane and given 50ul 0.5% v/v carprive subcutaneously. Mice were placed on a heatmat, 
eyes covered with Viscotears and sterile drape put over the mouse. Anaesthesia was 
maintained with 2-2.5% isofluorane. Before proceeding, the absence of hindpaw pinch 
withdrawal reflexes were checked to ensure surgical anaesthesia depth and were monitored 
throughout the procedure.  An incision was made on the knee to expose the patella tendon. 
Glass needle was inserted through the tendon into the knee joint using micromanipulator and 
0.5 µl of virus was injected at a rate of 0.25 µl/min. The needle was left in place for 2 minutes 
to prevent backflow and skin was closed using a metal clip. Mice were monitored for weight 
loss and impairments. Clips were removed 7-10 days after surgery. 
2.2.6 Dissection and immunohistochemistry 
Mice were injected with 100 µl of Euthatal intraperitoneally. Reflexes were checked and once 
terminal anaesthesia was achieved mice were perfused transcardially using a handheld syringe 
first with 30 ml of phosphate-buffered saline (PBS) and then with 30 ml of 4% 
paraformaldehyde (PFA) for immunohistochemistry (IHC). After perfusion, 3 cervical and 3 
thoracic DRGs from both sides were dissected, as well as L4 DRGs and the lumbar spinal cord. 
They were placed in 4% PFA for 2 hours (DRGs) or overnight (spinal cords). Tissue was then 
washed in PBS and placed into 30% sucrose in PBS with 0.01% sodium azide overnight.  
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2.2.7 Tissue preparation and image acquisition 
Tissue was embedded in OCT (VWR 361603E), frozen on dry ice with Isopentane (Sigma, 
M32631), and stored at -80 °C. Blocks of tissue were cut using Bright Instruments Cryostat. The 
thickness of slices was 10 µm for DRGs and 20 µm for spinal cords. Sections were collected 
onto Superfrost slides (Thermo Fisher, J1800AMNZ) in series, ensuring that slices from all 
levels of thetissue are present and evenly distributed among the slide series. Slides were then 
stored at -20 °C. 
 
Table 2.3 – Antibodies used for ICC and IHC 
For IHC, slides were taken out of the freezer and left at room temperature for 30 minutes.  
Hydrophobic Pappen was applied to restrict the spread of the antibody solution. Sections were 
rehydrated with PBS and then incubated in blocking medium (1xPBS with 10% normal donkey 
serum (Sigma, S30-M) and 0.01% sodium azide) for 1 hour in humidifier chamber to prevent 
Type Fluorophore Antigen Species Dilution Provider ID 
Primary n/a β-III-
Tubulin Rabbit 1:1000 Abcam ab18207 
 
n/a β-III-
Tubulin Mouse 1:1000 Promega G7121 
 
n/a GFP Chicken 1:1000 Abcam ab13970 
 
n/a GFP Rabbit 1:1000 Abcam ab290 
 
n/a CGRP Rabbit 1:500 Enzo Life Sciences BML-CA1134 
 
n/a NF200 Mouse 1:500 Sigma N0142 
 
n/a NF200 Chicken 1:500 Millipore AB5539 
 
n/a NeuN Rabbit 1:500 New England Biolabs 12943 
 
n/a RFP Rabbit 1:1000 Abcam ab62341 
       
Secondary Alexa Fluor 568 Rabbit IgG Donkey 1:1000 Thermo Fisher A10042 
 
Alexa Fluor 488 Chicken IgG Goat 1:1000 Thermo Fisher A11039 
 
Alexa Fluor 546 Mouse IgG Donkey 1:1000 Thermo Fisher A10036 
 
Alexa Fluor 488 Rabbit IgG Donkey 1:1000 Thermo Fisher A21206 
       
Special Alexa Fluor 647 IB4, biotin-
conjugated n/a 1:250 Thermo Fisher L32450 
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non-specific binding. Blocking solution was then removed and 300 µl of primary antibody 
diluted in PBS with 0.1% Triton X and 0.01% sodium azide was applied to the slides and left 
overnight at room temperature. Slides were then washed 3 times with PBS and secondary 
antibody diluted in PBS with 0.1% triton X and 0.01% sodium azide was applied for 2 hours at 
room temperature. After 3 PBS washes slides were coveslipped using Fluoromount-G with 4',6-
diamidino-2-phenylindole (DAPI) (Thermo Fisher, 00-4959-52) and left to dry overnight. 
Antibodies used are shown in Table 2.3. Images were taken on the Carl Zeiss microscope with 
10x and 20x objectives, using AxioVision software. At least 3 sections were imaged per DRG, 
giving preference to section with the largest number of neurons. As the minimum distance 
between two consecutive sections on the same slide is 60 µm (due to collecting tissue on the 
cryostat in series), we assumed that we would not be sampling the same cell twice. 
After acquisition, images were processed using Fiji, an ImageJ package available online 
(Schindelin et al., 2012; Rueden et al., 2017). To determine the percentage of positive eGFP 
neurons in DRG, all cells positive for β-III-tubulin were selected and the selection was used as a 
mask to measure the intensities of the corresponding ROIs in the eGFP channel. To determine 
the cut-off for eGFP-positive cells, intensity of the 5 visually least positive cells was taken, and 
threshold was set as the mean of these cells + 1 SEM. Cells with a higher intensity than the cut-
off were deemed positive. The proportion of eGFP-positive neurons to all neurons was 
calculated for each image. The results from the same DRG were then averaged to give the final 
proportion of neurons transduced for that DRG. Same principle was applied for neuronal 
marker quantification, however in the absence of  β-III-tubulin innate neuronal 
autofluorescence coupled with the presence of a neuronal-like DAPI nucleus was used to 
create a mask.   
2.2.8 Von Frey test 
All testing was done between 9:00am and noon. An up-down Von Frey method has been used   
(Chaplan et al., 1994). Mice were baselined 1 week before the surgeries. They were left to 
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acclimatise in the Von Frey cages for 45 minutes. Von Frey filaments of varying strength were 
used to assess the hindpaw mechanical threshold. The first filament used on either paw was 
0.6g, and if there was no response, a stronger filament was used next. Conversely, if the 
response was elicited, a weaker filament was used next. There were 10 testing rounds in total, 
alternating between paws, with 5 rounds per paw. The mechanical threshold for each paw was 
calculated based on the pattern of filament responses (Bonin, Bories and De Koninck, 2014). 
2.2.9 Mixed DRG tissue cultures 
Coverslips in 4 well plates were pre-coated with 10% poly-L-lysine (PLL) (Sigma, P4707) for at 
least 2 hours prior to use. PLL was removed and coverslips were washed with autoclaved Milli-
Q H2O and left to dry for 30 minutes. Then, 30 µl of 1:100 of Laminin (1-2 mg/ml )(Sigma, 
L2020) in Ham’s F12 (Life technologies, 17502-048) were put on the coverslips and incubated 
for 2 hours in the tissue culture incubator. 
Mice were sacrificed according to Schedule 1. DRGs from all levels and both sides were 
harvested into Ham’s F12 on ice. Ham’s F12 was removed and the 3 ml of dissociation enzyme 
cocktail (3mg/ml dispase (Sigma, 4942078001), 0.1% collagenase (Sigma, C9891) and 200 
units/ml DNAse (Sigma, 10104159001), diluted in Ham’s F12) was added to dissociate the 
DRGs and placed into the incubator for 45 minutes. 
Enzyme cocktail was removed and 1 ml of Ham’s F12 was added, followed by mechanical 
trituration of DRGs using a P1000 pipette. Cells were then centrifuged at 1000 RPM for 10 
seconds and the supernatant containing the dissociated cells was moved to a new tube. The 
dissociation process was then repeated 4 more times. The final cell suspension was passed 
through a 70 µm filter to remove debris. The filtered cell suspension was centrifuged at 1000 
RPM for 7 minutes, and cells were resuspended in BS medium (10% FBS (Sigma, F9665), 1% N-
2 supplement (Life technologies, 17502-048) in Ham’s F12). Laminin was aspirated off the 
coverslips and 20 µl of cell suspension was plated onto the coverslips. Cells were left in the 
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incubator for 30 minutes, after which 500 µl BS media was added. If cells were not used the 
next day, half the medium in the wells was replaced with fresh BS media. 
For immunocytochemistry, warm (37 °C) 4% PFA was added to the wells with coverslips, for a 
final concentration of 2% PFA, and incubated for 20 minutes at 37 °C. Coverslips were then 
washed three times with PBS, and then incubated in the blocking medium (1xPBS with 10% 
normal donkey serum (Sigma, S30-M) and 0.01% sodium azide) for 1 hour at RT. Coverslips 
were then washed 3 times with PBS for 5 minutes each, before incubating in 300 µl of primary 
antibody solution (see Table 2.3) diluted in PBS with 0.1% Triton X and 0.01% sodium azide for 
1 hour in the dark at RT. After that, coverslips were washed three times with PBS for 5 minutes 
each, and then incubated in 300 µl of secondary antibody solution (see Table 2.3) diluted in 
PBS with 0.1% Triton X and 0.01% sodium azide for 1 hour in the dark at RT. Finally, coverslips 
were washed 3 times in PBS for 5 minutes each, before mounting the coverslips onto 
microscope slides using Fluoromount-G with 4',6-diamidino-2-phenylindole (DAPI) (Thermo 
Fisher, 00-4959-52) and left to dry overnight. 
Three non-overlapping mosaic images were taken per coverslip, ensuring the maximum 
number of cells in the FOV. Image acquisition and method of quantification was identical to 
the IHC, using the β-III-tubulin staining to create a mask which is then used to calculate the 
proportion of transduced neurons per image, and then averaged for each coverslip (see 2.2.7). 
2.2.10 Neuronal enriched cultures using magnetic-assisted cell sorting (MACS) 
This technique has first been optimised by Dr J. Kelleher (Thakur et al., 2014). Coverslips were 
coated with PLL in the same way as for mixed cell cultures (described above). After washing, 30 
µl of Matrigel (BD bioscience, 356230) dissolved in Ham’s F12 was applied to the coverslips 
before they were placed in an incubator for 2 hours in 4 well dishes. Dissection, dissociation, 
trituration, and centrifugation were carried out in the same way to mixed culture. After 
centrifugation, cells were resuspended in 2 ml Dulbecco's phosphate-buffered saline (DPBS) 
(Gibco, 14190144) and centrifuged for 7 minutes at 1000 RPM. DPBS was replaced with 130 µl 
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of 0.5% w/v bovine serum albumin in MACS buffer + 30 µl of biotin-conjugated antibody 
cocktail that binds to non-neuronal cells, including astrocytes, oligodendrocytes, satellite glia 
cells, fibroblasts and epithelial cells (MACS kit (Miltenyi biotec, 130-098-752)). Suspension was 
left at 4 °C for 5 minutes to allow antibody binding. 1840 µl of MACS buffer were added and 
suspension centrifuged at 1000 rpm for 7 minutes. Supernatant was discarded, and cells were 
resuspended in 130 µl MACS buffer and 30 µl of anti-biotin microbeads, followed by 
incubation at 4 °C for 10 minutes. After that, 340 µl of MACS buffer was added. LD columns 
were primed with 2 ml of MACS buffer, after which the cell suspension was added to them. 
Columns were washed through with 1 ml of MACS buffer before the elute was centrifuged for 
8 minutes at 1000 rpm. Cells were then resuspended in a desirable amount of BS before being 
plated onto the Matrigel-coated coverslips.  
2.2.11 In vitro viral transfection 
Cells were processed for culture as described above. After resuspending them in the desired 
volume of BS, various amounts of AAV9-eGFP, AAV9-Cre or AAV9-GCaMP6s were added to 
reach the desired virus concentration (see 2.3.7) and left to incubate at 37 °C for 20 minutes in 
suspension before plating cells onto the coverslips. 
2.2.12 Flow cytometry 
Mice were intrathecally injected with either AAV9-eGFP or vehicle and left to incubate for 14 
days. DRGs were extracted, enzymatically digested and passed through a 70 µm filter as 
described above. Cells were suspended in 50 µl Live/Dead fixable yellow dye (L-34959, Life 
Technologies) and incubated in the dark for 15min on ice. 2x 50ul antibody mix was then 
added, consisting of mFACS buffer (HBSS with 0.4% BSA, 15  mM HEPES and 2 mM EDTA), 1:10 
Fc block (purified anti-mouse CD16/32, Cambridge Bioscience, 101302, 1:20) and 1:150 of the 
following antibodies from Biolgened: CD45 (immune cells) – PercPCy5.5 (103108); CD11b 
(myeloid lineage) – APC-Cy7 (101212); Ly6G (neutrophils, granulocytes) – Pac blue (127612); 
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Ly6C (monocytes) – PE (128007); CD11c (dendritic cells) – APC (117328); CD19 (B cells) – 
BV605 (115540); TCRβ (T cells) – PE-Cy7 (109222).  
Cells were incubated a further 15min on ice in the dark and centrifuged at 1500 rpm at 4 °C for 
3 minutes. Supernatant was removed, and cells were fixed with 50 µl of 4% PFA for 5 minutes 
on ice. Finally, cells were centrifuged at 1500 rpm at 4 °C for 3 minutes and resuspended in 50 
µl mFACS. Cells were then processed using a BD SORP Fortessa at the NIHR BRC flow core 
facility at King’s College London. Unstained cells, cells stained with viability dye only and 
controls beads (BD Bioscience Comp beads, rat and hamster, cat. # 552845) stained with each 
antibody on its own were used for compensation. FlowJo was used to analyse the data. Basic 
gating for all events was as follows: all cells based on forward (FSC) and side scatter (SSC); 
single cells based on SSC area and width; live cells based on FSC and viability dye and finally 
FSC and CD45 for all immune cells. For quantification, all gates were kept constant between 
conditions (Lopes et al., 2017). 
2.2.13 Statistics 
All statistical analysis and data visualisations were performed using GraphPad Prism 7 
(GraphPad). Paired and unpaired Two-tailed T-tests were used when comparing means of two 
groups. Dunnett, Tukey and Sidak multiple comparisons correction post-hoc tests were used 
after One-Way ANOVA, and the choice of the test was based on the dataset and the type of 
comparison required. When multiple means were compared to one control mean, Dunnett 
post-hoc test was used. When means of all columns were compared to each other, and when 
the number of entries per column was not the same, Tukey’s post-hoc method was used. 
When a select set of means out of the whole dataset was compared, Sidak post-hoc test was 
used. Non-parametric Kolmogorov-Smirnov test was used to assess the neuronal diameter 
distribution for eGFP-positive and all neurons in L4 DRG following intrathecal administration of 
AAV9-eGFP. Individual two-tailed t-tests were used to compare the transduction efficiency for 
each DRG level between 30 days and 14 days after AAV9-eGFP injection timepoints, and for 30 
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days and 7 days after AAV9-eGFP injection timepoints. Similarly, two-tailed t-tests were used 
to compare transduction at each DRG level between 30 days and 14 days after AAV9-GCaMP6s 
injection, as well as AAV9-Cre. One-Way ANOVA with Sidak multiple comparisons correction 
was used to compare the L4 transduction after injection of AAV9-eGFP at different titres. 
Individual two-tailed t-tests were used to compare the transduction in L4, T and C DRGs after 
AAV9-eGFP injection between high (2.5x1013 gc/ml) and lower (6.39x1012 gc/ml) titres. One-
Way ANOVA with Tukey’s multiple comparisons was used to assess the AAV9 transduction in 
different neuronal subpopulations following AAV9-eGFP injection. For Von Frey behavioural 
test, One-Way ANOVA with Dunnett multiple comparisons correction was used to compare the 
mechanical thresholds at each timepoint to that of baseline, and One-Way ANOVA with Sidak 
multiple comparisons to compare the mechanical thresholds between the two groups at each 
timepoint. To compare the proportion of different immune cell types in the DRGs after AAV9-
eGFP injection, One-Way ANOVA with Sidak multiple comparisons was used. Two-tailed t-tests 
were used to compare transduction after AAV9 and AAV8 injection, and after AAV9-eGFP and 
AAV9-mCherry injection. Two-tailed t-tests were used to compare transduction after 
intraneural, intraarticular and intraplantar injections. For in vitro ICC experiments, two-tailed t-
tests were used to compare the proportion of transduced neurons after incubation with AAV9-
eGFP or vehicle, same for AAV9-Cre. One-Way ANOVA with Tukey’s multiple comparisons 
correction was used to compare in vitro transduction after incubating with different titres of 
AAV9-GCaMP6s. 
For in vitro calcium imaging experiments, One-Way ANOVA with Tukey’s multiple comparisons 
correction was used to compare the amplitude of neuronal responses for each stimulus before 






2.3.1 AAV9-eGFP delivery by lumbar puncture transduced over 50% of L4 DRG neurons  
Initially, we performed intrathecal delivery of AAV9-eGFP via a lumbar puncture to transduce 
DRG neurons. Mice were injected via percutaneous lumbar puncture with 5 µl of AAV9-eGFP at 
2.5x1013 gc/ml and incubated for 30 days. We found that transduction efficiency was not 
uniform across DRG levels. It was highest at the lumbar (52.41% ± 5.07%) and cervical levels 
(52.97± 7.29%), while at the thoracic level it was considerably lower (24.73% ± 6.49%) (Fig. 2.1 
a-d). Further, we investigated the cell size distribution of the transduced DRG neurons and 
found that there is no difference in size between AAV9-eGFP transduced and all L4 DRG 
neurons (Fig. 2.1 e), suggesting that AAV9 does not have a preference for neurons of a 
particular diameter. We also investigated transduction of the spinal cord. We observed a 
strong eGFP signal in the superficial laminae and white matter above the dorsal horns but not 
in the deeper laminae, suggesting that DRG projections into the spinal cord also fill up with 
eGFP. (Fig. 2.1 f).  
Next, we evaluated the influence of the time post injection on the transduction efficiency. 
Mice were injected with 5 µl of AAV9-eGFP at 2.5x1013 gc/ml and incubated for 10, 20, 30 or 
40 days. At the L4 DRG, we observed 0% transduction at 10 days, 21.5% ± 15.8% at 20 days, 
52.41% ± 5.07% at 30 days and 28.9% ± 28.9% at 40 days (Fig. 2.2 a-e). Since there was no 
improvement of efficiency between 30 and 40 days post injection we chose to incubate the 
animals for 30 days in future experiments. Of note, there was a high level of variability in our 
results. The potential reasons for that are discussed in 2.4.1.   
Taken together, or data suggest that lumbar puncture delivery method has moderate 
transduction success with no value higher than 60%. However, the reliability and 
reproducibility were suboptimal (Table 2.4). Therefore, we decided to set up a different 
method of vector delivery to the intrathecal space, which had to allow greater control over the 











AAV9-eGFP 10 days 2 0 0% 
AAV9-eGFP 20 days 2 1 50% 
AAV9-eGFP 30 days 17 9 53% 
AAV9-eGFP 40 days 2 1 50% 
AAV9-mCherry 30 days 4 0 0% 
AAV9-TurboRFP 30 days 2 0 0% 
AAV9-GCaMP6s 30 days 5 3 60% 
AAV9-Cre 30 days 4 1 25% 
AAV8-eGFP 30 days 2 0 0% 
 




Figure 2.1 – Intrathecal delivery of AAV9 via percutaneous lumbar puncture results in DRG 
neuron transduction after 30 days. Animals were injected with 5 ul AAV9-eGFP at 2.5x1013 
gc/ml. Representative IHC images of a) lumbar 4, b) thoracic and c) cervical DRG sections. 
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Sections were stained for β-III-Tubulin (red) and GFP (green). Example of transduced and non-
transduced neurons are marked with black and white arrows respectively. Scale bar = 100 µm.  
d) quantification of transduction efficiency for lumbar (52.51% ± 5.07%, n = 9), thoracic 
(24.73% ± 6.49%, n = 4) and cervical (52.97± 7.29%, n = 3) DRGs. e)  cumulative frequency plot 
of neuronal diameters for all (blue), eGFP-negative (orange) and eGFP-positive (green) L4 DRG 
neurons. Kolmogorov-Smirnov test showed no significant difference in diameter distribution 
between all and eGFP-positive neurons, p-value = 0.146, n = 4. f Representative IHC image of 






Figure 2.2 – Time after intrathecal delivery of AAV9-eGFP via lumbar puncture affects 
transduction efficiency. Animals were injected with 5 ul AAV9-eGFP at 2.5x1013 gc/ml. 
Representative IHC images of lumbar 4 DRG a) 10, b) 20, c) 30 and d) 40 days after virus 
delivery. Sections were stained for β-III-Tubulin (red) and GFP (green). Example of transduced 
and non-transduced neurons are marked with black and white arrows respectively. Scale bar = 
100 um. e quantification of transduction efficiency for lumbar, thoracic and cervical DRGs for 
10 (0%, 0%, 0%, respectively, n=2), 20 (21.5% ± 15.8%, 8.45% ± 8.45%, 10.5% ± 10.5%, 
respectively, n=2), 30 (52.51% ± 5.07%, 24.73% ± 6.49%, 52.97% ± 7.29%, respectively, n = 3-9) 





2.3.2 Intrathecal delivery via a catheter achieves transduction efficiency similar to 
lumbar puncture 
To achieve this, we designed and optimized an intrathecal catheter (see 2.2.4). In this set up, 
the dura was cut after exposure and a thin (~0.2 mm outer diameter) catheter connected to a 
syringe pump was gently inserted into the intrathecal space of an anaesthetized mouse (Fig. 
2.3). We then infused the virus at a set rate of 1.2 µl/min until all the loaded virus was infused. 
Intrathecal targeting was confirmed by insertion of the catheter into the cut in the dura.  
Connecting the catheter to a syringe gave us greater control over the rate of delivery 
compared to a hand-infused system. 
Delivery of AAV9-eGFP using this method produced results similar to that of lumbar puncture, 
with good transduction efficiency at the lumbar (61% ± 6.06%) and cervical (49.86% ± 11.03%) 
DRG levels and worse efficiency at the thoracic (11.5% ± 3.33%) level (Fig. 2.4 a-d). Also, the 
cell size distribution of the transduced L4 DRG neurons closely resembled the cell size 
distribution for all L4 DRG neurons (Fig. 2.4 e, green and blue lines respectively). Although the 
Kolmogorov-Smirnov test showed statistically significant differences in the population 
distribution between eGFP neurons and all neurons (p<0.05, n = 4, Fig. 2.4 e), this may not be 
biologically significant as the difference is minimal. The central terminals of the DRG neurons 
were also labelled with eGFP, as shown by eGFP signal in the superficial dorsal horn and the 
white matter above and between the dorsal horns. There was little eGFP signal in the deeper 
laminae and little transduction of the spinal cord neurons (Fig. 2.4 f), which may indicate that 
the majority of the eGFP signal in the spinal cord comes from projections of transduced DRG 





Figure 2.3 – Intrathecal cannula delivery set up. a) Example picture of an intrathecal cannula 
viral delivery.b) Image taken through the surgery microscope objective, showing the cannula 









Figure 2.4 – Intrathecal delivery of AAV9 via intrathecal cannula results in DRG neuron 
transduction after 30 days. Animals were injected with 5 ul AAV9-eGFP at 2.5x1013 gc/ml. 
Representative IHC images of a) lumbar 4, b) thoracic and c) cervical DRG sections. Sections 
were stained for β-III-Tubulin (red) and GFP (green). Example of transduced and non-
transduced neurons are marked with black and white arrows respectively. Scale bar = 100 um. 
d) Quantification of transduction efficiency for lumbar (61.12% ± 6.06%, n = 11), thoracic 
(11.5% ± 3.33%, n = 5) and cervical (49.86% ± 11.03%, n = 5) DRGs. e) cumulative frequency 
plot of neuronal diameters for all (blue), eGFP-negative (orange) and eGFP-positive (green) in 
L4 DRG neurons. Kolmogorov-Smirnov test showed significant difference in diameter 
distribution between all and eGFP-positive neurons, approximate p-value < 0.0001, n = 4. f) 
Representative IHC image of lumbar spinal cord, stained for NeuN (red) and eGFP (green). Scale 
bar = 500 um. 
 
After confirming that intrathecal delivery via a cannula is as effective as the lumbar puncture 
at transducing L4 DRG neurons, we decided to investigate the influence of time post injection 
on this method. If successful, shorter time period would speed up experimental turn over and 
allow greater flexibility. Reducing the time post injection from 30 days to 14 days did not have 
a significant influence on transduction efficiency of L4 or thoracic DRG neurons (66% ± 3.41% 
vs 61% ± 6.06%, Two-tailed t-test, p = 0.625, n = 5 for L4 and 11.5% ± 3.33% vs 11.8% ± 2.8%, 
Two-tailed t-test, p = 0.96, n = 5 and 2 for thoracic) (Fig. 2.4 e and 2.5 a-b,d). Central terminals 
in the spinal cord were also positive for eGFP (Fig. 2.5 e). However, transduction in the cervical 
region was significantly lower compared to the 30 days post injection (16% vs 50%, Two-tailed 
t-test, p = 0.0439, n = 5) (Fig. 2.4 e and 2.5 c-d).  
Further reduction of the post injection time period to 7 days did not significantly reduce 
transduction efficiency in either L4 (58% vs 61%, Two-tailed t-test, p = 0.77, n =6) or cervical 
(61% vs 50%, Two-tailed t-test, p = 0.971, n = 5) DRGs compared to 30 days (Fig. 2.4 e and 2.6 
a-c). We did not check labelling in the thoracic DRGs. EGFP labelling of the central terminals 
was also present, but mostly restricted to the superficial laminae (Fig. 2.6 d). These 
experiments suggest that the previously observed lack of transduction at shorter post injection 





Figure 2.5 – L4 DRG neuronal transduction after 14 days is similar to that after 30 days. 
Animals were injected with 5 µl AAV9-eGFP at 2.5x1013 gc/ml. Representative IHC images of a) 
lumbar 4, b) thoracic and c) cervical DRG sections. Sections were stained for β-III-Tubulin (red) 
and GFP (green). Example of transduced and non-transduced neurons are marked with black 
and white arrows respectively. Scale bar = 100 µm. d) Quantification of transduction efficiency 
for lumbar (65.83% ± 3.41%, n = 5), thoracic (11.08% ± 2.8%, n =2) and cervical (15.64% ± 
9.14%, n = 5) DRGs. e) Representative IHC image of lumbar spinal cord, stained for NeuN (red) 






Figure 2.6 – Majority of lumbar and cervical DRG neurons are transduced 7 days after 
intrathecal injection of AAV9-eGFP using the intrathecal catheter method. Animals were 
injected with 5 µl AAV9-eGFP at 2.5x1013 gc/ml. Representative IHC images of a) lumbar 4 and 
b) cervical DRG sections. Sections were stained for β-III-Tubulin (red) and GFP (green). Example 
of transduced and non-transduced neurons are marked with black and white arrows 
respectively. Scale bar = 100 µm. c) Quantification of transduction efficiency for lumbar (58.5% 
± 3.93%, n = 6) and cervical (50.32% ± 5.25%, n = 5) DRGs. d) Representative IHC image of 
lumbar spinal cord, stained for NeuN (red) and eGFP (green). Scale bar = 500 µm.  
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2.3.3 The viral titre of AAV9-eGFP influences the transduction efficiency in DRG neurons 
Next, we wanted to know what effect the viral titre had on transduction efficiency. To evaluate 
this, we assessed the transduction efficiency of AAV9-eGFP 30 days after intrathecal cannula 
delivery of either 0.25, 0.5, 1.25 or 2.5 x1013 gc/ml. The L4 DRG transduction efficiencies with 
these titres were 32.53% ± 16.35%, 43.27% ± 9.99%, 61.48 % ± 4.36% and 61.12% ± 6.06%, 
respectively. Decreasing the titre had no significant impact on transduction efficiency in L4 
DRG, however this may be due to high variability of lower-titre data (Fig. 2.7 a-e, One-Way 
ANOVA, p = 0.15, n = 3 - 11). In addition, linear regression of the percentage of transduced 
neurons in L4 DRG shows a positive trend with increasing titre, suggesting that titre and 
transduction efficiency may have a positive linear relationship (slope = 17.31 ± 3,635, R square 
= 0.919) (Fig. 2.7 f).  
After carrying out characterization of AAV9-eGFP transduction, our stock of 2.5x1013 gc/ml 
AAV9-eGFP was depleted. The next batch that was purchased from the supplier was of lower 
titre (6.39x1012 gc/ml).  Since our experiments suggested that lower titre may reduce the 
transduction efficiency, we investigated the transduction efficiency of the new AAV9-eGFP 
titre after 30 days post injection. The transduction efficiency in the L4 DRG 30 days after 
delivery did not significantly differ between 6.39x1012 gc/ml and 2.5x1013 gc/ml AAV9-eGFP 
(Fig. 2.8 a,e, 58% vs 61%, Two-tailed t-test, p = 0.61, n = 11-15). However, the transduction 
efficiency in thoracic and cervical regions was significantly reduced comparted to 2.5x1013 
gc/ml AAV9-eGFP (0.6% ± 0.3% vs 11.5% ± 3.33%, Two-tailed t-test p<0.05, n = 5-14 for 
thoracic, 7.91% ± 4.23% vs 49.9% ± 11.03%, Two-tailed t-test p<0.05, n = 5-14 for cervical,  Fig. 
2.4 b,c,e and 2.8 b-d). We also investigated whether lowering the titre would impact eGFP 
signal in the spinal cord. Similar to high-titre AAV9-eGFP, there was eGFP signal in the lumbar 
dorsal spinal cord, but there was no evidence of eGFP-NeuN double-positive cells, suggesting 
that transduction with AAV9-eGFP is restricted to DRG neurons, and the eGFP signal observed 
in the spinal cord comes from the projections of DRG neurons (Fig. 2.8 e). These data suggest 
that the new lower-titre (6.39 x1012 gc/ml) AAV9-eGFP is as efficient at transducing L4 DRG 
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neurons as the high-titre virus, however transduction at thoracic and cervical levels is 
significantly worse. 
Next, we wanted to investigate whether the serotype 9 of the AAV has a preference for a 
particular sub-population of DRG neurons, as we have found significant difference in the 
cumulative frequency distribution of the neuronal diameter of transduced neurons Therefore, 
we quantified transduction rates among the different sub-populations of DRG neurons, namely 
large (neurofilament 200 (NF200)-positive), small peptidergic (CGRP-positive) and non-
peptidergic (IB4-positive) neurons in mice injected with AAV9-eGFP. We found no significant 
difference in the distribution of marker-positive neurons between eGFP-positive neurons and 
all DRG neurons (One-way ANOVA with Tukey’s Multiple comparisons correction; 42.23% ± 
4.34% vs 32.21% ± 2.16%, p = 0.124, n = 10 for CGRP; 32.21% ± 3.32% vs 31.19% ± 3.0%, p = 
0.97, n = 10 for NF200; 24.98% ± 1.31% vs 27.54% ± 1.25%, p = 0.983, n = 10 for IB4; Fig. 2.9 a-
d,). This suggests that AAV9 is effective in transducing a large proportion of L4 DRG neurons 






Figure 2.7 – Viral titre affects transduction efficiency after 30 days. Representative IHC 
images of lumbar 4 DRG 30 days after 5 ml AAV9-eGFP injection at a) 2.5x1012, b) 5.0x1012 , c) 
1.25x1013 and d) 2.5x1013 gc/ml. Sections were stained for β-III-Tubulin (red) and GFP (green). 
Example of transduced and non-transduced neurons are marked with black and white arrows 
respectively. Scale bar = 100 µm. e) quantification of transduction efficiency for lumbar, 
thoracic and cervical DRGs at various virus titres. The number of L4 neurons transduced from 
lowest to highest titre were 32.53% ± 16.35% (n = 3), 43.27% ± 10% (n = 3), 61.48% ± 4.36% (n 
= 3) and 61.12± 6.06% (n = 11). f) Linear regression of L4 DRG transduction efficiency plotted 






Figure 2.8 – Decreasing viral titre does not significantly impact lumbar transduction but 
reduces thoracic and cervical transduction.  Animals were injected with 5 µl AAV9-eGFP at 
6.39x1012 gc/ml. Representative IHC images of a) lumbar 4, b) thoracic and c) cervical DRG 
sections. Sections were stained for β-III-Tubulin (red) and GFP (green). Example of transduced 
and non-transduced neurons are marked with black and white arrows respectively. Scale bar = 
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100 µm. d) Quantification of transduction efficiency for lumbar (58.1% ± 2.36%, n = 15), 
thoracic (0.636% ± 0.26%, n = 14) and cervical (7.91% ± 4.23%, n = 14) DRGs. e) Representative 
IHC image of lumbar spinal cord, stained for NeuN (red) and eGFP (green). Scale bar = 500 µm. 




Figure 2.9 – Transduction is not selective for DRG neuronal subpopulations. Animals were 
injected with 5 µl AAV9-eGFP at 6.39x1012 gc/ml. Representative IHC images of lumbar 4 DRG 
sections. Sections were stained for GFP (green) and a) CGRP (red), b) NF200 (red) or c) IB4 (red). 
Example of transduced and non-transduced neurons are marked with black and white arrows 
respectively. Scale bar = 100 µm. d) Quantification of the number of cells stained for the 
different markers. There was no significant difference in the proportion of total neurons and 
eGFP-positive neurons co-labelled with subpopulation markers (One-way ANOVA with Tukey’s 




2.3.4 Impact of surgical procedure and viral transduction on mechanical sensitivity and 
DRG immune cell composition 
Further, we wanted to elucidate whether intrathecal delivery of AAV9-eGFP via an intrathecal 
cannula had any undesired side effects, such as pain or an immune response. Intrathecal 
delivery of AAV9 via a cannula is an invasive procedure. Extreme care must be taken when 
performing it, as the cannula insertion into the intrathecal space could compress or damage 
the spinal cord, potentially causing pathology, which would undermine the experiment. To 
minimise the potential damage to the spinal cord, we used the smallest cannula size possible. 
In order to evaluate the impact of the procedure and AAV9 transduction on mechanical 
sensitivity we used an established sensory test, the Von-Frey Test. After 3 baseline 
assessments over one week, mice were split into 2 groups of 8 and injected with either AAV9-
eGFP or saline. Their mechanical thresholds were then assessed up to 34 days after injection 
(Fig. 2.10). This experimental set up also allowed us to evaluate the effect of the surgical 
procedure by comparing the baseline (0.66g ± 0.035) to the timepoint after surgery of the 
vehicle injected animals (0.66g ±  0.05, 0.74g ±  0.05, 0.7g ±  0.06, 0.63g ±  0.05, 0.64g ±  0.04 
and 0.64g ±  0.02 for 4-, 7-, 14-, 20- 26- and 34-day timepoints). We found no significant 
difference between the baseline value and the value for any timepoint after vehicle injection 
(One-way ANOVA with Dunnett’s multiple comparisons correction, p = 0.71 – 0.99, n=8). Our 
data suggest that our surgical procedure does not result in a mechanical sensory deficit. 
Furthermore, there was also no evidence that AAV9-eGFP infusion results in a mechanical 
sensory deficit, as there is no significant difference between the two groups at any timepoint 
(One-way ANOVA with Sidak’s Multiple comparisons correction, p = 0.08 – 0.99, n = 8 per 
group).  
Since expression of non-self protein in DRG neurons has been reported to cause an immune 
response in primates (Ciesielska et al., 2013; Yang et al., 2016) , we next investigated the 




Figure 2.10 – Neither intrathecal cannula delivery nor AAV9-eGFP transduction change 
mechanical sensitivity. Mechanical sensitivity was assessed using the Von Frey test. For the 
vehicle-treated group, there was no difference between any timepoint and the baseline, 
suggesting that the intrathecal cannulation procedure itself does not produce significant 
change in mechanical sensitivity (One-Way ANOVA with Tukey’s Multiple comparisons 
correction, p > 0.76 – 0.99, n = 8). Additionally, there was no significant difference in 
mechanical thresholds between vehicle and AAV9-eGFP injected animals at any timepoint, up 
to 34 days post injection (DPI) (One-way ANOVA with Tukey’s Multiple comparisons correction, 
p > 0.08, n = 8 animals in each group).  
 
proceeded to compare the immune cell composition of DRGs from virus- or vehicle-injected 
mice by flow cytometry. We harvested and dissociated lumbar DRGs 30 days after injection. 
Cells were then stained using a panel of immune cell markers (see 2.2.12) and their absolute 
numbers were analysed using flow cytometry. Our gating strategy is shown in Fig. 2.11 a. 
There was no significant difference in the number of marker-positive cells between AAV- and 
vehicle-treated groups (CD45+ immune cells 66.9 vs 64.6; B cells 4.08 vs 4.6; T cells 28.9 vs 
13.79; Neutrophils 0.13 vs 0.26; Dendritic cells 0.122 vs 0.09; Macrophages 28.13 vs 32.68; 
Monocytes 3.49 vs 1.85; One-way ANOVA with Sidak’s Multiple comparisons correction, p = 
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Figure 2.11 – Viral transduction does not cause significant changes in the immune cell profile 
of the L4 DRGs. Mice were injected with 5 µl of 6.39x1012 gc/ml of AAV9-eGFP or vehicle 14 
days before tissue collection for flow cytometry. a) Example of gating strategy that was used to 
obtain cell counts from AAV9-eGFP or vehicle-treated mice. b) Quantification of cell number for 
AAV9-eGFP and saline injected mice. There was no significant difference between any types of 





2.3.5 AAV8 is less efficient than AAV9 at transducing DRG neurons after intrathecal 
delivery 
After establishing that AAV9 was efficient at transducing lumbar DRG neurons at different 
timepoints and titres, we next assessed DRG neuronal transduction with a different AAV 
serotype. We investigated the transduction efficiency of high titre (1.78x1013 gc/ml) AAV8-
eGFP 30 days after intrathecal injection. 35.16% ± 7.37% of L4 DRG neurons were transduced, 
which is significantly lower than the proportion of neurons transduced with AAV9-eGFP (58.1% 
± 2.36%, Two-tailed t-test, p = 0.0009, n = 5).  Cervical and thoracic transduction was very low, 
5.72% ± 3.5%, and 0%, respectively (Fig. 2.12). The difference in transduction efficiency may be 










Figure 2.12 - Intrathecal delivery of AAV8-eGFP results in lower transduction of DRG neurons 
compared to AAV9. Mice were injected with 5 µl of AAv8-eGFP at 1.78x1013 gc/ml. a) 
Representative IHC images of lumbar 4 DRG sections. Sections were stained for β-III-Tubulin 
(red) and GFP (green). Example of transduced and non-transduced neurons are marked with 
black and white arrows, respectively. Scale bar = 100 µm. b) Quantification of transduction 
efficiency of AAV8-eGFP for lumbar (35.16% ± 7.36%, n = 5), thoracic (0.00% ± 0.0%, n = 5) and 
cervical (5.72% ± 3.49%, n = 5) DRGs. There was a significant difference in L4 transduction 
compared to AAV9-eGFP (35.16% ± 7.36% vs 58.1% ± 2.36%, Two-tailed t-test, p = 0.0009 n = 5). 
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2.3.6 AAV9 can deliver transgenes other than eGFP 
As AAV8 was found to be less efficient at transducing DRG neurons, we decided to continue 
using AAV9. Next, we tested if a transgene other than eGFP could be successfully expressed 
and compared its expression to eGFP expression. We used AAV9-mCherry to express a red 
fluorophore in the DRGs. Expression of mCherry in the L4 DRG 30 days after injection was not 
significantly different from eGFP expression 30 days after AAV9-eGFP injection (64.48% ± 
9.57% and 58.1% ± 2.36%, respectively, Two-tailed t-test, p = 0.345, n = 3) (Fig. 2.13).  
After that, we investigated whether co-transduction of two different viral vectors was possible 
and how this would impact the transduction pattern. Animals were injected simultaneously 
with 2.5 µl each of AAV9-eGFP and AAV9-mCherry.  Overall, percentage of L4 DRG neurons 
expressing either eGFP or mCherry following co-transduction was not significantly lower than 
after transduction with AAV9-eGFP or AAV9-mCherry alone (52.38 ± 11.25% vs 58.1 ± 2.36% 
and 59.9% ± 9.77% vs 64.5 ± 9.57%, respectively; One-way ANOVA with Sidak’s multiple 
comparisons correction, p = 0.73 and 0.34, respectively, n = 4; Fig. 2.14b and Fig. 2.13b). The 
percentage of L4 DRG neurons that expressed both eGFP and mCherry was 39.28% ± 12.13% 
(Fig. 2.14b). The number of eGFP positive cells expressing mCherry and mCherry positive cells 
expressing eGFP was similar, 68.1% ± 7.92% and 71.45% ± 9.89%, respectively (Fig. 2.14b).  
Overall, there was no indication of one viral vector interfering with another. 
Detailed above are a number of experiments investigating the efficacy of intrathecal infusion 
of AAV9 using a cannula, varying post injection time, virus titre and transgene. Our data shows 
that AAV9 is a good serotype to get roughly 60% transduction in the lumbar DRGs. We have 
shown that a titre of 2.5x1013 gc/ml is ideal but can be reduced to 6.39x1012 gc/ml without 
significant impact on transduction. We also found that post injection time of 30 days is 
sufficient, however this can also be reduced without significant impact on lumbar DRG 
transduction. Overall, this method of delivery of AAV9 resulted in the average success rate of 




Figure 2.13 – AAV9-mCherry achieves transduction efficiency comparable to AAV9-eGFP in L4 
DRG. Animals were injected with 5 µl AAV9-mCherry at 1.49x1013 gc/ml and compared to our 
data for L4 DRG transduced with 6.39x1012 gc/ml AAV9-eGFP. a) Representative IHC image of 
lumbar 4 DRG section. Sections were stained for β-III-Tubulin (green) and RFP (red). Example of 
transduced and non-transduced neurons are marked with black and white arrows, respectively. 
Scale bar = 100 µm. b) Quantification of transduction efficiency for mCherry (64.48% ± 9.57%, n 
= 3). There was no significant difference compared to AAV9-eGFP transduction (Two-tailed t-






Figure 2.14 – Combined intrathecal delivery of AAV9-eGFP and AAV9-mCherry results in both 
fluorophores being expressed in L4 DRG neurons. Animals were injected with 2.5 µl AAV9-
eGFP at 6.39x1012 gc/ml and 2.5 µl of AAV9-mCherry at 1.49x1013 gc/ml. a) representative IHC 
image of lumbar 4 DRG section. Sections were stained for RFP (red) and GFP (green). Example 
of double-transduced and RFP+ and GFP+ neurons are marked with dashed, white and black 
arrows respectively. Scale bar = 100 µm. b) Quantification of transduction for fluorophores, 
both individually and as a proportion of co-transfected cells. No significant difference between 
GFP+ and RFP+ (Two-tailed T-test, p =0.22, n = 4) or %GFP+ cells that are RFP+ and %RFP+ cells 













AAV9-eGFP 2.5x1013 7 days 7 6 86% 
AAV9-eGFP 2.5x1013 14 days 7 5 71% 
AAV9-eGFP 6.39x1012 14 days 10 10 100% 
AAV9-eGFP 2.5x1013 30 days 10 10 100% 
 
1.5x10
13 30 days 3 3 100% 
 
6.39x10
12 30 days 13 12 92% 
 
2.5x10
12 30 days 3 2 67% 
AAV9-mCherry 1.49x1013 30 days 3 3 100% 
AAV9-GCaMP6s 1.69x1013 30 days 5 5 100% 
AAV9-GCaMP6s 1.69x1013 14 days 12 12 100% 
AAV9-Cre 3.29x1013 40 days 4 4 100% 
AAV9-Cre 3.29x1013 30 days 7 7 100% 
AAV9-Cre 3.29x1013 14 days 5 4 80% 
AAV8-eGFP 1.78x1013 30 days 5 5 100% 
 
Table 2.5 – Summary table for intrathecal cannula delivery success. 
 
2.3.7 Peripheral delivery of AAV9-eGFP successfully transduces DRG neurons 
After our success with the intrathecal delivery method, we explored other avenues of AAV9 
vector delivery. In particular, we were interested in transducing sensory neurons by virus 
injection into distinct anatomical structures. First, we injected 1 µl of AAV9-eGFP into the 
sciatic nerve. After 12 days, there was moderate labelling (21.48% ± 2.33%) in L4 DRG 
ipsilateral to the injection, while labelling on the contralateral side was absent (Fig. 2.15 a-c). 
This suggests that intraneural injections may be a feasible method of labelling an anatomically 
distinct population of DRG neurons. 
We also performed intraarticular and intraplantar injections of AAV9-eGFP. Labelling on the 
ipsilateral side was present, however minimal, in L3 DRG neurons after intraarticular (1.05% ± 
0.27%, Fig. 2.16 a) and in L4 DRG neurons after intraplantar (3.83% ± 1.44%, Fig. 2.17 a) 
injections. Furthermore, both intraarticular and intraplantar delivery methods resulted in 




Figure 2.15 – Intrasciatic injection of AAV9-eGFP results in eGFP signal on the ipsilateral side 
12 days after injection. Animals were injected with 1 µl AAV9-eGFP at 6.39x1013 gc/ml. 
Representative IHC images of lumbar 4 DRG a) ipsilateral and b) contralateral to injection. 
Sections were stained for β-III-Tubulin (red) and GFP (green). Example of transduced and non-
transduced neurons are marked with black and white arrows respectively. Scale bar = 100 µm. 
c) quantification of L4 transduction on ipsilateral (21.48% ± 2.33%, n = 5) and contralateral 
(0.00%, n = 5) sides. There was a significant difference between ipsilateral and contralateral L4 
transduction (Two-tailed t-test, p < 0.0001, n = 5). 
 
and 2.17 b). Further refinement of the injection technique as well as the injection parameters, 









Figure 2.16 – Intraarticular injection of AAV9-eGFP results in low transduction efficiency on 
both ipsi- and contralateral sides 14 days after injection. Animals were injected with 0.5 µl 
AAV9-eGFP at 6.39x1013 gc/ml. Representative IHC images of L3 DRG a) ipsilateral and b) 
contralateral to injection. Sections were stained for β-III-Tubulin (red) and GFP (green). 
Example of transduced and non-transduced neurons are marked with black and white arrows 
respectively. Scale bar = 100 µm. c) Quantification of L3 neuronal transduction on ipsilateral 
(1.045% ± 0.28%, n = 4) and contralateral (0.33% ± 0.14%, n = 4) sides. There was no significant 






Figure 2.17 – Intraplantar injection of AAV9-eGFP results in low transduction efficiency on 
both ipsi- and contralateral sides 28 days after injection. Animals were injected with 5 µl 
AAV9-eGFP at 6.39x1013 gc/ml. Representative IHC images of L4 DRG a) ipsilateral and b) 
contralateral to injection. Sections were stained for β-III-Tubulin (red) and GFP (green). 
Example of transduced and non-transduced neurons are marked with black and white arrows 
respectively. Scale bar = 100 µm. c) Quantification of L4 neuronal transduction on ipsilateral 
(3.83% ± 1.44%, n = 3) and contralateral (4.57% ± 0.95%, n = 3) sides. There was no significant 






2.3.8 AAV9 transduces adult DRG neurons in vitro 
In addition to in vivo applications, we studied AAV9 as a useful tool to transduce adult DRG 
neurons in vitro. To explore in vitro transduction efficiency, we first transduced MACS-purified 
DRG cultures, which are neuronally-enriched (Thakur et al., 2014). We used these neuronally 
enriched cultures to maximise neuronal transduction by removing any non-neuronal cells that 
may reduce the number of viral particles available to neurons. After neurons were extracted 
and MACS-sorted, virus or vehicle was added to cell suspension and incubated for 20 minutes. 
A high number of viral particles (6.39x109 gc AAV9-eGFP per 100 µl cell suspension) was used 
to increase the chance of successful transfection. Transduction efficiency was evaluated three 
days after. 78.9% ± 0.6% of neurons were transfected and no eGFP positive neurons were 
detected in the control samples (Fig. 2.18 a-c). 
Next, we transfected MACS purified adult DRG cultures using a vector that expressed a 
different transgene, the Cre-recombinase. Cre recombinases can be used to control gene 
expression by cutting out LoxP sites and therefore excising the DNA sequence located between 
LoxP sites. To assess the efficiency of AAV9-Cre transduction as well as Cre functionality in vitro, 
we used MACS purified and cultured DRGs from GCaMP6s-floxed-STOP-cassette mice. Cells 
that were successfully transduced and expressing a functional Cre-recombinase will lose the 
STOP sequence and express GCaMP6s. 3 days after virus treatment we fixed the cells and 
stained for GFP, which is a part of GCaMP6s and can be used to detect it. Analysis of the 
staining revealed that there was a high proportion (67.45% ± 6.75%) of GCaMP6s-positive 
neurons 3 days transfection. There was a low percentage of GFP-positive neurons in the 
control coverslips (1.4% ± 1.4%, Fig. 2.19 a-c). 
Lastly, we tested whether neuronal transduction was affected by the presence of non-
neuronal cells in the culture. We transfected mixed DRG cultures with varying titres of AAV9-
GCaMP6s and examined GCaMP6s expression 24 hours later. We found highest transduction at 




Figure 2.18 – AAV9-eGFP can transduce DRG neurons in vitro. DRGs from all spinal levels were 
collected and MACS-purified before incubation with 6.39x109 gc of AAV9-eGFP or vehicle for 3 
days. Total virus 6.39x109 gc per 100 µl. Representative ICC images of MACS DRG neurons in 
culture with a) AAV9-eGFP or b) vehicle after 3 days in vitro. Sections were stained for β-III-
Tubulin (red) and GFP (green). Example of transduced and non-transduced neurons are marked 
with black and white arrows respectively. Scale bar = 100 µm. c) Quantification of transduction 
for cultures with eGFP (78.9% ± 0.6%) and vehicle (0.00%). There was a significant difference in 
transduction between vehicle and AAV9-eGFP cultures (Two-tailed t-test, p <0.0001, n = 3765 
neurons, 2 coverslips each, 1 animal). 
 
decreased with lower viral titre (Fig. 2.20 a-e). Compared to a 3-day culture with AAV9-Cre, 
there was no significant difference in the percentage of transduced neurons (Two-tailed t-test, 
p = 0.95, n = 2 coverslips each), suggesting that 1 day incubation period is sufficient for 
transduction with AAV9 in vitro. It also suggests that the presence of non-neuronal cells does 
not reduce the percentage of transduced DRG neurons, which may be due to the neuronal 





Figure 2.19 – Cre recombinase is functional in DRG neurons as early as 3 days after in vitro 
transduction with AAV9-Cre. Transgenic mice where GCaMP6s expression is under control of a 
Cre recombinase were used to assess AAV9-Cre functionality in vitro. DRGs form all spinal levels 
were collected from GCaMP6s-floxed-STOP-cassette transgenic mice and MACS-purified before 
incubation with 3.29x1010 gc of AAV9-Cre. Total virus 3.29x1010 gc per 100 µl. Representative 
ICC images of MACS DRG neurons in culture with a) AAV9-Cre or b) vehicle after 3 days in vitro. 
Sections were stained for β-III-Tubulin (red) and GFP (green) (to enhance the green GCaMP6s 
signal). Example of transduced and non-transduced neurons are marked with black and white 
arrows respectively. Scale bar = 100 µm. c) Quantification of transduction efficiency for cultures 
treated with AAV9-Cre (67.45% ± 6.75%) and vehicle (1.4% ± 1.4%). There was a significant 
difference in transduction between vehicle and AAV9-eGFP cultures (Two-tailed t-test, p = 






Figure 2.20 – Transgene expression in mixed DRG culture is present as early as 1 day in vitro 
following transduction with AAV9-GCaMP6s and is influenced by viral titre. DRGs from all 
spinal levels were collected and cultured before addition of 1.54x1010 , 3.08x109 , 1.54x109  or 
7.7x108 gc of AAV9-GCaMP6s to 100 µl of cell suspension. a-d) Representative ICC images of 
mixed DRG neuronal culture with decreasing concentrations of AAV9-GCaMP6s after 1 day in 
vitro. Sections were stained for β-III-Tubulin (red) and GFP (green) (to enhance the GCaMP6s 
signal). Example of transduced and non-transduced neurons are marked with black and white 
arrows respectively. Scale bar = 100 µm. e) Quantification of neuronal transduction for cultures 
with decreasing AAV9-GCaMP6s titres. Transduction efficiency ranged from 66.89% ± 4.30% (n 
= 2971 neurons over 2 coverslips, 1 animal) for highest titre and 4.9% (n = 1007, 1 coverslip 
from 1 animal) for the lowest titre. There was a significant difference in transduction between 






2.4.1 Methods of intrathecal delivery 
The first intrathecal delivery method that we assessed in this study was LP. This is a well-
established intrathecal delivery method that was applied in a large number of studies in 
several fields, including pain (Hayek and Hanes, 2014; Ver Donck et al., 2014; Wang et al., 
2015).  
It allows quick and relatively simple access to the intrathecal space and is applicable to a wide 
range of experimental species and humans. In mice, this method was first described by Hylden 
& Wilcox in 1980 (Hylden and Wilcox, 1980). The surgical procedure does not require extensive 
preparation or specialised equipment and only takes a couple of minutes, reducing the amount 
of stress the animal is subjected to. Furthermore, it is a relatively non-invasive procedure, 
compared to other methods of accessing CSF and CNS, e.g. ICV or CM. Lastly, with sufficient 
experience this technique can be used for repeated administration (Fairbanks, 2003). However, 
LP also has several disadvantages. For instance, it is not possible to confirm needle placement 
in the correct location. This increases the probability of positioning the needle outside of the 
intrathecal space, as well as possible spinal cord damage caused by inserting the needle too far 
into the intrathecal space. Finally, if the needle is withdrawn too fast the negative pressure will 
carry most of the injected substance back out of the intrathecal space. 
In our hands, delivery of AAV9-eGFP via LP produced extensive transduction in the lumbar DRG, 
as well as cervical DRGs. However, the success rate for this technique was sub-optimal. We 
had to uncover the reason for the low success rate in order to try to improve the experimental 
technique. All injections were performed by Dr Clive Gentry, who is highly skilled in LPs. 
Therefore, we ruled out incorrect needle placement as the reason for low success rate. After 
consulting with Dr Gentry, we concluded that a probable cause was difficulty in accurate 
loading of the syringe and delivering such small volumes of virus.  
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To circumvent this problem, we then used an intrathecal catheter to deliver the AAV vector. 
Intrathecal catheter implantation is a technique that is often used to allow access to the 
intrathecal space for chronic treatments without the need for repeated surgery. We have 
adapted this technique to use a lumbar level catheter to deliver a single infusion of the virus 
into the intrathecal space, after which it is withdrawn. The strengths of this technique 
addresses some of the disadvantages listed above for LP. Firstly, by using methylene blue we 
could visualise the otherwise transparent dura, making it easier to manipulate. The coloured 
dura can be lifted, and the catheter inserted into the intrathecal space, allowing visual 
verification of placement. Secondly, by connecting the catheter to a syringe pump we could 
precisely control the injection speed, allowing us to infuse the virus at rates unachievable with 
hand-held syringes. This is important, since it has been shown that the virus infusion rate 
influences the transduction pattern (D. Li et al., 2017). Furthermore, the syringe pump allowed 
us to keep the infusion rate consistent across all experiments. Thirdly, it is easier to ensure the 
correct volume of virus is delivered with this set up, as the catheter is transparent, and we can 
monitor the movement of the meniscus, stopping delivery as soon as it reaches the 5 µl mark. 
Finally, the speed at which the catheter is withdrawn can be controlled with more finesse, 
ensuring that little negative pressure is created and therefore minimising backflow. 
However, this delivery method also has its disadvantages. The catheter insertion procedure is 
not as quick and simple as the LP delivery. It requires more equipment and a dedicated surgery 
set-up, which, combined with the time needed per injection, makes injecting many animals a 
considerable resource investment. Introduction of a catheter into the intrathecal space may 
exert pressure onto the spinal cord, or even damage it if the insertion was not done with the 
necessary care. Considering also the dura exposure and anaesthesia requirement, this 
procedure is quite invasive and stressful for the animal.   
We addressed the mentioned shortcoming by: 1) choosing a catheter that was small enough to 
fit into the intrathecal space without causing damage, but with a large enough inner diameter 
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to avoid being clogged up, and thick walls to prevent excessive bending in the intrathecal 
space to avoid accidental spinal cord damage. 2) Securing the animal with a custom-made 
animal support device in a slightly elevated hunched position, which makes intrathecal space 
more accessible. In addition, it removes the need for the surgeon to support the animal, which 
allows more freedom of movement. This allowed the surgeon to more precisely manipulate 
the dura and place the catheter, further reducing the chance of the catheter damaging the 
spinal cord. 3) Performing the dura exposure in a way that avoids removing any bone, which is 
beneficial for animal recovery. 4) Monitoring all animals for behaviour indicating any spinal 
cord damage.  
In general, the majority of the animals recovered well and showed no signs of spinal cord of 
dorsal root damage. However, spinal cord damage is known to affect mechanical sensitivity, so 
to further assess potential damage to the spinal cord we also tested for mechanical sensitivity 
changes after virus infusion using a Von Frey test (Hoschouer, Basso and Jakeman, 2010; Nees 
et al., 2016). The analysis of our behavioural tests suggested that there is no spinal cord 
damage and that our surgical procedures are carried out with the necessary finesse. However, 
deficits in mechanical sensitivity is not the only sign of spinal cord damage, and further 
behavioural tests are needed to gain more insight into the impact of intrathecal cannulation on 
the animal. For instance, assessment of other sensory modalities, like Hargreaves test for heat 
sensitivity (Hargreaves et al., 1988), as well as motor function tests, such as the beam walk test 
or rotarod (Brooks and Dunnett, 2009), may reveal effects that are not uncovered by the 
mechanical sensitivity Von Frey test. 
Overall, we found that intrathecal delivery of AAV via a catheter produced more reliable and 
repeatable results than the LP delivery. 
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2.4.2 The transduction pattern in the DRGs and the spinal cord after intrathecal AAV 
delivery 
The main aim of this part of my project was to characterise the transduction pattern of AAV9 
in the DRGs and to identify the optimal parameters for variables such as titre or post injection 
time. 
We found high transduction levels in L4 DRGs in almost all experimental conditions, which is in 
agreement with a number of studies (Towne et al., 2009; VulchanovaDaniel, 2012; Xu et al., 
2012; Schuster et al., 2014). When we tested if the viral titre affects the transduction efficiency 
we found evidence of a linear correlation between the viral titre and the transduction 
efficiency of L4 DRGs, with a trend for lower transduction with decreasing titre. However, the 
difference in the mean L4 transduction was not significant. Interestingly, there was almost no 
transduction the in the cervical region when the viral titre was decreased, suggesting that 
DRGs more distal from the injection epicentre are more sensitive to the viral titre. The limited 
transduction efficiency in the thoracic region might be explained by the fact the virus particles 
will be carried by the CSF and both lumbar and cervical levels, are surrounded by abundant CSF 
volumes, while the thoracic region is covered in relatively little CSF. This could result in 
thoracic DRGs being exposed to fewer AAV particles and therefore could explain the relatively 
low transduction efficiency in the thoracic DRGs observed across all our experiments.   
Next, we explored the effect of the time after AAV9 delivery on transduction efficiency. Most 
studies using intrathecal AAV9 administration assessed transduction efficiency or its effect 3-5 
weeks after injection (Snyder et al., 2011; Hirai et al., 2012; Schuster et al., 2014; Bey et al., 
2017). Our first experiments showed high levels of transduction 30 days after injection (61%), 
so we wanted to explore the impact of shorter times post injection. Our results following LP 
delivery showed no transduction with AAV9-eGFP at 10 days and unreliable transduction at 20 
days. In comparison, delivery of AAV9-eGFP via intrathecal cannula produced strong labelling 
in L4 DRG neurons as early as 7 days after injection (58%). This discrepancy may be explained 
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by the lower reliability of the LP method for delivery of small volumes of AAV9, as well as low 
number of animals tested at shorter post injection time periods. The fact that good 
transduction is achievable as soon as 7 days is a great asset, as this considerably speeds up 
experimental turnover, allowing quicker exploration of various experimental avenues, as well 
as reducing the cost of animal housing. 
Most of the characterization in this chapter is performed with AAV9-eGFP. However, we also 
wanted to investigate if the transgene expressed by the AAV impacts the transduction 
efficiency. We assessed the efficiency of AAV9-mCherry at 30 days following intrathecal 
catheter delivery. mCherry is a modified red fluorescent protein (RFP), and, unlike eGFP, its 
signal is in a different spectral channel to neuronal autofluorescence. This makes its expression 
in neurons easier to detect. Our experiments showed that AAV9-mCherry has the same 
labelling efficiency as AAV9-eGFP in L4 DRGs. The red fluorophore is useful in settings where 
the green channel is already taken, such as transgenic lines expressing GFP in particular cell 
types. It’s also possible to use it in combination with other AAVs, each of them delivering 
fluorophores of different colours, for instance for tracing experiments. However, it is 
important to keep in mind that mixing two AAVs for injection will lower each individual virus 
concentration. As the intrathecal injection has a limited volume, using an equal mix of two 
different viruses halves the amount of each individual virus. Our data supports this, as the 
percentage of DRG neurons transduced with either AAV9-eGFP or AAV9-mCherry alone is 
greater, compared to the mixed situation.  
Next, we wanted to assess the effect of the viral serotype on transduction pattern and 
efficiency, since there is abundant evidence in the literature that the viral serotype plays a 
great role in determining these parameters (Mason et al., 2010; Snyder et al., 2011; 
VulchanovaDaniel, 2012). We compared transduction patterns of AAV8-eGFP and AAV9-eGFP 
and observed that AAV9 performed better in transducing sensory neurons. However, there is 
evidence in the literature of AAV8 having stronger tropism for large-diameter NF200 positive 
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DRG neurons (Jacques et al., 2012), so for studies that focus on that DRG neuronal sub-
population, AAV8 may be a more suitable serotype. 
When we stained L4 DRG sections with markers for different neuronal DRG populations we 
discovered no preference of AAV9 for a specific neuronal subtype, implying that serotype 9 
does not preferably transduce any DRG neuronal subtypes in the lumbar region and can 
therefore be used for studies including all neuronal subtypes. However, it has been reported 
that low AAV9 titre preferentially targets large DRG neurons (Schuster et al., 2014), suggesting 
that transduction of DRGs at higher spinal levels may have a different transduction pattern 
since the virus concentration decreases with the distance from the infusion centre. 
Furthermore, other serotypes may have different transduction preferences that can be 
employed to study different neuronal sub-populations in the DRG. For example, AAV8, that has 
a preference for large-diameter DRG neurons (Jacques et al., 2012), may be useful for studying 
proprioception.  
Not only did we find eGFP signal in DRG neurons, but also in the lumbar spinal cord, in 
particular in the dorsal white and grey matter 30 days after AAV9-eGFP delivery. When 
sections were co-stained with NeuN to visualise the cell bodies of spinal neurons, we found 
little to no co-localisation of NeuN and eGFP in spinal neurons. This suggests that all the eGFP 
signal in the dorsal spinal cord came from afferents of transduced DRG neurons. This 
restriction of transduction to DRG neurons is significant, as it allows expression of functional 
transgenes in DRG neurons without impacting the physiology of cells harbouring their cell 
bodies in the spinal cord. However, this finding contradicts several other studies, where 
extensive spinal cord labelling was present after intrathecal delivery of AAV9 (Schuster et al., 
2014; Bey et al., 2017; Hu et al., 2018). There are several possible reasons for this discrepancy. 
Snyder et al investigated how the viral promoter of a transgene influenced the CNS 
transduction pattern after intrathecal delivery of AAV9-eGFP (Snyder et al., 2011). They found 
that extensive labelling of primary afferent projections in the spinal cord can be achieved using 
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either a CBA or a CMV promoter, but labelling of CNS neurons, in particular motor neurons, 
was only observed with a CMV promoter. As the transgene promoter used in our study is CB7, 
a modified version of the CBA promoter, this may explain the absence of transduction of spinal 
cord neurons in our case. Another possible reason is the restrictive properties of the pia mater. 
Miyanohara et al have recently published a study comparing transgene expression after 
subpial or intrathecal delivery of AAV9-eGFP in rodents and pigs. They report extensive 
transduction of neurons and glia throughout the spinal cord segment after subpial delivery, 
while intrathecal delivery produced labelling restricted to the dorsal horn and white matter, 
with only few transduced CNS neurons (Miyanohara et al., 2016). This suggests that the pia 
may form a protective barrier that prevents AAV9 particles from entering the deep spinal cord. 
Indeed, during the early stages of our study, when our technique was not yet refined and the 
risk of damaging the pia or spinal cord was higher, we did occasionally observe labelling of 
spinal cord neurons.  
Interestingly, several studies have shown intrathecal delivery of AAV9 also results in 
transduction in the peripheral tissues, such as liver, heart and ileum (Haurigot et al., 2013; 
Schuster et al., 2014; Bailey et al., 2018). This is likely to be a result of AAV9 leaking into the 
bloodstream and transducing these tissues, likely due to liver and heart having a high affinity 
for AAV9 particles (Sands, 2011; Haurigot et al., 2013). Although we did not conduct a 
thorough experimental investigation of off-target transduction following intrathecal delivery of 
AAV9 using our delivery method, there is some anecdotal evidence encountered during mouse 
dissection that suggests that it results in some transduction in the liver. Further experiments 
looking at the transduction in the peripheral tissues are required to make any conclusions. 
Importantly, this off-target transduction may reduce the specificity of our approach, since cells 
other than primary afferent neurons are transduced. However,  some studies would find this 
off-target transduction beneficial, for instance for correcting pathology such as both in the CNS 
and the periphery (Haurigot et al., 2013). 
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One important aspect of the AAV9-eGFP transduction pattern characterization is the impact 
the eGFP transgene itself has on the transduced cells, and what effect that might have on the 
animal. While eGFP is a relatively simple protein that does not have any functions in the cell 
other than to fluoresce, the rapid increase in the number of foreign protein molecules, 
associated with AAV-driven expression of transgenes, may have a detrimental effect on the 
cell. There are a number of studies showing that overexpression of non-self-protein in both 
rodents and non-human primates with AAV9 can cause an immune response (Mays et al., 
2009; C. Yang et al., 2013; Ciesielska et al., 2013; Samaranch et al., 2014; Hinderer et al., 2018). 
Inflammation observed in these studies was centred around the brain region that was 
overexpressing the transgene. Importantly, the delivery methods utilised in these studies 
result in a very high concentration of viral particles immediately at the injection epicentre. In 
our model, this would cause inflammation and cell death in the DRGs and dorsal spinal cord, 
both targeted by the virus. If there was inflammation this should manifest in behavioural 
alterations, such as mechanical and thermal hyperalgesia. However, our Von Frey data show 
that there is no significant change in the mechanical threshold between AAV9-eGFP and 
vehicle infused groups, for up to 34 days post infusion. Additionally, an immune response 
would result in increased numbers of immune cells in the DRGs. However, when we assessed 
the numbers of several immune cell types in lumbar DRGs with flow cytometry, there was no 
significant difference in any major immune cell category, including lymphocytes and 
macrophages. These findings suggest that intrathecal delivery of AAV9-eGFP and transgene 
expression does not trigger an immune response. It is possible that this is the result of optimal 
transgene expression levels. They are high enough for the detection of a signal, but low 
enough to avoid triggering an immune response. Intrathecal injection of high titre AAV9, unlike 
direct CNS injections, does not restrict the viral particles to a small area, which would result in 
transduction with a higher number of viral particles per cell and stronger transgene 
overexpression. Instead, viral particles are diluted and spread out via the CSF, which helps to 
avoid excessive expression of the transgene. To further assess the immunogenicity of AAV9-
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eGFP, longer-term exposures with regular assessments of mechanical and thermal sensitivity 
could be performed, as that would allow more time for an immune response to be triggered. 
In addition, it is possible that although there is no change in the immune cell composition of 
the DRG, the immune cells already present at the site are activated by the AAV transduction, 
for instance macrophages or microglia (Fischer et al., 2011; Xu et al., 2012). Therefore, future 
experiments must be conducted to assess whether immune cell activation profile in the DRG 
changes following AAV transduction after intrathecal delivery, for instance by assessing Iba1 
immunoreactivity (Xu et al., 2012). 
2.4.3 Transgene expression in the DRG neurons after AAV delivery via different delivery 
routes 
One of the ways that expression of a specific transgene using a viral vector differs from 
transgenic lines is that transduction patterns can be altered by using different delivery 
methods. Confining the virus spread to a specific anatomical structure results in transduction 
restricted to cells in that structure. Using viruses that are capable of retrograde transport, such 
as AAV9 or rAAV2-retro, allows transduction of sensory neurons via injection of the virus to 
the site where these neurons send their projections (Cearley and Wolfe, 2007; Castle, Perlson, 
et al., 2014; Tervo et al., 2016). This enables to study specific neuronal populations (e.g. knee-
joint afferents) in more detail. For instance, expression of fluorescent proteins in specific 
anatomical subpopulations allows precise circuitry interrogation, while expression of 
functional transgenes such as ion channels or other genetically-encoded tools assists in 
studying their physiology. 
We attempted to label specific anatomical subpopulations of sensory neurons by performing 
intraarticular and intraplantar AAV9 injections. Our results showed that a low level of 
transduction was present in both ipsilateral and contralateral DRGs. Expression in the 
contralateral side is likely the result of a virus leakage into the bloodstream, as in the literature 
there is evidence that intramuscular injection of AAV9 results in widespread transduction in 
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the CNS as well as in the contralateral muscle. In that case the cause was found in the virus 
leaking into the bloodstream (Benkhelifa-Ziyyat et al., 2013). In the future, it may be possible 
to reduce off-target labelling by using smaller volumes of more concentrated virus, as well as 
by restricting animal movement right after the injection so that the virus suspension remains 
at the site of injection. Next, we performed intraneural injections of AAV9-eGFP into the sciatic 
nerve with AAV9-eGFP and observed moderate transduction in the ipsilateral L4 DRG with no 
labelling on the contralateral side. This is in line with the literature (Pleticha et al., 2014). 
Similarly, high transduction in the DRG is found after intraganglionic injection of AAV (Fischer 
et al., 2011). However, there is evidence that direct injection of AAV into the DRG causes 
neural damage resulting in behavioural alterations such as thermal hypersensitivity, 
mechanical allodynia and worse motor control (Fischer et al., 2011). 
Further to using different administration routes to target different subpopulations, it is also 
possible to change the transduction pattern of the same injection route by altering the 
parameters. For instance, when studying front limb function or migraine, it is beneficial to 
achieve high levels of transduction in the cervical and trigeminal ganglia. This should be 
possible to achieve by altering the intrathecal infusion route by infusing the virus through the 
atlanto-occipital membrane into the cisterna magna, as this moves the delivery epicentre 
closer to the target ganglia. This method has been used for AAV vector delivery in mice, with 
good transduction in the spinal cord and brain (Sinnett et al., 2017). Unfortunately, the 
authors of this study did not investigate the transduction in the DRG. 
 The primary focus of this project was on the in vivo transduction of DRG neurons with AAV9. 
However, AAV9 is also capable of transducing adult neurons in vitro. We observed transgene 
expression after AAV9-GCaMP6s transduction after only 1 day in culture. Furthermore, we 
explored the specificity of transduction with AAV9 by incubating mixed DRG cultures with 
AAV9-GCaMP6s and observed no difference in the percentage of transduced neurons 
compared to neuronally-enriched cultures. We only observed a small percentage of GCaMP6s-
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positive non-neuronal cells (data not shown), supporting the notion of neuronal tropism of 
AAV9. Transduction in vitro can be a valuable asset for a number of approaches, as it allows 
quick expression of a transgene in a system that can be precisely controlled. For instance, in 
vitro transduction with two fluorophores can be combined with a microfluidics system to study 
neuronal connectivity (Tsantoulas et al., 2013). It can also be used to express proteins that may 
affect neuronal physiology, where a cellular response can be assessed later using readouts 
such as RNA analysis of gene expression and assess their responses with calcium imaging, or 
extract RNA and proteins for western blot/sequencing.  
2.4.4 Methods of influencing transduction pattern 
There are several variables not explored in this study that may influence AAV transduction in a 
way that is beneficial to studying DRG neurons and related neural circuits. Among them is the 
choice of transgene promoter. 
By changing the promoter, it is possible to restrict expression to cells that express genes using 
that specific promoter. There are studies that use transgenes under a control of neuronal-
specific promoter. This can eliminate the chance of off-target expression associated with some 
methods of AAV delivery, such as intravenous injection (Jackson et al., 2016). Others tailored 
the promoter so that the transgene is only expressed in a subset of neurons, such as in the 
tyrosine hydroxylase (TH) positive neurons (Oh et al., 2009; Gompf et al., 2015). The TH 
positive neuron subpopulation in the DRG are small to medium sized neurons that have low 
CGRP and IB4 expression, and are known to play an important part in nociception, so targeting 
this subpopulation may be beneficial to pain research (Brumovsky, Villar and Hökfelt, 2006; 
Brumovsky, 2016). There are also promoters available that can restrict expression to non-
neuronal cells such as glia, e.g. the glial fibrillary acidic protein (GFAP) promoter can be used to 
restrict expression to astrocytes (Dashkoff et al., 2016), or the myelin associated glycoprotein 
(MAG) promoter restricts expression to oligodendrocytes (von Jonquieres et al., 2016). 
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Moreover, even the use ubiquitously-expressed promoters, such as the CMV or CBA promoters, 
can produce different transduction pattern.  One study reported that expression of transgenes 
under the CMV promoter diminishes overtime in the CNS and DRGs. In addition, this study 
reported that the CBA promoter achieved higher transduction in the CNS compared to the 
CMV promoter (Gray, Foti, et al., 2011). 
2.4.5 Conclusion 
In this chapter we have shown that extensive labelling of DRG neurons in mice can be achieved 
by a single intrathecal injection of 5 µl of AAV9-eGFP. Transduction was more reliable and 
consistent when the virus was delivered via an intrathecal catheter compared to by lumbar 
puncture. We found that 60-70 % of L4 DRG neurons were transduced after intrathecal 
injection of AAV9-eGFP (6.39x1012 gc/ml), while cervical DRGs required a higher titre of AAV9 
for efficient transduction. AAV9 also showed no preference for any neuronal DRG sub-
population. We further demonstrated that the transduction profile can be influenced by 
several factors, including titre, post injection time and AAV serotype. Finally, we confirmed 
that intrathecal delivery of AAV9-eGFP via a cannula did not result in adverse side-effects, as it 
did not elicit mechanical hypersensitivity or trigger an immune response in transduced DRGs. 
Overall, this technique is applicable to a wide variety of studies investigating the function and 
pathology of DRG neurons, as it can be used to deliver a wide variety of transgenic tools to 
expand our understanding of pain circuitry. Furthermore, intrathecal infusion can be used to 
deliver functional transgenes, such as a Cre recombinase, that can be used to study various 




Chapter 3: Assessing acute neuronal sensitisation in vitro using 
electrical stimuli 
3.1 Introduction 
In the previous chapter we explored AAV9 transduction capabilities in DRG neurons with 
relatively simple transgenes encoding fluorophores like eGFP or mCherry. We found that both 
in vivo and in vitro application of AAV9 to DRG results in a high proportion of transduced 
neurons. AAV vectors that encode fluorophores are useful for the initial characterisation of the 
AAV transduction, as the use of these transgenes produces an unambiguous and easy-to-
detect indication of successful transduction. In addition, the transgene fills the whole cell, 
making it useful in anatomical interrogations of the nervous system, for instance by 
transducing select neuronal sub-populations via targeted peripheral injections and then 
assessing their central projections in the spinal cord. However, this experimental approach 
does not use one of the core strengths of viral vectors – the ability to deliver a wide variety of 
functional transgenes. AAV vectors are capable of delivering complex transgenic tools that can 
be used in a wide variety of experiments, from those that report neuronal activity (like 
genetically encoded calcium indicators (GECIs)) to those that can influence gene expression 
(like Cre recombinase).  To assess how suitable the AAV9 vector is for delivery of these 
“functional” transgenic tools into the DRG neurons, we decided to use AAV9 to deliver a GECI 
GCaMP6s to primary afferent neurons and to explore its use for in vitro calcium imaging. 
3.1.1 The Importance of calcium ions in neurons 
Calcium ions play a crucial role in regulating a vast number of cellular processes, from 
exocytosis to gene transcription (Berridge, Lipp and Bootman, 2000). In neurons, a sharp 
increase in calcium levels is associated  with membrane depolarisation (Clapham, 2007; Simms 
and Zamponi, 2014). For instance, as seen in dendritic spines after neurotransmitter binding 
(Malinow et al., 1994; Yuste and Denk, 1995), or in the cell body after the initiation of an 
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action potential (Bolsover and Spector, 1986; Simons, 1988; Smetters, Majewska and Yuste, 
1999). These rapid changes in intracellular calcium levels are crucial for neuronal physiology. 
Calcium signalling is of great importance for the generation of post-synaptic potentials in 
dendritic spines after detection of neurotransmitter (Kovalchuk et al., 2000; Bloodgood and 
Sabatini, 2007). Calcium signalling in cell soma is important for modulating neuronal activity 
(Sterratt et al., 2012; Tonini et al., 2013). Moreover, the ability of neurons to communicate to 
each other through the release of neurotransmitters is dependent on local, transient changes 
in presynaptic terminal calcium ion concentration (Adler et al., 1991; Stanley, 1993; 
Bucurenciu et al., 2008; Neher and Sakaba, 2008). It is also crucial for activity-dependent 
regulation of gene transcription that is vital for controlling synaptic strength and long-term 
plasticity (Lyons and West, 2011; Brini et al., 2014). These and many other functions make 
calcium ions one of the most important signalling molecules in neurons (Berridge, Bootman 
and Roderick, 2003; Clapham, 2007). 
There are several sources of calcium in neurons that can contribute to calcium signalling. 
These include both the entry of extracellular calcium ions via ion channels and the release of 
calcium ions from intracellular stores such as endoplasmic reticulum (ER) and mitochondria 
(Verkhratsky and Petersen, 1998; Brini et al., 2014). One of the major contributors to neuronal 
activity-associated rise in intracellular calcium are Voltage-Gated Calcium Channels (VGCC). 
These ion channels are located on the extracellular membrane and are activated by membrane 
depolarization, which allows extracellular calcium ions to enter the cytoplasm (Simms and 
Zamponi, 2014). VGCCs can be divided into  high and low voltage-activated channels (HVA and 
LVA, respectively) (Catterall, 2000). Both types have several functions in the neuron. For 
instance, LVA channels can create a positive-feedback loop of small membrane depolarisations 
causing more LVA calcium channels to open and increase the influx of calcium ions, 
depolarising the membrane further until voltage-gated sodium channels are activated and an 
action potential is triggered (Molineux et al., 2006; Alviña, Ellis-Davies and Khodakhah, 2009). 
HVA channels facilitate calcium ion entry into the presynaptic terminal, where it interacts with 
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the SNARE complex and facilitates exocytosis of neurotransmitter vesicles (Südhof, 2004; 
Catterall, 2011). Calcium ions may also enter a neuron as a direct consequence of a 
neurotransmitter binding to its receptors, for example through N-Methyl-D-Aspartate (NMDA) 
or α-Amino-3-Hydroxy-5-Methyl-4-Isoxazolepropionic Acid (AMPA) receptors that respond to 
glutamate (Kyrozis et al., 1995; Reichling and MacDermott, 1996; Bloodgood and Sabatini, 
2009). These channels are typically found on postsynaptic dendritic spines, and calcium entry 
through these channels is important for long-term regulation of synaptic strength, often in the 
form of long-term potentiation (LTP) (Man, 2011; Wang and Peng, 2016). 
Neurons also possess intracellular calcium stores, mostly in the endoplasmic reticulum (ER) 
and mitochondria, that retain calcium ions within the cell but are isolated from the cytosol, 
preventing them from participating in calcium signalling (Verkhratsky and Petersen, 1998; Brini 
et al., 2014). Release of calcium from these stores can be triggered by neurotransmitters, such 
as glutamate, binding to receptors that can trigger production of a secondary messenger 
molecule, such as inositol-triphosphate production after metabotropic glutamate receptor 
(mGluR) activation (Zirpel, Lachica and Rubel, 1995; Rose and Konnerth, 2001). This secondary 
messenger cascade results in release of calcium ions from the ER, which makes these ions 
available for various signalling pathways in the cell (Coutinho and Knöpfel, 2002; Valenti, 
Jeffrey Conn and Marino, 2002; Niswender and Conn, 2010). 
As calcium signalling is involved in many cellular processes, the calcium ion levels in the cell 
must be tightly regulated. In neurons, the calcium ion concentration is maintained around 100 
nM, but it can increase up to 100-fold during electrical activity associated with neuronal firing 
(Berridge, Lipp and Bootman, 2000). Therefore, the excess calcium ions following neuronal 
firing should be cleared from the cytosol as quickly as possible. The main methods to clear 
cytosolic calcium is to transport it outside of the cell or into cellular compartments that restrict 
its participation in signalling, such as the ER and mitochondria (Brini et al., 2014). The two main 
transmembrane proteins responsible for transporting calcium ions out of the cells are Plasma 
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Membrane Ca2+ ATPase (PMCA) and the Na+/Ca2+ exchanger (NCX). PMCA has high affinity for 
calcium ions but low capacity, therefore its function is mostly to maintain a low concentration 
of intracellular calcium ions at rest. On the other hand, NCX is a low affinity, high capacity 
exchanger that is mostly responsible for quickly reducing high intracellular calcium 
concentration back to resting levels following calcium entry into the cell, e.g. following an 
action potential (Roome, Knöpfel and Empson, 2013; Brini et al., 2014). These two proteins are 
crucial for normal neuronal functioning, and their malfunction is associated with several 
diseases, including Parkinson’s (Kip and Strehler, 2007; Kurnellas, Donahue and Elkabes, 2007; 
Brendel et al., 2014). Another way for the excess calcium ions to be cleared is by uptake into 
endoplasmic reticulum and mitochondria. The main proteins that mediate this are 
sarco/endoplasmic reticulum calcium ATPase (SERCA) for the ER and the mitochondrial calcium 
uniporter (MCU) for the mitochondria (Verkhratsky, 2004; Mammucari et al., 2018). These 
proteins make it possible for ER and mitochondria to act as readily-available calcium ion pools 
that can help fine-tune the calcium signalling pathways in the cell  (Gunter and Pfeiffer, 1990; 
Dupont and Combettes, 2016).  
The cellular machinery described above ensures that the concentration of calcium ions in a 
neuron is tightly regulated. In neurons, the quick rise and fall of calcium that correlates with 
action potential firing makes cytosolic calcium concentration a good proxy for measuring 
neuronal activity. 
3.1.2 Imaging calcium dynamics in neurons 
In the nervous system, neurons communicate with each other via action potentials. This 
communication lies at the core of virtually every aspect of the nervous system and is the 
cornerstone of correct functioning of the whole organism. Recording and studying neuronal 
activity is one of the most widely used methods to interrogate nervous system physiology and 
pathology. Electrophysiological recordings have given us insight into neuronal activity patterns 
in health and disease (Kucyi and Davis, 2017), however they are limited by the low number of 
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neurons that can be recorded simultaneously. To record activity of a large number of neurons 
or neuronal networks, a different approach has to be taken.  
As discussed above, a rise in calcium ion levels in the neuronal cytosol can serve as a proxy for 
action potential and, therefore, neuronal activity. Tools known as calcium indicators provide a 
visual readout of the levels of calcium ions within the cell, and therefore have been widely 
used to study neuronal activity (Grienberger and Konnerth, 2012). When calcium binds to a 
calcium indicator molecule, it causes a conformational change in the indicator molecule that 
results in either emission of light or a change in its fluorescence properties  (Grienberger and 
Konnerth, 2012). Optical imaging of neuronal activity holds several advantages over 
electrophysiological techniques. Firstly, it enables simultaneous imaging of many neurons 
(Ahrens et al., 2013; Ziv et al., 2013; Lecoq et al., 2014). Secondly, it is possible to study a 
specific cell compartment, such as dendritic spines (Korkotian and Segal, 1998; Chiu et al., 
2013; Siegel and Lohmann, 2013). Lastly, electrophysiological techniques often require 
electrode placement close to, or onto the cells of interest, which inevitably damages the tissue. 
Optical recordings using calcium indicators do not require tissue damage past initial exposure 
in vivo, or tissue processing in vitro. There are two types of calcium indicators: calcium dyes 
and genetically encoded calcium indicators (GECI). They are different in the way that they are 
introduced into the cells. Calcium dyes can either be directly loaded into the cell via 
micropipettes, or can be taken up into the cell from the extracellular space (Paredes et al., 
2008; Grienberger and Konnerth, 2012). On the other hand, GECI are transgenic tools that are 
produced by the cell itself, however the sequence encoding them has to be first introduced 
into the cell, either by inserting the sequence directly into the DNA or by using viral vectors for 
its delivery into the cell (Broussard, Liang and Tian, 2014).  
One of the first calcium indicators developed was aequorin, a bioluminescent protein that 
emits a photon of around 470 nm wavelength upon the binding of calcium ions (Shinomura, 
Johnson and Saiga, 1962; Ohmiya and Hirano, 1996). In comparison to fluorescent dyes, 
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aequorin is bioluminescent. This means that the cells are not required to be exposed to light at 
an excitation wavelength in order for the signal to be detected. In turn, this helps to avoid 
phototoxicity and noise due to autofluorescence. In addition, it can be modified to have 
different affinities for calcium ions or to target different subcellular compartments (Montero 
et al., 1995; Alonso, Manjarrés and García-Sancho, 2009). However, only one photon of light is 
produced per aequorin molecule, and the regeneration time of aequorin is relatively long, 
meaning that the emitted light is very dim (Shimomura, Kishi and Inouye, 1993; Baubet et al., 
2000). In addition, aequorin does not readily cross the cell membrane, making its delivery into 
cells problematic. Initially, it had to be loaded into cells through micropipettes or by 
permeabilization procedures, restricting its use to large cells such as muscle fibres (Ridgway 
and Ashley, 1967; Brini, 2008). Since then, the aequorin cDNA has been cloned, making it 
possible to direct its expression to the cells of interest. Many variations of aequorin exist, each 
having different properties and mostly being administered into cells via genetic methods, 
essentially making them a part of the GECI family (Chiesa et al., 2001; Brini, 2008; Bakayan et 
al., 2011). 
Another type of calcium indicators that has been broadly used to study in vitro and in vivo 
neuronal activity are chemical calcium indicators. These are chemically engineered molecules 
that change their fluorescent properties when bound to calcium (Paredes et al., 2008). There 
are many different chemical calcium indicators, each having their own affinity for calcium ions 
and fluorescent properties. Perhaps the most widely used one is Fura-2, a chemical calcium 
dye that can be taken up by the cells from the extracellular environment (Grynkiewicz, Poenie 
and Tsien, 1985). Fura-2 is a ratiometric dye, meaning that it changes the peak excitation or 
emission wavelengths upon calcium binding. Fura-2 that is not bound to calcium is excited by 
light at 340 and 380 nm wavelengths, and emission is between 505 and 520 nm, respectively 
(Tsien, Rink and Poenie, 1985). However, upon calcium binding, excitation shifts towards 340 
nm wavelength, emitting less light at 380 nm excitation wavelength. The change in the ratio of 
emission at 340 and 380 nm is used to quantify the changes in the levels of intracellular 
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calcium ions (Tsien, Rink and Poenie, 1985). The ratiometric nature of Fura-2 means that its 
signal is unaffected by uneven dye distribution between cells, dye leakage and photobleaching, 
as the ratio will stay the same independent of the number of Fura-2 molecules (Paredes et al., 
2008). Furthermore, Fura-2 has been modified to create Fura-2-acetoxymethyl ester (Fura-2 
AM), a dye that can readily cross the cell membrane, significantly increasing the efficiency of 
the dye uptake into the cells (Tsien, 1981; Grynkiewicz, Poenie and Tsien, 1985). This cell 
membrane permeability, coupled with a high signal to noise ratio and ratiometric properties 
has made Fura-2 AM one of the widely used calcium dyes both for in vitro and in vivo calcium 
imaging (Paredes et al., 2008). It has been used to image cortical neurons in vitro (Barreto-
Chang and Dolmetsch, 2009; Mauleon et al., 2013; Calvo-Rodríguez, Villalobos and Nuñez, 
2015; Cameron et al., 2016; Chen et al., 2017), as well as in vivo (Stosiek et al., 2003; Sohya et 
al., 2007). It has also been used to image neuronal activity in DRG neurons in vitro, especially in 
response to addition of various molecules and compounds used in pain research, including 
capsaicin and PGE2 (Thayer, Perney and Miller, 1988; Walker et al., 1988; Eun et al., 2001; Ma 
et al., 2005; Lu and Gold, 2008; Barabas, Kossyreva and Stucky, 2012). 
3.1.3 The use of Genetically Encoded Calcium Indicators (GECI) to image neuronal 
activity 
Despite being popular, chemical calcium dyes have several disadvantages that impede their 
usefulness. For instance, their expression cannot be targeted to a specific sub-population of 
cells, and the sole determinant of the cells labelled is the delivery of the dye (Paredes et al., 
2008; Grienberger and Konnerth, 2012). Furthermore, long-term or chronic imaging of 
neuronal activity in situ or in vivo requires repeated injections of the dye that are damaging to 
the tissue and may reduce the quality of data (Tian et al., 2012; Tian, Hires and Looger, 2012; 
Broussard, Liang and Tian, 2014). However, it is possible to overcome these drawbacks with 
the use of genetically encoded calcium indicators (GECI). 
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GECI are a group of calcium indicators that instead of having to be delivered into the cell can 
be expressed by the cell itself. Therefore, repeated imaging of GECI does not require repeated 
dye application that would be damaging to the tissue, and enables chronic imaging of neuronal 
activity (Mank et al., 2008; Sadakane et al., 2015; Silasi et al., 2016). GECI expression is 
achieved either by inserting the GECI DNA sequence through genetic manipulation into the 
host DNA, e.g. transgenic mouse line generation, or by viral vector-mediated delivery of a 
plasmid carrying the GECI sequence (Grienberger and Konnerth, 2012; Brini et al., 2014). This 
makes it possible to target the GECI expression to a specific cell type or anatomical subset of 
cells. For instance, crossing mice that express GECI under the control of Cre with transgenic 
lines that express Cre in parvalbumin-positive interneurons or retinal neurons will result in 
GECI expression only in those cells (Ivanova, Hwang and Pan, 2010; Madisen et al., 2010; 
Zariwala et al., 2012). In addition, it is possible to use viral vectors such as AAVs to deliver GECI 
sequence to specific cells. In this case the AAV delivery method and serotype will determine 
the transduction pattern (Komiyama et al., 2010; Harvey, Coen and Tank, 2012; Sekiguchi et al., 
2016). Furthermore, the expression of the GECI protein can be put under the control of a cell-
specific promoter to ensure targeted transgene expression. For example, it is possible to 
restrict expression of the GECI to pyramidal neurons in the hippocampus through the use of 
AAV-delivered GECI that is under the control of the CaMKIIα promoter (Ziv et al., 2013).   
All GECI can be split into two groups according to their mode of action: those that use Förster 
resonance energy transfer (FRET) and those that rely on a single fluorescent protein to 
produce signal. FRET-based GECI use two fluorophores that are tethered to each other, with 
the donor fluorophore emitting light of a particular wavelength upon excitation with a laser. 
When calcium binds to a FRET GECI molecule, the conformational change brings the 
fluorophores close together. The close proximity allows the donor to transfer the energy to the 
acceptor fluorophore, making it emit light at a different wavelength from the one emitted by 
the donor. Therefore, upon calcium detection donor fluorescence diminishes while acceptor 
fluorescence increases. The change in the ratio of emissions before and after calcium binding is 
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used to quantify the changes in the intracellular calcium (Jares-Erijman and Jovin, 2003). The 
ratio-based signal means that FRET GECI are ratiometric indicators, which makes them more 
resistant to motion- and uneven loading-related artefacts, which is especially important in live 
animal imaging (Lütcke et al., 2010; Thestrup et al., 2014). The most popular FRET-based GECI 
belong to the Cameleon family, members of which are mostly made up of two fluorescent 
proteins linked together by calmodulin and calmodulin-binding peptide M13, which facilitates 
a conformational change upon calcium binding (Miyawaki et al., 1997). Since its initial 
development in 1997, many different variants of the original Yellow Cameleon (YC) with better 
stability and stronger signal have been designed (Palmer et al., 2011). In addition, new variants 
of Cameleon family GECI have been developed that use Troponin C instead of calmodulin as a 
calcium binding site, reducing the probability of unwanted interactions with endogenous 
proteins (Mank et al., 2006, 2008; Thestrup et al., 2014). However, they have several 
drawbacks. FRET-based GECI suffer from low signal-to-noise ratio and often use blue-yellow 
light that has poor tissue penetrance and is prone to scatter (Miyawaki, 2011; Tian, Hires and 
Looger, 2012; Lin and Schnitzer, 2016). In addition, the use of two fluorescent proteins each 
with a separate set of excitation-emission wavelengths makes FRET-based GECI difficult to use 
in conjunction with any other fluorophores due to signal interference (Miyawaki, 2011).  
In comparison to FRET-based GECI, single fluorescent protein indicators are not ratiometric. 
This class of GECI have only one fluorescent protein in their structure, whose fluorescence 
changes upon calcium binding (Brini, 2008; Grienberger and Konnerth, 2012). Single-
fluorophore GECIs typically show greater signal-to-noise ratio, as well as larger responses than 
FRET-based GECIs. (Lin and Schnitzer, 2016). However, since single-fluorophore GECI are not 
ratiometric, they are more prone to movement artefacts as well as signal variation due to 
differential expression of the GECI (Anderson, Zheng and Dong, 2018).  
The most popular class of single fluorophore GECI is the GCaMP family. The basic structure of 
GCaMP is made up of a circular permutated enhanced green fluorescent protein (cpEGFP), 
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with its N-terminus connected to the M13 fragment of the myosin light chain kinase and the C-
terminus of calmodulin (Nakai, Ohkura and Imoto, 2001). Binding of calcium to calmodulin 
allows it to interact with the M13 fragment, inducing a conformational change in the cpEGFP 
that greatly increases its fluorescence (Baird, Zacharias and Tsien, 1999; Nakai, Ohkura and 
Imoto, 2001). GCaMP has gone through several iterations, each improving its fluorescence 
properties such as basal fluorescence and dynamic range, as well as increasing sensitivity, 
calcium affinity and pH stability (Ohkura et al., 2005; Tallini et al., 2006; Tian et al., 2009; 
Akerboom et al., 2012). Currently, the most widely used iteration of GCaMP is the GCaMP6 
series (T. W. Chen et al., 2013). The GCaMP6 members show fluorescence increases that are 
an order of magnitude greater than those of FRET-based GECI, and 5 to 10-fold greater than 
previous GCaMP iterations (T. W. Chen et al., 2013; Lin and Schnitzer, 2016). There are three 
types of GCaMP6, distinguished based on their kinetics: slow (GCaMP6s), medium (GCaMP6m) 
and fast (GCaMP6f) (T. W. Chen et al., 2013). GCaMP6s has the highest dynamic range and 
saturated fluorescence out of all GCaMP6 family members (T. W. Chen et al., 2013). GCaMP6f 
and its variant GCaMP6fRS09 are one of the fastest GECI available, with half-decay times in 
vitro of 71 s and 20 ms, respectively (Badura et al., 2014). These are comparable to the half-
decay times of calcium ion transients after a single action potential, which are 50-60 ms 
(Helmchen, Borst and Sakmann, 1997). These properties of GCaMP GECI have made them one 
of the most popular GECI, with hundreds of studies using them. In the neuroscience field, 
GCaMP indicators have been used to study neuronal activity associated with multiple 
physiological and pathological processes in various organisms. For instance, GCaMP1 was used 
to study activity patterns in the fly brain in response to different odours (Wang et al., 2003). In 
C. elegans GCaMP6s has been used to visualise neuronal activity associated with locomotion 
(Venkatachalam et al., 2016). In mice, GCaMP has been used in studies of many processes, 
including olfaction, memory, navigation and sensation (Fletcher et al., 2009; Dombeck et al., 
2010; O’Connor et al., 2010; Mittmann et al., 2011; Harvey, Coen and Tank, 2012; Huber et al., 
2012). Furthermore, GCaMP has been used to monitor the activity of DRG and TG neurons in 
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the context of chronic pain in rodents, and uncovered strong neuronal coupling between 
neuronal cell bodies after tissue injury (Y. S. Kim et al., 2014; Kim et al., 2016; Anderson, Zheng 
and Dong, 2018).  
In this study, we wanted to use intrathecal delivery of AAV9 to express GCaMP in DRG neurons. 
This will allow us to study their activity in vivo in healthy animals and in pain pathologies such 
as neuropathic pain. Since GCaMP6s showed the greatest dynamic range and fluorescence, we 
decided to use it for our experiments. However, before transitioning into an in vivo setting, we 
first wanted to explore GCaMP6s properties in vitro. When cultured, neurons change their 
properties, and the longer they spend in culture the more their phenotype differs from that in 
vivo. Typically, cultured DRG neurons for calcium imaging experiments with chemical dyes are 
used after a day in culture. This allows them to attach to the coverslip but does not give them 
enough time to significantly change their phenotype. In the previous chapter we have shown 
that cultured DRG neurons incubated with AAV9-GCaMP6s express the GCaMP6s transgene in 
less than 24 hours (see 2.3.8). This short incubation time means that these neurons can 
express the transgene before their phenotype significantly changes in culture, making in vitro 
transduction with AAV9 compatible with calcium imaging. 
3.1.4 Aim 
In this chapter, we wanted to explore the use of virally-delivered GCaMP6s for calcium imaging 
of adult DRG neurons. We used in vitro delivery of AAV9-GCaMP6s to ensure high levels of 
transduction and quick turnover of experiments. We aimed to investigate whether virally-
delivered GCaMP6s can be used to visualise the responses of adult DRG neurons to electrical 
field stimulation, and whether this can be enhanced by acute application of sensitising agents, 





3.2.1 DRG Culture for calcium imaging 
Cell culture dishes with glass coverslips attached to the bottom of the dish (MatTek, P35G-0-
14-C) were used for calcium imaging. Their treatment and the rest of the cell culture protocol 
were identical to that of a standard mixed DRG culture protocol outlined in chapter 2 (2.2.9). 
Cells were imaged the day after they were cultured. 
3.2.2 Calcium imaging 
For imaging with Fura-2, cells were loaded with a mix of 2 µM Fura-2 AM (Invitrogen, F1201) 
and 1mM probenecid, each dish being treated with 400 µl and incubated for 1 hour, then the 
cells were immediately imaged. For GCaMP6s imaging, cells were transfected with AAV9-
GcaMP6s on the day of the culture, as described in chapter 2 (2.2.11). 
Immediately prior to imaging, media was replaced with 200 µl of Calcium Imaging Buffer (1X 
HBSS with MgCl2 and Ca2+ (Thermo Fisher, 14065072) + 10 mM Hepes, (pH 7.4)). The cell 
culture dish was placed onto the imaging stage and secured. A custom-made electrode holder 
was placed on top, ensuring the electrodes were on the same level as the cells and in parallel. 
Electrical stimuli were created with a Neurolog Digitimer unit connected to a biphasic stimulus 
isolator (Warner Instruments, SIU-102B). Calcium imaging was performed on a PTI 
EasyRatioPro Fluorescence Calcium Imaging (Horiba Scientific), Fura-2 dye fluorescence was 
measured at 340 and 380 nm excitation wavelengths. 
3.2.3 Imaging protocol 
The protocol is illustrated in Fig. 3.1. After the desired field of view was found, the baseline 
was recorded for 75 seconds. Next, the threshold was determined. This was done by keeping 
the stimulation frequency at 5 Hz and increasing the current slowly from 0 up to the point 
when at least one neuron starts responding. This current was then taken as the threshold for 
that coverslip. Cells are then stimulated at 1.5, 2, 2.5 and 3 times the threshold. Each train of 
stimuli was at 5 Hz and contained 10 stimuli. Cells were allowed to recover for 1 minute 
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between trains of stimuli. After 4 trains of stumuli, 20 µl of buffer was removed and 20 µl of 
vehicle or sensitizer was added to the coverslip. 
Cells were incubated with the sensitizer for 5 minutes, and then the trains of stimuli were 
repeated. Sensitizers used were: Prostaglandin E2 (PGE2) 5 or 10 µM (Sigma, P5640), 
Bradykinin (BK) 5 µM (Sigma, B3259), Inflammatory soup (PGE2, BK, serotonin (Sigma, H9523) 
2.5 or 5 µM each), Nerve Growth Factor (NGF) 50 ng/ml (Cambridge Bioscience, GFM11-1000) 
and Forskolin (Fsk) 10 µM (Sigma, 93049). Finally, 20 µl of 50 mM KCl was added to the 
coverslip to stimulate all neurons to serve as positive control. 
3.2.4 Quantification 
Images were processed using Fiji distribution of ImageJ. The background was subtracted, and 
the 340 nm fluorescence channel signal was divided by the 380 nm fluorescence channel to 
obtain the Fura-2 ratio signal. Neurons that responded to KCl were circled and the intensity 
measured for each frame. All values for an individual neuron were divided by the mean of that 
neuron’s baseline intensity as a way of normalising the data. Data for each neuron were then 
individually plotted and screened for any abnormalities. Abnormal neurons were excluded 
from analysis.  The remaining data were then used to analyse neuronal responses to stimuli 
and the impact of the sensitizers on their responses. Analysis parameters and rationale are 







3.3.1 In vitro calcium imaging set-up and experimental protocol 
The basic concept applied in this study was to record neuronal response to several trains of 
electrical stimuli of increasing strength, add a potential sensitizer and then reassess neuronal 
responses to the same trains of stimuli. The effect of the sensitizer could then be assessed as 
the change in neuronal response, as well as the change in the number of neurons responding. 
To assess neuronal sensitization using electrical field stimulation in vitro the calcium imaging 
set-up had to be modified. Cells were cultured in a Petri dish with glass coverslip bottom to 
allow visualisation of cells on the calcium imaging stage without the need to transfer the cells 
into an imaging chamber. The top of the dish contained electrodes positioned in parallel to 
each other. (Fig. 3.1 a-b). Electrodes were then connected to a stimulus isolator that delivered 
biphasic current stimuli of varied intensity. The volume of the calcium imaging buffer was kept 
the same between coverslips, to minimize the impact of the liquid volume on the spread of 
electrical current. Each train of stimuli comprised of 10 shocks of 2 ms duration delivered at 5 
Hz frequency. However, we decided against using set stimuli intensities, as the variations in 
the electrode alignment, imaging solution volume and cell position relative to electrodes will 
result in inconsistent stimuli intensities across different coverslips. To ensure that the relative 
intensity of the stimulus was similar for all coverslips we used multiples of each coverslip’s 
electrical threshold (e.g. 1.5, 2.0, 2.5, and 3.0 times threshold) to determine the stimulus 
intensities instead of a set current value. The threshold was determined as the minimum 
current sufficient to activate at least one neuron in the field of view (see 3.2.3). Using relative 
threshold instead of set current reduces the variability that is introduced by the liquid volume 






Figure 3.1 – In vitro calcium imaging dish with electrodes and experimental protocol. a) 
Diagram and b) photograph of the calcium imaging glass-bottom dish with electrodes attached. 
c) Experimental protocol typically used in a calcium imaging session. Neuronal responses to 
electrical stimuli of increasing amplitude were assessed before and after incubation with a 






Example images of an AAV9-GCaMP6s transfected culture before and after an electrical 
stimulus was applied is depicted in Fig. 3.2 a, b. Cells responding to the electrical stimulus are 
marked with black arrows. An example of overlaid traces of several responding and non-
responding neurons is shown in Fig. 3.2 c. The difference between the minimum and maximum 
fluorescence signal during stimulus application (ΔF) was used to quantify neuronal responses 
(Fig. 3.2 d). To determine whether a neuron is activated by a specific stimulus, the ΔF was 
compared to the relative baseline activity of that neuron in the period between 20 and 15 
seconds prior to the stimulus (Fpr, Fig. 3.2 d). If the ΔF was greater than Fpr + 5 times Fpr SEM, 
then that neuron was counted as a responder for that particular stimulus. After addition of 
sensitizer cells were left to incubate for 5 minutes before the stimulation was repeated. The 
difference in this response before and after sensitizer addition was used to assess neuronal 
sensitization. In addition, we can assess the percentage of neurons responding to each 
electrical stimulus before and after the addition of the sensitizer or the vehicle. We can then 
derive the change in the percentage of neurons responding to each electrical stimulus caused 
by the addition of the sensitizer or vehicle. After that, we can compare this change between 
the sensitizer and the vehicle groups for each electrical stimulus to assess whether that 








Figure 3.2 – Examples of neuronal responses and fluorescence traces. Mixed DRG neurons 
were cultured and incubated with AAV9-GCaMP6s for 24 hours and neuronal responses to 
electrical stimuli were assessed. An increase in GCaMP6s fluorescence was observed in 
transduced neurons that responded to a given stimulus (black arrows, a) before stimulus, b) 
immediately after stimulus). c) Example fluorescence traces from neurons that responded to 
KCl at the end of the protocol. Dashed area: d) example traces of one neuron that responded to 
a particular electrical stimulus and one that did not. The neuronal response is quantified as the 
difference between the minimum and maximum fluorescence signal during the 5 second 
application of the stimulus (ΔF). If the ΔF is larger than the average fluorescence of that given 
neuron 15 seconds prior to the stimulus (Fpr) + 5xSEM, then the neuron is classified as a 
“responder”. The number of responsive neurons as well as magnitude of neuronal responses to 
each stimulus were compared before and after the incubation with a sensitising agent.  
 
3.3.2 In vitro transduction with AAV9-GCaMP6s can be used to assess sensitisation of 
neurons by application of sensitising agents 
To investigate whether virally-delivered GCaMP6s in neurons could be used to investigate 
neuronal sensitization, we assessed neuronal responses of the mixed DRG cultures to electrical 
field stimulation before and after addition of 5 µM of PGE2. The difference in neuronal 
responses to the same stimuli was used to assess neuronal sensitization after PGE2 or vehicle 
addition. There was a significant increase in neuronal response to the strongest stimulus (3 
times threshold) after PGE2 compared to vehicle (3 Con vs 3 PGE2, 200.1% ± 23.13% vs 499.4% 
± 96.9%, One-Way ANOVA with Tukey’s multiple comparisons, p = 0.038, n = 115 PGE2 
neurons and 189 vehicle neurons, Fig. 3.3 a). However, the data spread was very large, which 
may reduce the biological significance. When we split the neurons into large diameter (> 20 
µm) and small diameter (<20 µm), the difference in response to the strongest stimulus was no 
longer significant (3 Con vs 3 PGE2, One-Way ANOVA with Tukey’s multiple comparisons, p 
>0.05, n = 35 PGE2 neurons and 77 vehicle for large neurons, 38 PGE2 neurons and 50 vehicle 
for large neurons, Fig 3.3 b,c). Interestingly, small neurons exhibited a significant increase in a 
response to 2.5 times threshold (2.5 CON vs 2.5 PGE2, 100.3% ± 11.56% vs 482.2% ± 152.7%, 
One-Way ANOVA with Tukey’s multiple comparisons, p = 0.0316, n = 38 PGE2 neurons and 50 
vehicle neurons, Fig. 3.3 b). The responses for large neurons to all stimuli intensities did not 
significantly differ between PGE2 and vehicle (Con vs PGE2, all intensities, One-Way ANOVA 
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with Tukey’s multiple comparisons, p > 0.05, n = 35 PGE2 neurons and 77 vehicle neurons, Fig. 
3.3 c). Unfortunately, the neuronal diameter data was not available for some neurons, 
resulting in reduced number of neurons in the two diameter groups. Lastly, there was no 
significant difference between PGE2 and vehicle in the change in the percentage of neurons 
responding to stimuli for all three groups (Con vs PGE2, all intensities, One-Way ANOVA with 
Tukey’s multiple comparisons, p >0.05, Fig. 3.3 d).   
As PGE2 is a known neuronal sensitizer we were surprised by a relatively weak effect it had on 
the neuronal responses. To assess if a stronger effect could be achieved, we tested a mix of 10 
µM PGE2 and 10 µM Bradykinin (BK), both of which are known sensitizers for DRG neurons. 
However, there was no significant difference in response change for all stimuli intensities 
between sensitizer mix and vehicle for all diameters (Con vs PGE2 + BK, all intensities, One-
Way ANOVA with Tukey’s multiple comparisons, p >0.05, n = 104 PGE2 + BK neurons and 176 
vehicle neurons, Fig. 3.4 a), small diameter (Con vs PGE2 + BK, all intensities, One-Way ANOVA 
with Tukey’s multiple comparisons, p >0.05, n = 23 PGE2 neurons + BK and 95 vehicle neurons, 
Fig. 3.4 b) or large diameter groups (Con vs PGE2 + BK, all intensities, One-Way ANOVA with 
Tukey’s multiple comparisons, p >0.05, n = 81 PGE2 + BK neurons and 81 vehicle neurons, Fig. 
3.4 c). In addition, there was no significant change in the percentage of neurons responding to 
electrical stimuli after addition of sensitizer or vehicle for all three groups of neurons (Con vs 
PGE2 + BK, all intensities, One-Way ANOVA with Tukey’s multiple comparisons, p >0.05, Fig. 






Figure 3.3 – Impact of 5 µM PGE2 on the average GCaMP6s responses of DRG neurons in 
vitro following electrical filed stimulation.  Mixed cultures of DRG neurons from all spinal 
levels incubated with AAV9-GCaMP6s 24 hours prior to imaging (total n = 115 PGE2 neurons, n 
= 189 vehicle neurons, 6-7 coverslips per group, 2 animals total).  a – c Average change in 
response of a) all, b) small diameter (<20 µm), and c) large diameter (>20 µm) neurons to 
electrical stimuli after addition of 5 µM PGE2 or vehicle (Con). Following addition of PGE2, 
there was a significant increase in the neuronal response to 3 times the threshold stimulus for 
all neurons (a, 3 CON vs 3 PGE2, 200.1 % ± 23.13 % vs 499.4 % ± 96.9 %, One-Way ANOVA with 
Tukey’s multiple comparisons, p = 0.038). Small diameter neurons showed increased responses 
following PGE2 addition to 2.5 times the threshold stimulus (b, 2.5 CON vs 2.5 PGE2, 100.3 % ± 
11.56 % vs 482.2 % ± 152.7 %, One-Way ANOVA with Tukey’s multiple comparisons, p = 0.0316, 
n = 38 PGE2 and 50 vehicle). There was no significant difference in responses of large diameter 
neurons (c, One-Way ANOVA with Tukey’s multiple comparisons, p >0.05, n = 35 PGE2 and 77 
vehicle). Unfortunately, neuronal diameter data were unavailable for one of the animals, so the 
small and large diameter neuron analysis was performed only on 3-4 coverslips per group, 1 
animal total d) Average change in the percentage of neurons responding to electrical stimuli 
after addition of 5 µM PGE2 or vehicle. No significant difference in the change in the 
percentage of neurons responding to the same stimulus was observed for all, small diameter 
(<20 µm) and large diameter (>20 µm) neurons (d, One-Way ANOVA with Tukey’s multiple 





Figure 3.4 – Impact of 10 µM PGE2 + bradykinin (BK) mix on the average GCaMP6s responses 
of DRG neurons in vitro following electrical filed stimulation. Mixed cultures of DRG neurons 
from all spinal levels incubated with AAV9-GCaMP6s 24 hours prior to imaging (total n = 104 
PGE2 + bradykinin (BK) neurons, n = 176 vehicle neurons, 3-4 coverslips per group, 1 animal 
total).  a – c Average change in response of a) all, b) small diameter (<20 µm), and c) large 
diameter (>20 µm) neurons to electrical stimuli after addition of 10 µM PGE2 + BK mix or 
vehicle. Following addition of the sensitising mix, there was no significant increase in the 
neuronal responses to electrical stimuli for all (a, One-Way ANOVA with Tukey’s multiple 
comparisons, p >0.05, n = 104 PGE2 + BK and 176 vehicle), small diameter (b, One-Way ANOVA 
with Tukey’s multiple comparisons, p >0.05, n = 23 PGE2 + BK and 95 vehicle) or large diameter 
neurons (c, One-Way ANOVA with Tukey’s multiple comparisons, p >0.05, n = 81 PGE2 + BK and 
81 vehicle).  d) Average change in the percentage of neurons responding to electrical stimuli 
after addition of 10 µM PGE2 + BK mix or vehicle. No significant difference in the change in the 
percentage of neurons responding to the same stimulus was observed for all, small diameter 
(<20 µm) and large diameter (>20 µm) neurons (d, One-Way ANOVA with Tukey’s multiple 





3.3.3 Assessment of neuronal responses following addition of sensitizers using a 
chemical calcium indicator Fura-2 AM 
The lack of response with the PGE2 + BK mix could be due to the nature of the trigger stimulus 
(electrical vs. chemical, e.g. capsaicin), and prompted us to investigate a broader selection of 
possible sensitizers. We decided to use Fura-2 AM dye instead of AAV9-GCaMP6s virus to test 
the effect of a number of sensitising agents in vitro, using the electrical field stimulation set up. 
Fura-2 AM is easier to use and produces more consistent labelling, as well as being 
considerably cheaper. First, we reassessed the effect of 5 µM PGE2 on the neuronal responses 
to electrical stimuli in neurons loaded with Fura-2 AM instead of GCaMP6s. We found no 
significant difference in the change in neuronal responses to all electrical stimuli after addition 
of 5 µM PGE2 for all diameter neurons (Con vs PGE2, all intensities, One-Way ANOVA with 
Tukey’s multiple comparisons, p >0.05, n = 140 PGE2 neurons and 121 vehicle neurons, Fig 3.5 
a). When neurons were split into small and large diameter groups, we found no significant 
difference for all electrical stimuli in the small diameter group (Con vs PGE2, all intensities, 
One-Way ANOVA with Tukey’s multiple comparisons, p >0.05, n = 66 PGE2 neurons and 45 
vehicle neurons, Fig 3.5 b) and the large diameter group (Con vs PGE2, all intensities, One-Way 
ANOVA with Tukey’s multiple comparisons, p >0.05, n = 74 PGE2 neurons and 76 vehicle 
neurons, Fig 3.5 c).  Furthermore, no significant difference in the change in the percentage of 
responding neurons for all electrical stimuli was observed between the 5 µM PGE2 and vehicle 
treatment in any of the three neuronal groups (Con vs PGE2, all intensities, One-Way ANOVA 
with Tukey’s multiple comparisons, p >0.05, Fig 3.5 d). We also tested 10 µM PGE2 to see 
whether the higher concentration would have a stronger effect. However, the results with 10 
µM PGE2 were similar to 5 µM PGE2. We found not significant difference in the change in 
neuronal responses to all electrical stimuli for all three groups of neurons (All neurons: Con vs 
PGE2, all intensities, One-Way ANOVA with Tukey’s multiple comparisons, p >0.05, n = 96 PGE2 
neurons and 123 vehicle neurons, Fig 3.6 a; Small neurons: Con vs PGE2, all intensities, One-




Figure 3.5 – Impact of 5 µM PGE2 on the average Fura-2 AM responses of DRG neurons in 
vitro following electrical filed stimulation.  Mixed cultures of DRG neurons were prepared 24 
hours prior to imaging and loaded with 2 µM Fura-2 AM 1 hour before imaging (total n = 140 
PGE2 neurons, n = 121 vehicle neurons, 3-4 coverslips per group, 1 animal total).  a – c Average 
change in response of a) all, b) small diameter (<20 µm), and c) large diameter (>20 µm) 
neurons to electrical stimuli after addition of 5 µM PGE2 or vehicle. Following addition of the 
PGE2, there was no significant increase in the neuronal responses to electrical stimuli for all (a, 
One-Way ANOVA with Tukey’s multiple comparisons, p >0.05, n = 140 PGE2 and 121 vehicle), 
small diameter (b, One-Way ANOVA with Tukey’s multiple comparisons, p >0.05, n = 66 PGE2 
and 45 vehicle) or large diameter neurons (c, One-Way ANOVA with Tukey’s multiple 
comparisons, p >0.05, n = 74 PGE2 and 76 vehicle). d) Average change in the percentage of 
neurons responding to electrical stimuli after addition of 5 µM PGE2 or vehicle. No significant 
difference in the change in the percentage of neurons responding to the same stimulus was 
observed for all, small diameter (<20 µm) and large diameter (>20 µm) neurons (d, One-Way 




Figure 3.6 – Impact of 10 µM PGE2 on the average Fura-2 AM responses of DRG neurons in 
vitro following electrical filed stimulation.  Mixed cultures of DRG neurons were prepared 24 
hours prior to imaging and loaded with 2 µM Fura-2 AM 1 hour before imaging (total n = 96 
PGE2 neurons, n = 123 vehicle neurons, 3-4 coverslips per group, 1 animal total).  a – c Average 
change in response of a) all, b) small diameter (<20 µm), and c) large diameter (>20 µm) 
neurons to electrical stimuli after addition of 10 µM PGE2 or vehicle. Following addition of the 
PGE2, there was no significant increase in the neuronal responses to electrical stimuli for all (a, 
One-Way ANOVA with Tukey’s multiple comparisons, p >0.05, n = 96 PGE2 and 123 vehicle), 
small diameter (b, One-Way ANOVA with Tukey’s multiple comparisons, p >0.05, n = 64 PGE2 
and 56 vehicle) or large diameter neurons (c, One-Way ANOVA with Tukey’s multiple 
comparisons, p >0.05, n = 23 PGE2 and 95 vehicle). d) Average change in the percentage of 
neurons responding to electrical stimuli after addition of 10 µM PGE2 or vehicle. No significant 
difference in the change in the percentage of neurons responding to the same stimulus was 
observed for all, small diameter (<20 µm) and large diameter (>20 µm) neurons (d, One-Way 





vehicle neurons. Fig 3.6 b; Large neurons: Con vs PGE2, all intensities, One-Way ANOVA with 
Tukey’s multiple comparisons, p >0.05, n = 23 PGE2 neurons and 95 vehicle neurons, Fig 3.6 c). 
Similar to 5 µM PGE2, we found no significant difference in the change in the percentage of 
responding neurons for all electrical stimuli between the 10 µM PGE2 and vehicle treatment 
for all three neuronal groups (Con vs PGE2, all intensities, One-Way ANOVA with Tukey’s 
multiple comparisons, p >0.05, Fig 3.6 d). These results disagree with those obtained with 
AAV9-GCaMP6s, however that could be due to a large data spread in our AAV9-GCaMP6s 
experiments. 
In addition, we also tested a number of other sensitizer which have been shown to produce 
neuronal sensitisation, including 10 µM bradykinin, 2.5 and 5 µM inflammatory soup (PGE2, 
Bradykinin and Serotonin), 10 µM forskolin and 50 ng/ml nerve growth factor (NGF). We found 
no significant difference in the change in neuronal responses between treatment with 10 µM 
bradykinin (BK) and vehicle for the all neurons group (Con vs BK, all intensities, One-Way 
ANOVA with Tukey’s multiple comparisons, p >0.05, n = 64 BK neurons and 41 vehicle neurons, 
Fig 3.7 a). Both small and large diameter neuronal groups also showed no significant difference 
(Con vs BK, all intensities, One-Way ANOVA with Tukey’s multiple comparisons, p >0.05, n = 27 
small, 37 large BK neurons, 21 small and 20 large vehicle neurons, Fig 3.7 b,c). The change in 
the percentage of neurons responding to each electrical stimulus after BK addition was not 
significantly different from that after vehicle treatment (Con vs BK, all intensities, One-Way 






Figure 3.7 – Impact of 10 µM bradykinin (BK) on the average Fura-2 AM responses of DRG 
neurons in vitro following electrical filed stimulation.  Mixed cultures of DRG neurons were 
prepared 24 hours prior to imaging and loaded with 2 µM Fura-2 AM 1 hour before imaging 
(total n = 64 bradykinin (BK) neurons, n = 41 vehicle neurons, 3 coverslips per group, 1 animal 
total).  a – c Average change in response of a) all, b) small diameter (<20 µm), and c) large 
diameter (>20 µm) neurons to electrical stimuli after addition of 10 µM BK or vehicle. Following 
addition of the BK, there was no significant increase in the neuronal responses to electrical 
stimuli for all (a, One-Way ANOVA with Tukey’s multiple comparisons, p >0.05, n = 64 BK and 
41 vehicle), small diameter (b, One-Way ANOVA with Tukey’s multiple comparisons, p >0.05, n 
= 27 BK and 21 vehicle) or large diameter neurons (c, One-Way ANOVA with Tukey’s multiple 
comparisons, p >0.05, n = 37 BK and 20 vehicle. d) Average change in the percentage of 
neurons responding to electrical stimuli after addition of 10 µM BK or vehicle. No significant 
difference in the change in the percentage of neurons responding to the same stimulus was 
observed for all, small diameter (<20 µm) and large diameter (>20 µm) neurons (d, One-Way 






Next, we tested 2.5 µM and 5 µM inflammatory soup (IS). When we assessed all neurons 
together, we found no significant difference in the change in neuronal responses between 2.5 
µM IS, 5 µM IS and vehicle (Con vs 2.5 IS vs 5 IS, all intensities, One-Way ANOVA with Tukey’s 
multiple comparisons, p > 0.05, n = 86 2.5 µM IS neurons, 105 5 µM IS neurons and 95 vehicle 
neurons, Fig 3.8 a). However, assessment of the inflammatory soup (IS) effect on responses in 
small neurons revealed that 2.5 µM IS significantly increases the change in neuronal responses 
to 2.5 times the threshold electrical stimulation, compared to vehicle (3 Con vs 3 2.5 IS, 147.3% 
± 35.86% vs 256.4% ± 107.1%, One-Way ANOVA with Tukey’s multiple comparisons, p = 0.036 , 
n = 50 2.5 µM IS neurons and 59 vehicle neurons, Fig 3.8 b). No sensitisation effect was 
observed after 5 µM IS treatment in small diameter group (Con vs 5 IS, all intensities, One-Way 
ANOVA with Tukey’s multiple comparisons, p > 0.05, n = 53 5 µM IS neurons and 59 vehicle 
neurons, Fig 3.8 b), and after 2.5 µM and 5 µM IS treatment in large diameter neurons (Con vs 
2.5 IS vs 5 IS, all intensities, One-Way ANOVA with Tukey’s multiple comparisons, p > 0.05, n = 
36 2.5 µM IS neurons, 52 5 µM IS neurons and 36 vehicle neurons, Fig 3.8 c). We also did not 
detect a significant difference in the percentage of neurons responding to any electrical stimuli 
between 2.5 µM IS, 5 µM IS and vehicle (Con vs 2.5 IS vs 5 IS, all intensities, One-Way ANOVA 
with Tukey’s multiple comparisons, p >0.05, Fig 3.9 d). 
Forskolin (Fsk) treatment, compared to vehicle, did not significantly affect the change in 
neuronal responses to all electrical stimuli in all diameter, small diameter and large diameter 
groups (All neurons: Con vs Fsk, all intensities, One-Way ANOVA with Tukey’s multiple 
comparisons, p >0.05, n = 135 Fsk neurons and 123 vehicle neurons, Fig 3.9 a; Small neurons: 
Con vs Fsk, all intensities, One-Way ANOVA with Tukey’s multiple comparisons, p >0.05, n = 77 
Fsk neurons and 56 vehicle neurons. Fig 3.9 b; Large neurons: Con vs Fsk, all intensities, One-
Way ANOVA with Tukey’s multiple comparisons, p >0.05, n = 58 Fsk neurons and 67 vehicle 
neurons, Fig 3.9 c). Similar to other treatments, we did not observe a significant difference in 
the change in the percentage of neurons responding to any electrical stimulus between Fsk 
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and vehicle for all three neuronal diameter groups (Con vs Fsk, all intensities, One-Way ANOVA 
with Tukey’s multiple comparisons, p >0.05, Fig 3.9 d). 
Finally, we also assessed the effect of 50 ng/ml NGF on neuronal responses. Unfortunately, this 
experiment was done while the experimental paradigm was not in its final form, so the 
electrical stimuli used were higher than those in other experiments. We found that NGF 
treatment significantly decreased the change in the neuronal responses to 5 times the 
threshold stimulus, compared to vehicle (5 Con vs 5 NGF, 308.6% ± 17.51% vs 245.1% ± 6.386%, 
One-Way ANOVA with Tukey’s multiple comparisons, p = 0.0001, n = 345 NGF neurons, 310 
vehicle neurons, Fig 3.10 a). However, there was no significant difference in the change in 
percentage of neurons responding between NGF and vehicle treatment (Con vs NGF, all 
intensities, One-Way ANOVA with Tukey’s multiple comparisons, p > 0.05, n = 345 NGF 







Figure 3.8 – Impact of 2.5 µM and 5 µM inflammatory soup (IS) on the average Fura-2 AM 
responses of DRG neurons in vitro following electrical filed stimulation. Mixed cultures of DRG 
neurons were prepared 24 hours prior to imaging and loaded with 2 µM Fura-2 AM 1 hour 
before imaging (total n = 86-105 inflammatory soup (IS) neurons, 95 vehicle neurons, 2-3 
coverslips per group, 1 animal total).  a – c Average change in response of a) all, b) small 
diameter (<20 µm), and c) large diameter (>20 µm) neurons to electrical stimuli after addition 
of 2.5 µM and 5 µM IS or vehicle. Following addition of 2.5 µM IS, there was a significant 
increase in the neuronal response to 3 times the threshold stimulus for small diameter neurons 
(b, 3 CON vs 3 2.5 µM IS, 147.3% ± 35.86% vs 256.4% ± 107.1%, One-Way ANOVA with Tukey’s 
multiple comparisons, p = 0.036, n = 50 2.5 µM IS and 59 vehicle). There was no significant 
difference in responses of all (a, One-Way ANOVA with Tukey’s multiple comparisons, p > 0.05, 
n = 86 2.5 µM IS, 105 5 µM IS and 95 vehicle).  or large diameter neurons (c, One-Way ANOVA 
with Tukey’s multiple comparisons, p > 0.05, n = 36 2.5 µM IS, 52 5 µM IS and 36 vehicle). d) 
Average change in the percentage of neurons responding to electrical stimuli after addition of 
2.5 µM and 5 µM IS or vehicle. No significant difference in the change in the percentage of 
neurons responding to the same stimulus was observed for all, small diameter (<20 µm) and 







Figure 3.9 – Impact of 10 µM forskolin (Fsk) on the average Fura-2 AM responses of DRG 
neurons in vitro following electrical filed stimulation.  Mixed cultures of DRG neurons were 
prepared 24 hours prior to imaging and loaded with 2 µM Fura-2 AM 1 hour before imaging 
(total n = 135 Fsk neurons, 123 vehicle neurons, 3 coverslips per group, 1 animal total).  a – c 
Average change in response of a) all, b) small diameter (<20 µm), and c) large diameter (>20 
µm) neurons to electrical stimuli after addition of 10 µM BK or vehicle. Following addition of 
the Fsk, there was no significant increase in the neuronal responses to electrical stimuli for all 
(a, One-Way ANOVA with Tukey’s multiple comparisons, p >0.05, n = 135 Fsk and 123 vehicle), 
small diameter (b, One-Way ANOVA with Tukey’s multiple comparisons, p >0.05, n = 77 Fsk and 
56 vehicle) or large diameter neurons (c, One-Way ANOVA with Tukey’s multiple comparisons, 
p >0.05, n = 58 Fsk and 67 vehicle. d) Average change in the percentage of neurons responding 
to electrical stimuli after addition of 10 µM Fsk or vehicle. No significant difference in the 
change in the percentage of neurons responding to the same stimulus was observed for all, 
small diameter (<20 µm) and large diameter (>20 µm) neurons (d, One-Way ANOVA with 








Figure 3.10 – Impact of 50 ng/ml nerve growth factor (NGF) on the average Fura-2 AM 
responses of DRG neurons in vitro following electrical filed stimulation.  Mixed cultures of 
DRG neurons were made 24 hours prior to imaging and loaded with 2 µM Fura-2 AM 1 hour 
before imaging (total n = 345 NGF neurons, n = 310 vehicle neurons, 3-4 coverslips per group, 1 
animal total).  a) Average change in response of all DRG neurons to electrical stimuli after 
addition of 50 ng/ml NGF or vehicle. Following addition of NGF, there was a significant 
decrease in the neuronal response to 5 times the threshold stimulus (a, 5 CON vs 5 NGF, 308.6% 
± 17.51% vs 245.1% ± 6.386%, One-Way ANOVA with Tukey’s multiple comparisons, p = 
0.0001). Unfortunately, there is no neuronal diameter data available for this experiment. b) 
Average change in the percentage of neurons responding to electrical stimuli after addition of 
50 ng/ml NGF or vehicle. No significant difference in the change in the percentage of neurons 
responding to the same stimulus was observed (b, One-Way ANOVA with Tukey’s multiple 






Here, we have described our results following in vitro imaging of adult DRG neuron activity in 
response to short term application of various sensitising agents. In our setup, we used trains of 
electrical field stimuli of varying strength to evoke responses in cultured DRG neurons. Various 
known sensitizers, such as PGE2, were then applied to the cells and the electrical stimuli were 
repeated to assess the effect of the sensitising agent on the neuronal responses to each 
stimulus strength.  However, before discussing the results I would like to address the reasons 
behind our choice of the electrical field stimulation as the trigger for neuronal activity. 
3.4.1 Triggering neuronal activity in vitro 
Calcium imaging is used to visualise fluctuations in intracellular calcium, which in neurons 
serves as a proxy for action potential firing (see 3.1.1). However, uninjured adult DRG neurons 
in culture are not spontaneously active (Ma and LaMotte, 2007; Xie, Strong and Zhang, 2010; 
Djouhri et al., 2015). Unless a compound elicits neuronal activity, its sensitising or desensitising 
effect on a cell cannot be easily observed during calcium imaging. Therefore, a trigger stimulus 
needs to be applied to elicit neuronal activity before and after addition of a compound to see 
its modulatory effect. An ideal trigger allows control of the strength and temporal profile of 
the stimulus, has to be easy to apply, and does not affect the neurons in any other way, i.e. 
repeated applications of the stimulus would trigger the same amount of activity. In pain 
research, different types of chemical, thermal and electrical triggers are used.  
Perhaps the most widely-used chemical trigger in pain research for in vitro DRG calcium 
imaging is capsaicin, a transient receptor potential vanilloid 1 (TRPV1) agonist (Caterina et al., 
1997). TRPV1 is expressed in small and medium sized peptidergic and non-peptidergic 
nociceptors in the DRG (Guo et al., 1999; Caterina and Julius, 2001; Hwang and Valtschanoff, 
2003). Its application elicits pain in vivo and can activate DRG neurons in vitro (Heyman and 
Rang, 1985; Marsh et al., 1987; Bleakman, Brorson and Miller, 1990; Szallasi and Blumberg, 
1999). Due to capsaicin’s robust activation of nociceptors, as well as a quick return of neuronal 
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activity to baseline after its removal, capsaicin has been widely used as a trigger for neuronal 
activity in numerous studies. For instance, it has been used to investigate the mechanisms of 
neuronal sensitisation to various endogenous compounds, such as bradykinin, nerve growth 
factor (NGF) and  adenosine triphosphate (ATP) (Piper and Docherty, 2000; Eun et al., 2001; 
Vellani et al., 2001; Bonnington and McNaughton, 2003; Zhang, Huang and McNaughton, 
2005; Vellani, 2006; Honan and McNaughton, 2007; Malin et al., 2008). However, use of 
capsaicin as a neuronal activity trigger is not without its downfalls. Only a small proportion of 
large-diameter neurons express TRPV1 under normal physiological conditions, so most of them 
cannot be activated by capsaicin (Yu et al., 2008). Furthermore, capsaicin-induced neuronal 
activity exhibits tachyphylaxis, diminishing with every successive application of capsaicin 
(Caterina et al., 1997; Koplas, Rosenberg and Oxford, 1997; Shu and Mendell, 2001; Mohapatra 
and Nau, 2005; Maurer et al., 2014). Therefore, care must be taken when comparing capsaicin-
evoked neuronal activity after application of a potential activity-modulating compound. Finally, 
the application of capsaicin and its wash-off are not instantaneous, reducing the amount of 
temporal control over the stimulus. 
In our set up, we used electrical field stimulation to trigger neuronal responses, instead of a 
chemical stimulus. Electrical stimulation has an advantage over chemical triggers in that its 
parameters such as duration and strength, as well as precise time of stimulation start and end 
can be easily controlled. In addition, the stimulation does not require perfusion, and therefore 
is not affected by the fluid movement. However, field stimulation is affected by the total 
amount of liquid in the dish as well as electrode arrangement. Electrical field stimulation using 
two parallel platinum electrodes has been shown to trigger consistent intracellular calcium 
responses in DRG neurons that did not show desensitisation, in contrast to capsaicin 
tachyphylaxis (Duflo, Zhang and Eisenach, 2004). It is important to note that prolonged 
electrical field stimulation (~60 seconds) of DRG neurons has been shown to reduce neuronal 
excitability (Koopmeiners et al., 2013). Therefore, the stimulation parameters play an 
important role on the effect the electrical stimuli have on DRG neurons. 
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Electrical filed stimulation has been used to trigger activity in DRG neurons to study aspects of 
their physiology and pathology. For instance, prolonged electrical field stimulation has been 
used to elicit substance P release from DRG neurons and study the action of opioids (Holz, 
Dunlap and Kream, 1988; Chang et al., 1989). It has also been used as a trigger during calcium 
imaging to investigate mitochondrial buffering of intracellular calcium ions and release of 
protons in rat DRG neurons (Werth and Thayer, 1994). Finally, Eisenach and colleagues used 
electrical field stimulation as a trigger during in vitro calcium imaging to look at the actions of 
α2-adrenoreceptor agonists and antagonists on DRG neurons from wild-type or spinal nerve-
ligated rats (Eisenach, Zhang and Duflo, 2005; Ma et al., 2005).  
In our experiments, we opted for the use of electrical field stimulation over capsaicin 
stimulation because it showed much tighter control over neuronal activation parameters as 
well as uniform activation of neurons regardless of their TRPV1 expression. After identifying 
the coverslip threshold, we use a train of stimuli of increasing strength, and we found 
proportional increase in the number of neurons responding to stimuli, both with GCaMP6s and 
Fura-2 AM, suggesting that virally-delivered GCAMP6s performance is comparable to that of 
Fura-2 AM. In the literature, GCaMP6 has been shown to have equal or superior performance 
when compared to chemical dyes (T. W. Chen et al., 2013). However, further experiments are 
needed to evaluate how various parameters of GCaMP6s, such as decay times and signal-to-
noise ratio, compare to those of Fura-2 AM.  
3.4.2 Selection of potential sensitizers 
The aim of this chapter was two-fold: to assess performance of the GCaMP6s GECI in DRG 
neurons, and to set up an in vitro model of neuronal sensitisation to be used in future 
experiments. After showing that electrical stimulation can be used as a trigger for neuronal 
activity, we aimed to find a sensitizer that would either increase the number of neurons 
responding to each stimulus or increase the magnitude of neuronal responses.  
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Our first choice was prostaglandin E2 (PGE2). PGE2 is known to increase the frequency of 
neuronal firing by lowering the threshold of a voltage-gated sodium channel Nav1.8 that is 
specific to nociceptors, in addition to playing a role in reducing the time between 
depolarisations (Gold et al., 1996; Momin et al., 2008). This is achieved through activation of 
the cAMP-PKA pathway that results in phosphorylation of the sodium channel (England, Bevan 
and Docherty, 1996; Gold, Levine and Correa, 1998; Fitzgerald et al., 1999). Furthermore, PGE2 
is a known sensitizer of the TRPV1 channel, increasing neuronal responses to capsaicin and 
heat (Pitchford and Levine, 1991; Moriyama et al., 2005; Zhang, Li and McNaughton, 2008). 
Application of PGE2 has been shown to enhance action potential firing in small DRG neurons in 
response to a depolarising current injection and capsaicin application (Lopshire and Nicol, 
1997; Gu, Kwong and Lee, 2003; Momin et al., 2008). Mimicking PGE2 action by activating 
cAMP with forskolin has also been shown to sensitise DRG neurons (Smith, Davis and Burgess, 
2000; Nicolson et al., 2007). Taken together, these and many other studies show that PGE2 is a 
potent sensitizer of DRG neurons (McMahon, Cafferty and Marchand, 2005).  
Another sensitizer whose effect on DRG neuronal activity we assessed during this study was 
bradykinin. Bradykinin has been shown to both excite nociceptive fibres and sensitise them to 
capsaicin, heat and mechanical stimuli (Lang et al., 1990; Khan et al., 1992; Cesare and 
McNaughton, 1996; Banik et al., 2001; Koda and Mizumura, 2002). Bradykinin exerts its 
excitatory effect through release of calcium from intracellular stores via the PLC pathway 
(Bandell et al., 2004; Ferreira, Da Silva and Calixto, 2004; Tang et al., 2004; Liu et al., 2010). In 
addition, it induces activation of the PKC and PKA pathways, which results in sensitization of 
TRPV1 and TRPA1 channels (Mizumura, Koda and Kumazawa, 1997; Wang et al., 2008; 
Mizumura et al., 2009). These and many other studies show that bradykinin can sensitise DRG 
neurons (Petho and Reeh, 2012). 
In addition to assessing these sensitizers separately, in this study we investigated the 
sensitisation of the DRG neurons following an application of the PGE2, bradykinin and 
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serotonin mix, to mimic the “inflammatory soup” released upon injury in vivo (Basbaum et al., 
2009). Serotonin on its own has been show to excite as well as sensitize DRG neurons via its 
action on the TRPV1 channel (Linhart, Obreja and Kress, 2003; Salzer et al., 2016). When 
applied together with PGE2 and bradykinin, the application of this “inflammatory soup” has 
been shown to activate TRPV1-positve DRG neurons in vitro and result in augmented capsaicin 
responses (Vyklický et al., 1998; Ma, Greenquist and Lamotte, 2006). 
The last potential sensitizer that we used in our experiments was nerve growth factor (NGF). 
NGF is released at the site of injury from non-neuronal cells such as fibroblasts and 
inflammatory cells (Ringkamp et al., 2013). It is known to target TRPV1 through the PLC 
pathway, inducing sensitization to heat and capsaicin, in addition to promoting increased 
expression of TRPV1 (Chuang et al., 2001; Ji et al., 2002; Bonnington and McNaughton, 2003; 
Galoyan, Petruska and Mendell, 2003; Pezet and McMahon, 2006).  
3.4.3 Effect of sensitizers on neuronal responses triggered by electrical field stimulation 
Unfortunately, the sensitization to the electrical field stimulation produced by these 
compounds was moderate at best. In DRG cultures incubated with AAV9-GCaMP6s, we 
recorded a significant increase in the neuronal response to 3 times threshold stimulation after 
5 µM PGE2 treatment (Fig. 3.3a). In addition, when we investigated at a subset of neurons 
with diameter of less than 20 µm, we recorded a trend towards an increased neuronal 
response for all stimulation intensities, with 2.5 times threshold intensity reaching significance 
(Fig. 3.3b). However, repeating the same experiment with Fura-2 AM did not show any 
significant sensitisation of neuronal activity for all neurons (Fig. 3.5a). Nevertheless, there was 
a trend towards increased response in the small diameter neuronal population, which is also 
evident in the GCaMP6s experiments (Fig. 3.3b and 3.5b). This discrepancy between the 
results with different calcium indicators is likely to be caused by a large data spread. There was 
no significant change in the percentage of neurons responding to each electrical trigger after 
PGE2 treatment. This is discordant with the literature, which shows that PGE2 increases the 
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number of neurons responding to chemical triggers, such as bradykinin (Smith, Davis and 
Burgess, 2000). This disagreement could be due to the nature of the stimulus, as electrical 
activity directly depolarises neurons, while chemical triggers exert their action via specific 
receptors and signalling pathways (see 3.4.1).  
Interestingly, increasing the concentration of PGE2 to 10 µM did not significantly enhance 
neuronal responses (Fig 3.6). This could suggest that increasing PGE2 concentration reduced 
the sensitisation of DRG neurons to the electrical field stimulation. Alternatively, it could mean 
that the results we obtained with lower PGE2 (5 µM) concentration were false positives, 
appearing significant as a result of a large data spread. We did not see any neuronal 
sensitisation to electrical stimuli following an application of forskolin, an activator of cAMP 
that mimics PGE2 action and can sensitise sensory neurons to capsaicin (England, Bevan and 
Docherty, 1996; Lopshire and Nicol, 1998) 
We found no potentiation of neuronal responses following treatment with 10 µM bradykinin 
alone, or in conjunction with 10 µM PGE2 (Fig. 3.8 and 3.4). However, we observed neuronal 
activation directly after application of bradykinin. As our set up does not allow for removal of 
the sensitizer once it has been introduced, it is possible that persistent activation of the DRG 
neurons by bradykinin masked the potential sensitisation to electrical stimuli. 
When we assessed the sensitizing effect of the “inflammatory soup” on the DRG neurons, we 
found a trend towards potentiation of neuronal activity in DRG neurons (Fig. 3.8 a). It was 
even more pronounced in the small diameter sub-population of DRG neurons, reaching 
significance at 3 times the threshold stimulation (Fig 3.8 b). Surprisingly, this effect was only 
observed with 2.5 µM IS, and was completely gone when the concentration was increased to 5 
µM. This dampening of neuronal sensitisation with increasing concentrations is similar to that 
seen of PGE2 (see above). 
We also investigated the potential sensitising effect that NGF might have on the DRG neurons. 
In these experiments we used higher stimulation intensities to trigger responses in a larger 
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number of neurons. We did not see any potentiation of neuronal responses after NGF 
treatment compared to vehicle. In fact, there was a small but significant decrease in neuronal 
response to the highest stimulation intensity (Fig. 3.10 a). However, this may be a false 
positive due to the large data spread. Unfortunately, cell size information was not available 
during analysis, so we could not analyse small and large diameter sub-populations individually. 
It is also important to note that as these experiments follow a different stimulation protocol. 
Therefore, we cannot compare NGF with other sensitising agents shown here. In order to do 
so this experiment must be repeated with the final stimulation protocol.  
3.4.4 Potential reasons for the lack of sensitisation effect 
Overall, out of all sensitizer compounds we tested, we found weak sensitisation only with 5 µM 
PGE2 and 2.5 µM inflammatory soup. This was unexpected, as all tested sensitizers have been 
shown in the literature to sensitise sensory neurons in vitro and in vivo (Huang, Zhang and 
McNaughton, 2006; Basbaum et al., 2009). There are several possible reasons for the lack of 
sensitisation observed in our setup, including analysis method, stimulation and incubation 
parameters as well as the nature of activity trigger. 
Our data shows a high degree of variability, with a large spread of neuronal response changes. 
This could be due to our method of analysis. Our method corrects for signal degradation and 
baseline drift by calculating the difference between minimum and maximum values during 
each stimulation period instead of the absolute calcium indicator signal. The response to the 
same strength of field stimulation for the same neuron is then compared before and after the 
addition of a sensitizer. This difference in responses is then expressed as a percentage of the 
first response, with values less than 100% indicating a decreased neuronal response following 
addition of the sensitising agent. However, this can lead to small changes in calcium signal 
producing large differences in percentage response. For instance, a neuron that did not 
respond to a stimulus before the addition of the sensitizer but responded to the same 
stimulation after the addition of the sensitising agent. If the arbitrary change in the Fura-2 AM 
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signal is 0.015 before and 0.45 after the sensitizer addition, the difference between these two 




3000 % for this neuron. Using the percentage change for each neuron as the final readout 
increases the sensitivity of the analysis, making sure that even small changes in neuronal 
responses are detected. However, the caveat of the increased sensitivity is that it can also 
increase the data variability by potentially misrepresenting the extent of the change in 
neuronal responses, making small differences appear greater. This could result in masking a 
potentially significant difference.  
It is also possible that these sensitizers do not potentiate neuronal responses to electrical field 
stimulation. All of the compounds we used in our experiments have been shown to potentiate 
neuronal responses to chemical stimuli. Most of these compounds were shown to exert their 
effect through modulation of the TRPV1 channel, so the majority of studies that use these 
sensitizers also use capsaicin as the trigger for neuronal activity (Chuang et al., 2001; Shu and 
Mendell, 2001; Moriyama et al., 2005; Ohta et al., 2006; Sugiura et al., 2014). We used 
electrical field stimulation, which does not require the activation of TRPV1 to trigger neuronal 
activity. Thus, it might not exhibit robust sensitisation as seen in studies using capsaicin. 
Interestingly, PGE2 has been shown to exert its sensitising effect by lowering the 
depolarisation threshold for the action potential generation as well as increasing resting 
membrane potential (Momin and McNaughton, 2009). As this effect is independent of TRPV1, 
it could explain the potentiation of neuronal activity we see with PGE2 and IS. However, it 
would not explain why this was not potentiated at higher concentrations. 
There are other possible reasons for the lack of sensitization. Firstly, as these experiments 
were exploratory, we used a small sample size. In future experiments, larger animal and 
coverslip numbers may help improve the reliability of the data. Secondly, the strength of 
electrical field stimulation in a cell bath is influenced by the electrode arrangement as well as 
the amount of liquid in the bath. It is possible that non-uniform strength of electrical 
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stimulation resulted in biased neuronal activation. We attempted to control these factors by 
ensuring identical liquid volume for all experiments as well as using reusable electrode holders 
to keep electrodes in the same arrangement. Furthermore, it is possible that stimulation 
parameters were suboptimal for DRG stimulation. Unfortunately, it was beyond this thesis to 
further optimise each individual parameter used.  
Longer incubation times may enhance the sensitising effect of the potential sensitizers on the 
sensory neurons, making it detectible with electrical field stimulation. Finally, a different 
sensitisation protocol that does not rely on acute sensitizer treatment may be required. For 
example, DRG neurons have been shown to become sensitised to mechanical and electrical 
stimuli after spinal nerve ligation (Djouhri, 2016). It may be beneficial to assess whether this 
effect is present in response to electrical field stimulation, and whether it can be used as a 
sensitisation model for studying effects of various compounds. 
3.4.5 Conclusion 
In this chapter, we used electrical field stimulation as a trigger for neuronal activity during in 
vitro calcium imaging. We used this setup to assess performance of virally-delivered GCaMP6s, 
which was capable of accurately reporting neuronal activity. We also used electrical field 
stimulation of DRG cultures to create a model of neuronal sensitization by applying several 
known sensitizer compounds and assessing their effects on the electrical field stimulation-
triggered neuronal response. Only 5 µM PGE2 and 2.5 µM inflammatory soup enhanced 
neuronal response. The rest of the sensitizers did not produce sensitization. This may be due 
to the TRPV1-dependant mechanism of sensitisation produced by these compounds, which is 




Chapter 4: Exploring the use of AAV9-delivered functional 
transgenes in vivo 
4.1 Introduction 
AAV vectors have been used to deliver a variety of transgenic tools, in addition to relatively 
simple fluorophores whose use as markers has been described in chapter 2. Among these tools 
are transgenes that can be used to visualise neuronal activity in real time (such as GECI), 
control gene expression (Cre/Dre/Flp/CRISPR/ZFN etc.), and control neuronal activity 
(opto/chemogenetic tools such as DREADDs). All these tools are invaluable for studying the 
physiology and pathology of the nervous system, including peripheral and central pain circuitry 
and signal processing. Below, a number of these tools are described, and I present the results 
we obtained when using them in synergy with the intrathecal delivery method described in 
chapter 2.  
4.1.1 Real-time visualisation of neuronal activity in vivo 
Dysregulation of the neuronal activity is prominent in many neurological disorders, including 
chronic pain (Basbaum et al., 2009; Todd, 2010). There are numerous studies that successfully 
used in vivo electrophysiological recordings in the context of pain (Holle, Obermann and 
Katsarava, 2009; Lelic, 2014; Lin et al., 2014; Zhao et al., 2014; Kucyi and Davis, 2017; Bell and 
Dallas, 2018). This approach, however, has several drawbacks, including its inability to 
simultaneously record the activity of a large number of neurons with high spatial resolution, as 
well as the tissue damage caused by electrode insertion (Anderson, Zheng and Dong, 2018).  
These drawbacks can be overcome by using GECI that provide a visual readout of calcium 
transients associated with activity. Currently, the most popular type of GECI is GCaMP, which is 
a single-fluorophore calcium indicator that changes its fluoresce in response to a rapid 
increase in the intracellular calcium concentration that in a neuron is associated with an action 
potential (Nakai, Ohkura and Imoto, 2001; Grienberger and Konnerth, 2012; Yingxiao Chen et 
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al., 2013; Girven and Sparta, 2017). The use of GECI and GCaMP in vitro was introduced in 
chapter 3, however these tools can also be used in vivo, and they have several advantages over 
in vivo electrophysiological approaches. Firstly, the use of GCaMP eliminates the need for 
electrode insertion into the neuron or the surrounding tissue. Secondly, it allows simultaneous 
recording from a large number of neurons. The exact number of cells recorded is dependent 
on the field of view, which varies depending on the imaging setup and GCaMP expression. 
However, several studies that used GCaMP to elucidate pain-related neuronal activity have 
reported simultaneous recordings from over 100 DRG neurons (Emery et al., 2016; Kim et al., 
2016; Chisholm et al., 2018). Lastly, as GCaMP is a transgenic tool, its expression can be 
tailored to specific cell types. This can be achieved by using specific promoters, such as Thy1 
for neuronal expression (Q. Chen et al., 2012), Pirt promoter for specific expression in DRG and 
TG neurons (Y. S. Kim et al., 2014) and Aldh1l1 promoter for astrocyte-specific expression 
(Srinivasan et al., 2016).  
Global and cell-specific GCaMP expression can be achieved by using transgenic lines (Zariwala 
et al., 2012; Dana et al., 2014; Sato et al., 2015; Anstötz, Lee and Maccaferri, 2018). However, 
a large number of studies instead use AAV vectors to deliver GCaMP to the cells of interest (T. 
W. Chen et al., 2013; Yu et al., 2016; Ozbay et al., 2018; Yoshida et al., 2018). Using AAVs for 
GCaMP delivery offers several advantages. For instance, transgenic lines require a lot of time 
and resources to expand and maintain. Furthermore, as promoters for targeting different cell 
types are still under development, some cell types do not yet have a suitable promoter for cell-
specific GCaMP expression in mice. This is a major confounding factor in studies that require 
expression of a transgene in a subset of neurons, for example DRG or spinal cord neurons. This 
can be circumvented by using local administration of AAVs. Depending on the delivery method, 
it is possible to restrict GCaMP expression only to the cells of interest. For instance, 
intramuscular injection in mice have been used to image axons of sensory afferents in the 
peroneal nerve (Anderson et al., 2018). Direct injection into the dorsal horn of the spinal cord 
has been used to express GCaMP6f in mice and image activity in the spinal cord neurons in 
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awake behaving animals (Sekiguchi et al., 2016). Therefore, viral delivery of GCaMP could be 
an asset for studying nociceptive circuitry. As shown in chapter 2 intrathecal injection of AAV9-
eGFP results in transduction of the majority of L4 DRG neurons. Intrathecal delivery of AAV9-
GCaMP6s could make it possible to image responses of these neurons to various stimuli.  
4.1.2 Control of gene expression with transgenic tools 
Every living cell has a specific gene expression profile at any one time. Cell gene expression 
profiles change to adapt to different requirements, e.g. maturation, proliferation and 
apoptosis (Hamatani et al., 2004; Reik, 2007; Sato et al., 2008).  Furthermore, various external 
factors like chemical messengers, temperature fluctuations, external stress, damage and 
neuronal activity all influence the expression profile (Reik, 2007). Changes in gene expression 
are part of the normal functioning of the cell, for instance upregulation of genes in neurons 
during late-phase long-term potentiation (Nedivi et al., 1993; Lee et al., 2005). However, some 
changes can be a result of pathology, such as increased expression of voltage-gated sodium 
channels in sensory neurons after nerve injury (Cardoso and Lewis, 2017). These changes often 
contribute to symptoms of pathology, e.g. upregulation of HCN1 and HCN3 channels in IB4 
negative Aδ afferents leads to increased Ih current, which brings the membrane potential close 
to the action potential threshold and makes the neuron hypersensitive (Liu et al., 2015). 
Furthermore, preventing gene upregulation in pathology may attenuate the symptoms (Sun et 
al., 2018).  
For the gene to be expressed, it first has to be transcribed from DNA to mRNA, and then 
translated into a protein. Apart from direct replacement of the gene’s DNA sequence, there 
are several transgenic tools that can influence gene expression at various points in this 
pathway. Recombinases, such as Cre, can excise parts of the gene’s DNA that are flanked by 
pre-inserted LoxP sites. Excision can disrupt gene transcription and result in a protein that is 
truncated or misfolded, and is not functional (Hoess, Ziese and Sternberg, 1982; Hoess, 
Wierzbicki and Abremski, 1986). The recently developed CRISPR/Cas9 system can be used to 
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excise specific parts of the DNA, effectively silencing genes (Doudna and Charpentier, 2014; 
Sander and Joung, 2014). Moreover, RNA interference tools, such as shRNA or miRNA can 
cause degradation of the gene’s mRNA before it can be translated (Fire et al., 1998; Boudreau, 
Martins and Davidson, 2009).  
These genetic tools can be controlled so that they are expressed only in a specific cell type or 
in a particular temporal pattern. For instance, by using cell-specific promoter it is possible to 
restrict expression of Cre recombinase to specific cell types, such as small and medium 
diameter sensory fibres using the Nav1.8 promoter (Stirling et al., 2005). Furthermore, it is 
possible to achieve temporal control over Cre expression, e.g. by fusing the Cre recombinase 
with a mutated binding domain of the human oestrogen receptor (ERT2) which sequesters it in 
the cytoplasm. Upon tamoxifen interaction with CreERT2, the Cre enters the nucleus and 
excises the DNA sequence between the LoxP sites (Feil et al., 1997; Feil, Valtcheva and Feil, 
2009). Therefore, it is possible to exert temporal control over Cre activity through timing of 
tamoxifen administration. Using CreERT2 with transgenic lines that have regions of interest 
flanked by the LoxP sites has made it possible to study genes whose knockout in utero with a 
normal Cre is lethal, or severely reduces animal lifespan. For instance, conventional knockout 
in mice of histone deacetylase 4 protein (HDAC4) results in severely reduced life expectancy 
due to developmental defects (Vega et al., 2004; Majdzadeh et al., 2008). However, it is 
possible to study the importance of this gene in adult pain sensation by using the CreERT2 
system (Crow et al., 2015). Lastly, it is possible to place a STOP cassette flanked by LoxP sites 
before a gene of interest or a transgene. In that case, administration of Cre will excise the 
STOP signal, allowing gene expression (Sauer, 1998). This can be used in conjunction with 
transgenic lines that express Cre recombinase in specific cell types to achieve selective gene 
expression in these cells (Sauer, 1998). 
Gene expression can be readily manipulated using transgenic lines that already express these 
transgenic tools. However, the desired transgenic lines are not always readily available as 
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mentioned above. Moreover, temporal regulation of these tools is not always without side-
effects. For instance, tamoxifen used in Cre-ERT2 system has been show to induce cellular 
stress in the nervous system (Denk et al., 2015). Delivery of Cre recombinase using AAV vectors 
is one way to overcome these drawbacks. By varying the delivery time of AAV it is possible to 
achieve temporal control over expression of the Cre without the use of tamoxifen (see chapter 
2.3). Furthermore, it is possible to express the Cre in cells of interest by using cell-specific 
promoters and injecting AAV vectors at the desired location. For instance, intraganglionic and 
intrathecal AAV injections in rats have been successfully used to deliver shRNA to silence 
Nav1.3 in dorsal horn neurons and DRG neurons (Samad et al., 2013). Injection of AAV-Cre into 
the brain has been shown to successfully knock out P phosphatase and tensin homolog (PTEN) 
in PTEN-floxed mice (Yang et al., 2015). Furthermore, intrathecal injection of AAV5-Cre in 
Nav1.6-floxed mice resulted in Nav1.6 knockdown and attenuation of neuropathic pain 
behaviour (Chen et al., 2018).  
It is important to note, however, that using AAVs for delivery of these transgenic tools for gene 
expression modulation is not without pitfalls. The proportion of transduced cells depends 
heavily on the method of delivery and is rarely 100% (see chapter 2.3). This may obscure the 
effect of gene knockout by only knocking the gene out in some, but not all, cells. Therefore, it 
is essential to use the most efficient delivery strategy possible.  
4.1.3 Control of neuronal activity with transgenic tools 
One last example of a method of neural function interrogation in health and disease is to 
directly control neuronal activity by activating or silencing neurons. Modulating neuronal 
activity can help elucidate function of a particular neural circuit, or can counteract or 
exacerbate existing pathology, making it useful for identifying potential therapeutic targets 
(Roth, 2016; Wiegert et al., 2017). This can be achieved with the use of optogenetic and 
chemogenetic tools. Optogenetic tools are activated by light of a particular frequency and 
undergo changes that result in alterations in the cell’s physiology, most commonly changing 
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membrane conductivity and depolarising or hyperpolarising the cell (Boyden et al., 2005; Chow 
et al., 2010). Optogenetic tools are commonly used in the neuroscience field, including pain 
research, to interrogate circuit function and to modify an underlying pathology (Xie, Wang and 
Bonin, 2018). For instance, by expressing channelrhodopsin or archaerhodopsin in primary 
nociceptors it is possible to elicit or inhibit nocifensive behaviour, respectively, by shining light 
of a specific frequency onto the rodents skin (Daou et al., 2013; Li et al., 2015). Optogenetic 
tools respond to light stimuli within milliseconds, and are only active as long as the stimulus is 
present (Rein and Deussing, 2012). However, this may make optogenetic tools less viable for 
prolonged neuronal activity modulation. In addition, use of optogenetics requires a complex 
set up for light delivery, that depending on the target, may have to be implanted into the 
animal (Towne et al., 2013; Montgomery et al., 2015). In studies where access to the target 
tissue is restricted or that require prolonged activation of a large number of cells, 
chemogenetics may be a better option. 
There are many various chemogenetic tools, but they all operate in a similar way. All of them 
are receptors that are engineered to respond to a single exogenous ligand (Sternson and Roth, 
2014). When their respective ligand binds to these receptors, one type can initiate a secondary 
messenger cascade that in turn will depolarise or hyperpolarise a neuron (Alexander et al., 
2009). Another type of chemogenetic tool are ligand-gated ion channels (LGICs). Created by 
mutating the ligand binding domain of α7 nicotinic acetylcholine receptor (nAchR) to respond 
only to specific exogenous molecules, LGICs open an ion pore upon ligand binding, allowing 
flux of ions across the membrane (Magnus et al., 2011). By transplanting the nAchR ligand 
binding domain to other ion channels it is possible to influence the specific ions that LGICs are 
permeable to, therefore enabling both excitatory and inhibitory LGICs (Magnus et al., 2011; 
Wiegert et al., 2017). Another type of a potent chemogenetic tools is an engineered 
invertebrate-derived Ligand-Gated Chloride Channel (LGCC). LGCC allows ion flux across the 
membrane like the LGICs but does not rely on the nAchR domain to be activated. Instead, this 
glutamate-activated chloride channel that is inactive in mammals has been mutated to 
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respond only to Ivermectin (IVM), an anti-malaria drug that is inert in mammals (Cully et al., 
1994; Li, Slimko and Lester, 2002). Upon activation, LGCC opens an ion pore and allows 
chloride ions to pass across the cell membrane. In most neurons, this creates an inward flux of 
chloride ions, hyperpolarising the neuron and effectively silencing it (Slimko et al., 2002). An 
improved version of LGCC was developed in 2013, when Frazier and colleagues improved its 
structure by introducing two point-mutations that substantially improved sensitivity to IVM, as 
well as reduced degradation of LGCC protein within the cell (Frazier, Cohen and Lester, 2013). 
Both optogenetic and chemogenetic tools can be expressed using transgenic mouse lines, but 
most commonly these tools are delivered via viral vectors. As previously described, viral 
vectors can provide spatial and temporal control over the transgene expression. AAV vectors 
have been successfully used to target specific groups of cells, for instance the entorhinal cortex 
projection neurons (Ge et al., 2017). Furthermore, tighter restriction of expression can be 
made by using the Cre-dependent viral vectors and Cre-expressing transgenic lines, for 
example to target parvalbumin-expressing interneurons or GABAergic inhibitory neurons 
(Chandrasekar et al., 2018; T. Zhang et al., 2018).  
4.1.4 Chapter Aim 
In this chapter we show the assessment of GCaMP6s expression in DRG neurons after 
intrathecal infusion of AAV9-GCaMP6s, as well as characterisation of GCaMP6s responses to 
electrical stimuli, recorded using an in vivo calcium imaging setup. For a more extensive study, 
please see Chisholm et al. 2018. We were also interested in elucidating whether intrathecal 
delivery of AAV9-Cre using the method described in chapter 2 results in Cre expression that is 
sufficient to be useful in further studies. We investigated the activity of virally-delivered Cre in 
the TdTomato-floxed-STOP-cassette mice. Finally, we also investigated whether our method of 
viral delivery would be suitable for expressing chemogenetic tools in DRG neurons, and 
whether the expression level is high enough to be able to influence nocifensive behaviour. This 
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has been done in collaboration with Dr Weir of Prof Bennett’s group at the Oxford University 







4.2.1 Animals  
All procedures were in accordance with the UK Home Office guidelines and Animals (Scientific 
Procedures) Act 1986. Wild type C57Bl/6J mice, 6-8 weeks old, were obtained from Charles 
River or University of Oxford Breeding Unit. Transgenic mice were bred in King’s College 
London Biological Services Unit. Initially, 2 GCaMP6s-floxed-STOP-cassette heterozygous males 
were obtained from JAX (stock number 024106). These males were used to establish a 
homozygous colony. Homozygous 3-5 months old GCAMP6s-floxed-STOP-cassette males and 
females were used for in vivo calcium imaging experiments. TdTomato-floxed-STOP-cassette 
mice were obtained from JAX (stock number 007909). 
4.2.2 Genotyping of GCaMP6s-floxed-STOP-cassette mice 
To genotype animals from the GCaMP6s-floxed-STOP-cassette colony, ear biopsies were 
performed. Biopsies were dissociated in 450 µl of earclip lysis buffer (50 mM KCl, 1.5 mM 
MgCl2, 10 mM Tris, 0.45% Tergitol, 0.45% Tween-20) and 15 µl of 10mg/ml Proteinase K on a 
heat block at 55 °C for 3 hours. Samples were then heated up to 95 °C for 15 minutes to 
inactivate the Proteinase K. Samples were either stored at 4 °C for later processing or directly 
used in a PCR reaction. PCR plates were used for genotyping. Each reaction contained 12.35 µl 
of MQ H2O, 4 µl of 5x buffer, 0.4 µl of 200nM nucleotide mix (Promega, U1330), 1 µl of primers, 
0.25 of Taq Polymerase (Promega, M3175) and 2 µl of biopsy DNA. The plate was sealed and 
placed in a thermocycler. The cyclic program was as follows: 95 °C for 5 minutes, 35 cycles of 
95 °C for 30 seconds, 58 °C for 30 seconds, 72 °C for 30 seconds and then 72 °C for 7 minutes. 
Completed PCR reactions were run on a 2% w/v agarose (Sigma, A9539) gel with 4x10-5 % v/v 
ethidium bromide (Sigma, E1510-10ML). DNA bands were visualised under UV light. Primers 
used were: 
GGGAGTTCTCTGCTGCCTCCT – forward wild-type primer 
CTGTGGGAAGTCTTGTCCCTCCAA - reverse wild-type primer 
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GCATCAAGGCGAACTTCCAC – forward GCaMP6s primer 
CTCAGGTAGTGGTTGTCGGG – reverse GCaMP6s primer 
4.2.3 Intrathecal injections 
Intrathecal delivery procedure of AAV9-GCaMP6s and AAV9-Cre was identical to that of AAV9-
eGFP described in chapter 2 (2.2.4) and performed by me. Injections of AAV9-GluCl were 
performed together with Dr Weir. Transduction efficiency quantification for different times 
post injection and neuronal sub-population transduction was assessed by me. 
4.2.4 In vivo procedure 
For in vivo calcium imaging, exposure surgery and imaging was performed by Dr K. Chisholm, 
as described in (Chisholm et al., 2018). Briefly, mice were anaesthetised with 12.5% w/v 
urethane in saline. Initially 37.5 mg urethane was injected intraperitoneally.  Subsequent doses 
were given until the mouse reached surgical depth of anaesthesia, which was then monitored 
throughout the procedure. Mice were kept at 37 °C and hydrated with 0.5 ml sterile saline 
subcutaneously. A tracheal catheter was used to improve survival. An incision was made over 
the L3, L4, and L5 DRGs and the underlying muscle removed.  Next, the bone around the L4 
DRG was carefully removed. The animals were rotated to achieve a more horizontal 
orientation of the L4 DRG, which was then stabilised by clamping it to the neighbouring 
vertebrae using spinal clamps. DRG and exposed spinal cord were covered with silicone 
elastomer to prevent them from drying out. Then the animals were placed under the Eclipse 
Ni-E FN upright confocal/multiphoton microscope (Nikon). GCaMP6s signal in the L4 DRG was 
imaged using the 10x dry objective and 488 nm Argon ion laser. 
4.2.5 In vivo imaging stimuli 
Electrical stimulation was used to assess the sensitivity of GCaMP6s in vivo, fully described in 
(Chisholm et al., 2018). Electrical stimuli were applied directly to the ipsilateral sciatic nerve 
using custom-made cuff electrodes with Teflon coated silver wire. A biphasic stimulator was 
used to deliver individual or trains of stimuli at varying frequencies and intensities. Images 
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were processed and quantified using NIS Elements 4.30.01 (Nikon) and Fiji repack of ImageJ 
software. Cell bodies were selected, and their intensity measured in Fiji. Data were further 
processed by subtracting background signal and changes in fluorescence were calculated as a 
percentage of baseline fluorescence, 100% representing a signal that has an intensity of 
double the baseline fluorescence. To determine whether a neuron responded to a particular 
stimulus, a cut-off was used. The response had to be 70% above the baseline + 4 standard 
deviations for it to be counted as positive. 
4.2.6 GluCl transgene study 
Adapted from (Weir et al., 2017). Intrathecal injections were performed as described in 2.2.4, 
with the only difference being that the animals were injected with 8 µl of vector cocktail, 
containing 4 µl AAV9-GluClα and 4 µl AAV9-GluClβ. 3 weeks after injection, mice were used for 
histological or behavioural analysis. Ivermectin was used to activate GluCl channel. 
Intraperitoneal injection of 1 µl/g of 0.5 % ivermectin in sterile propylene glycol was 
performed. Hargreaves test was performed to assess thermal thresholds. An infrared light 
source was applied to the plantar surface of each hindpaw. Latency to withdrawal was 
measured three times per paw and averaged. Von Frey test was used to assess the mechanical 
threshold. The test was performed as described in 2.2.8. Tissue preparation for 
immunohistochemistry was identical to that described in 2.2.7. 
Detailed electrophysiological methods can be found in (Weir et al., 2017). Briefly, for ex vivo 
cell conductance assessment, DRG neurons were extracted from mice injected with AAV9-
GluClα and AAV9-GluClβ or AAV9-GluClβ alone. To assess conductance, voltage clamp ramp 
from -40mV to -90mV was used. Conductance was then derived from the linear part of the 
current response curve. For neuronal excitability assessment, the rheobase value was used. To 
determine the rheobase, cells were slowly depolarised from their resting membrane potential 
(-60mV) by a depolarising current of increasing magnitude until an action potential was elicited. 
Cell were then divided into three groups based on their rheobase value, compared to the value 
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of the control group (mean = 160.1 ± 160.6 pA): excitable (<3 SD above the control group 
rheobase), partial silencing (3-10 SD above the control group rheobase) and full silencing (>10 




4.3.1 AAV9-GCaMP6s is effective in transducing DRG neurons in vivo 
To explore the use of various functionally interesting transgenes we first had to establish their 
transduction efficiency in vivo. The first transgene we investigated was GCaMP6s, a member of 
GECI.  We assessed the transduction pattern 30 and 14 days after intrathecal delivery of AAV9-
GCaMP6s. Each injection consisted of 5 µl of AAV9-GCaMP6s, with a titre of 1.69x1013 gc/ml. 
The transgene was detected in the majority of L4 DRG neurons 30 days (64.98% ± 6.91%, n = 5, 
Fig. 4.1 a,d) and 14 days (51.82% ± 6.87%, n = 4, Fig. 4.2 a,c) after injection. Transduction in L4 
DRG 30 days after AAV9-GCaMP6s injection was similar to that observed with AAV9-eGFP 
(Two-tailed t-test, p = 0.71, n = 5, Fig 4.1 d). In addition, although the transduction in the L4 
DGR 14 days after AAV9-GCaMP6s injection was lower than that after 30 days, there was no 
significant difference between them (Two-tailed t-test, p = 0.227, n = 5-8, Fig. 4.2 c). There was 
little to no transduction in thoracic and cervical DRGs at 30 and 14 days (0.62% ± 0.4% and 
9.7% ± 7.45%, respectively, for 30 days and 3.88% ± 3.68% cervical for 14 days, Fig. 4.1 b-d, 4.2 
b, c).  
We further investigated whether AAV9-GCaMP6s has a preference for transduction of specific 
DRG sub-populations. We found no significant difference between the distribution of 
GCaMP6s-positive neurons across CGRP, IB4 and NF200 neuronal sub-populations when 
compared to the distribution of all L4 DRG neurons across these sub-populations (One-way 
ANOVA with Tuckey’s multiple comparisons correction p = 0.82 (CGRP), p > 0.99 (NF200), p = 
0.13 (IB4), n = 4, Fig. 4.3 a-d). These results were similar to those obtained with AAV9-eGFP in 







Figure 4.1 – Intrathecal delivery of AAV9-GCaMP6s results in DRG neuron transduction after 
30 days comparable to that of AAV9-eGFP. Animals were injected with 5 µl AAV9-GCaMP6s at 
1.69x1013 gc/ml. Representative IHC images of a) lumbar 4, b) thoracic and c) cervical DRG 
sections. Sections were stained for β-III-Tubulin (red) and GFP (green). Example of transduced 
and non-transduced neurons are marked with black and white arrows respectively. Scale bar = 
100 µm d) quantification of transduction efficiency for lumbar 4 (64.98% ± 6.91%, n = 5), 
thoracic (0.62% ± 0.40%, n = 5) and cervical (9.7% ± 7.45%, n = 5) DRGs, as well as the 
transduction in L4 DRG after AAV9-eGFP administration (61.12% ± 6.06%, n = 11). There was no 
significant difference in the number of transduced L4 DRG neurons for AAV9-GCaMP6s and 






Figure 4.2 – Transduction with AAV9-GCaMP6s after 14 days is not statistically different from 
30 days. Animals were injected with 5 µl AAV9-GCaMP6s at 1.69x1013 gc/ml. Representative 
IHC images a) lumbar 4, b) cervical DRG sections. Sections were stained for β-III-Tubulin (red) 
and GFP (green). Example of transduced and non-transduced neurons are marked with black 
and white arrows respectively. Scale bar = 100 µm. c) Quantification of transduction efficiency 
for lumbar 4 (51.82% ± 6.87%, n = 8), cervical (3.88% ± 3.68%, n = 4) 14 days and L4 DRG 30 
days after AAV9-GCaMP6s administration (64.98% ± 6.91%, n = 5). The difference in 
transduction between 14 and 30 days was not statistically significant (Two-tailed t-test, p = 






Figure 4.3 –  AAV9-GCaMP6s is not selective for any specific DRG neuronal subpopulation. 
Animals were injected with 5 µl AAV9-GCaMP6s at 1.69x1013 gc/ml. Representative IHC images 
of lumbar 4 DRG sections. Sections were stained for GFP (part of GCaMP6s, green) and a) CGRP 
(small diameter peptidergic population marker, red), b) NF200 (large diameter population 
marker, red) and c) IB4 (small diameter non-peptidergic population marker, red). Example of 
transduced and non-transduced neurons are marked with black and white arrows respectively. 
Scale bar = 100 µm. d) Quantification of marker labelling. There was no significant difference in 
the proportion of total neurons and GCaMP6s-positive neurons co-labelled with subpopulation 
markers (One-way ANOVA with Tukey’s multiple comparisons, p = 0.82 (CGRP), p > 0.99 





4.3.2 GCaMP6s retains its functionality and can be used for in vivo calcium imaging  
Following confirmation of the transduction efficiency in L4 DRG neurons after intrathecal 
delivery of AAV9-GCaMP6s, we investigated the functionality of the GCaMP6s transgene for in 
vivo calcium imaging. All AAV9 delivery was done by me, however all in vivo calcium imaging 
was performed by Dr Chisholm. Below, the results relevant to this thesis are presented, 
however, detailed information about the experimental set up as well as full results can be 
found in Chisholm et al. 2018. Typically, mice were left to incubate for 14 days after intrathecal 
injection of AAV9-GCaMP6s before imaging. Preliminary experiments were performed to test 
the ability to detect the GCaMP6s signal in our in vivo calcium imaging set up. We used post 
mortem increase in the cytosolic calcium to test the signal strength and detection ability of the 
GCaMP6s fluorescence. There was a clear increase in fluorescence 30 minutes post mortem 
(Fig. 4.4 b).  
After confirmation of the ability to visualize GCaMP6s in this system, we explored the use of 
external stimuli to drive neuronal activity. We used electrical stimulation of the sciatic nerve as 
a trigger and imaged ipsilateral L4 DRG to explore the limits of this set up. Electric stimuli at A-
fibre (250 µsec duration and 250 µA amplitude) and C-fibre strengths (1 msec duration and 5 
mA amplitude) were delivered to the ipsilateral sciatic nerve to see whether distinct 
populations of DRG neurons could be activated. We observed an increase in the number of 
active neurons that correlated with the increase in the stimulation frequency (Fig. 4.5 a,b). 
Interestingly, neurons responding to A-fibre stimulation also responded to C-fibre stimulation 
(Fig. 4.5 c). These results show that intrathecal administration of AAV9-GCaMP6s can be used 
to deliver functional GCaMP6s transgenes to the L4 DRG neurons. This technique can be used 
to study the neuronal activity in vivo in response to various stimuli in a wide variety of 





Figure 4.4 –  Example of the in vivo experimental set up and GCaMP6s response in AAV9-
GCaMP6s injected mice. Animals were injected with 5 µl AAV9-GCaMP6s at 1.69x1013 gc/ml 14 
days before in vivo calcium imaging. a) Diagram of the exposure procedure to access L4 DRG 
for confocal imaging. Preparation was stabilised by clamping the vertebra on either side of the 
exposure. b) Example of GCaMP6s fluorescence in DRG neurons at baseline and post mortem. 






Figure 4.5 – Electrical stimulation of the sciatic nerve elicits robust frequency and intensity 
dependent GCaMP6s responses in DRG neurons in vivo. Animals were injected with 5 µl AAV9-
GCaMP6s at 1.69x1013 gc/ml 14 days before in vivo calcium imaging. a) DRG neuronal 
responses to sciatic nerve stimulation at various frequencies and A- and C-fibre strengths. Scale 
bar = 200 µm. b) Quantification traces of neuronal cell bodies responding to A- and C-fibre 
stimulation. Yellow traces indicate neurons responding both to A- and C-fibre strength, while 
purple traces indicate C-fibre strength responders only (n = 774 neurons, 6 mice). c) Example 
traces of neurons responding to C- and A-fibre stimulations. The black trace is the average 





4.3.3 Transduction with AAV9-Cre is effective in regulating gene expression in 
transgenic animals 
Another widespread transgenic tool that can be delivered using viral vectors is the Cre 
recombinase. Cre recombinase excises parts of the DNA that are flanked by LoxP sites, which 
can be used to delete critical segments of the genome to knock out a gene of interest (Van 
Duyne, 2015). Cre recombinase can also be used to excise a pre-inserted STOP sequence, 
thereby allowing temporal control over the transcription of a gene of interest. Cre delivery 
using AAV9 serves as an alternative to transgenic lines as a method of Cre expression.  
To check whether Cre delivered via AAV9-Cre intrathecally retains its functionality, TdTomato-
flanked-STOP-cassette mice were injected with 5 µl of AAV9-Cre at 3.29x1013 gc/ml, as 
described in chapter 2.  This way, any cell that has a functional Cre recombinase in it will have 
the STOP cassette before the TdToamto gene excised, allowing expression of the TdTomato 
marker. We detected TdTomato protein in the majority of L4 (75.91% ± 2.6%, n = 4 Fig. 4.6 a,d) 
and minority of cervical (45.1% ± 10.85%, n = 4 Fig. 4.6 c,d) DRG neurons 30 days after the 
intrathecal administration of AAV9-Cre. We observed little signal in the thoracic DRGs (8.44% ± 
1.65%, n =4 Fig. 4.6 b,d), so the overall transduction pattern of AAV9-Cre resembles that of 
AAV9-eGFP (Fig. 2.4).  
Next, we injected AAV9-Cre into GCaMP6s-floxed-STOP-cassette mice to see if Cre-driven 
GCaMP6s expression is sufficient to be useful for in vivo calcium imaging. We found that 
transduction levels in the L4 and cervical DRGs were similar after 30-day (48.7% ± 6.1% and 0%, 
respectively, n = 4, Fig. 4.7 a-c) and 14-day post injection (45.95% ± 5.03% and 0%, respectively, 
n = 3, Fig 4.8 a-c), however the level of transduction was lower than that achieved with AAV9-
GCaMP6s (Fig 4.1 and 4.2). One pilot GCaMP6s-floxed-STOP-cassette mouse injected with 
AAV9-Cre was used to test the performance of Cre-dependent GCaMP6s in vivo 14 days after 





Figure 4.6 – Intrathecal delivery of AAV9-Cre into TdTomato-floxed-STOP-cassette mice 
results in TdTomato expression in DRG neurons after 30 days. TdTomato-floxed-STOP-cassette 
animals were injected with 5 µl AAV9-Cre at 3.29x1013 gc/ml. Representative IHC images of a) 
lumbar 4, b) thoracic and c) cervical DRG sections. Sections were stained for β-III-Tubulin 
(green) and RFP (part of TdTomato, red). Example of transduced and non-transduced neurons 
are marked with black and white arrows, respectively. Scale bar = 100 µm. d) Quantification of 
transduction efficiency for lumbar (75.91% ± 2.6%, n = 4), thoracic (8.44% ± 1.65%, n =4) and 
cervical (45.1% ± 10.85%, n = 4) DRGs.  
 
DRG to mechanical and thermal stimuli applied to the plantar side of the hindpaw (Fig. 4.9 a-c). 
Interestingly, same neurons could be seen responding to more than one modality of stimulus 







Figure 4.7 – Intrathecal delivery of AAV9-Cre into GCaMP6s-floxed-STOP-cassette mice 
results in GCaMP6s expression in DRG neurons after 30 days. GCaMP6s-floxed-STOP-cassette 
mice were injected with 5 µl AAV9-Cre at 3.29x1013 gc/ml. Representative IHC images of a) 
lumbar 4 and b) cervical DRG sections. Sections were stained for β-III-Tubulin (red) and GFP 
(green). Example of transduced and non-transduced neurons are marked with black and white 
arrows respectively. Scale bar = 100 µm. c) Quantification of transduction efficiency for lumbar 






Figure 4.8 – Reducing the time after injection to 14 days does not change the transduction 
profile of AAV9-Cre in GCaMP6s-floxed-STOP-cassette mice. GCaMP6s-floxed-STOP-cassette 
mice were injected with 5 µl AAV9-Cre at 3.29x1013 gc/ml. Representative IHC images of a) 
lumbar 4 and b) cervical DRG sections. Sections were stained for β-III-Tubulin (red) and GFP 
(green). Example of transduced and non-transduced neurons are marked with black and white 
arrows respectively. Scale bar = 100 µm. c) Quantification of transduction efficiency for lumbar 
4 (45.95% ± 5.03%, n = 3), cervical (0.0% ± 0%, n = 3), as well as lumbar 4 DRG 30 days after 
AAV9-GCamP6s injection (48.7% ± 6.1%, n = 4). There was no significant difference in the 
percentage of transduced L4 DRG neurons between 14-day and 30-day after AAV9-GCaMP6s 






Figure 4.9 – Delivery of AAV9-Cre into homozygous GCaMP6s-floxed-STOP-cassette mice can 
be used for in vivo imaging 14 days after injection. A homozygous GCaMP6s-floxed-STOP-
cassette mouse was injected with 5 µl AAV9-Cre at 3.29x1013 gc/ml. Representative frames 
from an in vivo recording of the L4 DRG while the plantar surface of the ipsilateral hindpaw was 
being stimulated mechanically a) or b, c) thermally. d) Example traces of GCaMP6s signals of 
three neurons that responded to pinch only (green), pinch and hot stimulus (red) and pinch and 





4.3.4 Intrathecal delivery of AAV9 can be used to express a functional engineered GluCl 
channel in L4 DRG neurons 
Lastly, we explored the use of AAV vectors to deliver chemogenetic tools that can be activated 
by specific exogenous compounds and are capable of controlling neuronal activity. This work 
was done in collaboration with Dr Weir, and my contribution was intrathecal delivery of AAV9 
vectors encoding the GluCl channel (see Weir et al. 2017 for the complete study). In this case 
we used intrathecal delivery of AAV9 to express an artificial GluCl channel in the L4 DRG 
neurons. This channel is activated by ivermectin (IVM), and upon activation facilitates an influx 
of chloride ions into the cytoplasm. In the DRG neurons, this leads to a large drop in 
membrane resistance that interferes with action potential generation and inhibits neuronal 
activity (Weir et al., 2017). For a functional channel, both alpha and beta subunits must be 
present. Because of their size, they have to be delivered by two separate AAV9 vectors. We 
injected 8 µl of a mix of  AAV9-GluClα and AAV9-GluClβ. Both GluCl channel subunits are 
expressed in 66.7% of L4 DRG neurons (Fig. 4.10 a,b). In cells expressing both subunits, when 
cultured, IVM treatment significantly increased membrane conductance, indicating that the 
GluCl channel is functional and responds to IVM. This effect is absent in vehicle-treated cells 
and in IVM-treated cells with only a beta-subunit (Fig. 4.10, c). To determine the effect of IVM 
treatment on the cell activity, current injections were used to determine the rheobase value of 
individual neurons. The cells were then classified based on their rheobase value. Values of < 3 
SD above the mean of control (Naive β-only, mean = 160.1 ± 160.6 pA) were classified as 
excitable, 3-10 SD as partially silenced and > 10 SD as fully silenced (Weir et al., 2017). Cells 
expressing both subunits of GluCl were readily silenced by IVM, while vehicle-treated or cells 
expressing one subunit only did not exhibit silencing (chi-squared test, χ2 = 32.52 with 6 
degrees of freedom, n = 7-10 animals per group Fig. 4.10 d). 
Importantly, the silencing that was seen ex vivo was also evident in vivo. IVM treatment 
increased the mechanical paw withdrawal threshold, as well as thermal threshold (Fig. 4.11). 
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This effect was not present in vehicle-treated animals or in those with only a single GluCl 
subunit (Fig. 4.11). These data suggest that viral delivery of chemogenetic transgenes can be 
used to study various aspects of DRG neurons, both in health and pathology, such as chronic 






Figure 4.10 – Intrathecal delivery of AAV9-GluCl results in expression of a functional GluCl 
channel in sensory neurons after 30 days. a) Representative IHC image of lumbar 4 DRG 
sections. Sections were stained for YFP (GluCl tag, green) and NeuN (red). Scale bar 100 µm. b) 
Quantification of the percentage of transduced neurons (66.7% ± 9.6%, n = 3). c) Ex vivo 
assessment of membrane conductance.  Membrane voltage ramp from -90 to -40 mV caused a 
change in membrane conductance in ivermectin (IVM) treated animals with both subunits, but 
not in those with only β subunit or those treated with vehicle. d) Ex vivo recording of DRG 
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neuronal membrane potential in response to depolarising current injection in animals injected 
with AAVs carrying only the β-subunit (left) or both subunits (right). Excitability status as 
defined by a rheobase value: <3 (excitable), 3–10 (partial silencing) or >10 (full silencing) 
standard deviations above the mean of control (Naive β-only, mean = 160.1 ± 160.6 pA). IVM 
treated animals with both GluCl subunits show silencing compared to vehicle-treated or single 
subunit groups (chi-squared test, χ2 = 32.52 with 6 degrees of freedom, n = 7-10 animals per 
group). Figure adapted from (Weir et al., 2017). 
 
 
Figure 4.11 – GluCl activation alters mechanical and thermal pain thresholds. a) Von-Frey test 
to assess mechanical pain threshold 30 days after AAV9-GluCl injection. Animals were given 5 
mg/kg ivermectin (IVM) 24h prior to testing. IVM treatment increased mechanical threshold of 
mice with both subunits by 63.04% ± 20.86%, p=0.015, n = 13 αβ subunit and n = 14 β only 
animals. b) Thermal threshold assessment using Hargreves test at different times after IVM 
treatment (One-way ANOVA with Bonferroni test, p<0.05, n = 9 both subunits and 8 β-subunit 





There is a great variety of transgenes that can be packaged into AAV vectors, with functions 
ranging from control of gene expression to visualization of neuronal activity to control of 
cellular activity. The ability to transduce a large number of lumbar DRG neurons using the 
intrathecal cannula infusion technique developed in this project (see chapter 2), coupled with 
the various transgenes packaged into AAVs, opens up numerous avenues of research into 
understanding the organisation, physiology and pathology of DRG neurons, as well as their role 
in the pain pathway. The aim of this chapter was to investigate the functionality of a range of 
transgenes delivered using the intrathecal catheter delivery method. 
4.4.1 Neuronal activity assessment with GECI 
It is possible to monitor neuronal activity visually with the use of GECI. We found that 
intrathecal catheter delivery of AAV9-GCaMP6s results in transduction of a majority of L4 DRG 
neurons, and the number of transduced neurons was still high when post injection time period 
was reduced from 30 to 14 days. Similar to our results with AAV9-eGFP (see chapter 2.3), we 
observed no preference for a particular sub-population of DRG neurons. Most importantly, we 
have shown that GCaMP6s delivered via intrathecal infusion can be used to image activity in a 
large number of DRG neurons in vivo, and that this set up can be used to study responses of 
these neurons to electrical, thermal, mechanical and chemical stimuli (Chisholm et al., 2018).  
It is common to use two-photon microscopy to image neuronal activity in vivo. It has several 
advantages over confocal microscopy, including greater penetrance of tissue that allows 
imaging of deeper structures; low out-of-focus noise due to limiting the excitation to the point 
of intersection of the laser beams; little bleaching and tissue damage due to longer 
wavelengths of individual beams and lack of excitation in regions other than the intersection 
point (Denk and Svoboda, 1997; Helmchen and Denk, 2005; Girven and Sparta, 2017). Two-
photon microscopy has been used to image neuronal activity in the brain and the spinal cord 
(Q. Chen et al., 2012; T. W. Chen et al., 2013; Peron et al., 2015; Tang et al., 2015; Howe and 
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Dombeck, 2016). However, it has several drawbacks that made us switch to single-photon 
confocal microscopy for GCaMP6s signal imaging in the DRGs. Two-photon microscopy is 
highly sensitive to tissue movement, so animal stabilisation is paramount. While the brain is 
easier to stabilise and make it largely unaffected by movement artefacts caused by animal 
respiration, this is a major problem in the spinal cord. In addition, aligning the DRG so that the 
whole structure is in one focal plane is problematic due to the convex surface of the DRG. 
Because of this, we opted for confocal microscopy with an open pinhole, which was not as 
affected by animal respiration and allowed for a greater number of DRG cells to be in focus. 
We observed no bleaching or phototoxicity across long imaging sessions (>2 hours) (Chisholm 
et al., 2018). In addition, confocal microscopy is not as sensitive to ambient light fluctuations 
as the two-photon system is, which allows us to access the imaging chamber and the animal 
inside it. This can be used to apply different stimuli to the animal, such as air puffs, stroking 
and pinching, as well as thermal stimuli using a Peltier device. Imaging a large group of 
neurons responding to different stimuli can give us insight into the distribution of stimulus-
specific neurons in the DRG (Chisholm et al., 2018). 
To characterise GCaMP6s performance in our system we used electrical stimulation of the 
ipsilateral sciatic nerve to drive neuronal activity in the L4 DRG, as electrical stimulation 
provides great control over the stimulus intensity and frequency. We found that GCaMP6s 
fluorescence was proportional to stimulus intensity and frequency. Greater fluorescence signal 
was observed during high frequency stimulation and more neurons were active as the stimulus 
frequency increased. We found that low intensity stimuli recruited primarily large-diameter 
neurons that correspond to A-fibres, while high intensity stimuli resulted in GCaMP6s 
fluorescence signal in both large and small-diameter nociceptive fibres. This is in accordance 
with DRG neuronal physiology, suggesting the observed GCaMP6s signal accurately reflects the  
neuronal activity patterns (Chisholm et al., 2018). Additionally, we found that although 
GCaMP6s kinetics do not allow its fluorescence signal to accurately follow the intracellular 
calcium fluctuations during high-frequency stimulation, we observed that GCaMP6s 
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fluorescence exhibits summation, with greater fluorescence observed at higher frequencies. 
Therefore, GCaMP6s fluorescence can serve as an indicator of the action potential frequency. 
Interestingly, when we used natural stimuli instead of electrical stimulation to test neuronal 
responses we found evidence of neuronal polymodality, with same neurons responding to 
mechanical and thermal stimuli, which contrasted a recently published study by Emery et al. 
(Emery et al., 2016; Chisholm et al., 2018).   
In vivo imaging of virally-delivered GCaMP6s in L4 DRG neurons makes it possible to study 
neuronal activity during pathology in great depth, as it allows us to apply various stimuli to the 
animal with pathology and record neuronal responses to these stimuli, to then be compared to 
results obtained in healthy controls. For instance, neuronal responses to both warming and 
cooling of the plantar surface of a hindpaw after UVB-induced inflammation are significantly 
higher than control group, which his consistent with electrophysiological findings (Bishop et al., 
2010). In addition, we found that the number of neurons responding to warming of the 
hindpaw following UVB-induced inflammation was greater than in control animals (Chisholm et 
al., 2018). This example serves to illustrate that our in vivo imaging method of studying 
neuronal activity in the primary sensory neurons can be applied to answer a number of 
biological questions and study neuronal activity both in health and in a range of pathological 
conditions, such as neuropathic pain and chronic inflammation. 
4.4.2 Control of gene expression with virally-delivered Cre recombinase 
One of the widespread transgenic tools used to control gene expression is targeting of LoxP 
floxed genes with Cre recombinase. We show in this study that expression of Cre recombinase 
using intrathecal delivery of AAV vectors is a viable strategy for controlling gene expression in 
the majority of L4 DRG neurons. With a single injection of AAV9-Cre we managed to express 
Cre recombinase in DRG neurons at a sufficient level to enable expression of TdTomato 
reporter in over 70% of L4 DRG neurons. This number is higher compared to our results after 
transduction with AAV9-eGFP (61%, see chapter 2.3). This is likely due to the differences 
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between Cre-dependent expression of TdTomato and eGFP expression after AAV9-eGFP 
transduction.  In case of AAV9-eGFP, transgene expression is tied to the genetic cargo of AAV9. 
The level of eGFP expression in a cell is proportional to the number of viral particles that 
transduced each individual cell, e.g. a cell with 10 times the virus particles will make 10 times 
the eGFP protein in a given time frame. For a cell to be detected with IHC, a certain threshold 
of eGFP expression must be reached, so cells that were transduced with few viral particles are 
not likely to be counted as positive, even though they were transduced. However, in 
TdTomato-floxed-STOP-cassette mice, Cre recombinase excises a single STOP cassette that in 
naïve animals prevents expression of TdTomato. Once the STOP signal is removed, the 
TdTomato transgene expression is driven by a strong innate promoter. Therefore, transduction 
with even a few AAV9-Cre particles can result in strong transgene expression.  
In addition to regulating expression of fluorescent markers, in this study we also show that 
virally-delivered Cre recombinase can control expression of complex transgenes. In our study, 
we used AAV9-Cre to express GCaMP6s in a GCaMP6s-floxed-STOP-cassette mouse line. The 
number of cells expressing GCaMP6s was lower than that in the TdTomato experiment (48% vs 
70%). The reason for the discrepancy in the number of transduced cells is unknown, and could 
be due to experimental variability. However, expression of GCaMP6s in the L4 DRGs was high 
enough to be used for in vivo calcium imaging. We show an in vivo recording of an L4 DRG that 
is responding to thermal stimuli applied to the hindpaw as a proof of concept. Further 
confirmation of successful transduction following intrathecal administration of AAV9-Cre could 
be achieved by analysing RNA composition using RT-PCR. Unfortunately, due to time 
constraints, we were unable to complete this experiment. 
These data illustrate that the Cre recombinase delivered via intrathecal infusion of AAV9-Cre 
retains its functionality in DRG neurons and can be used in cases when transgenic Cre animal 
lines are unavailable or when temporal control over Cre expression is required. Additionally, it 
may be possible to restrict Cre expression by targeted peripheral injection, such as intraneural 
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(see chapter 2.3) or intramuscular injection (Anderson et al., 2018), although the injection 
method has to be verified to avoid off-target transduction. 
4.4.3 Neuronal activity control with GluCl transgene 
Lastly, we used our intrathecal injection method to deliver chemogenetic tools to the DRG 
neurons and to investigate their effectiveness. Chemogenetic tools, such as DREADDs and 
GluCl channel, allow inhibition or excitation of cells by controlling ion flux across the cell 
membrane in response to binding of a specific ligand.  However, most chemogenetic channels 
are large proteins, and the DNA encoding the full channel may be too long to fit in a single AAV 
vector. Here, we show that it is possible to express complete GluCl channel by intrathecal 
infusion of two AAV9 vectors, each carrying a GluCl subunit (Weir et al., 2017). The majority of 
L4 DRG neurons in adult mice were transduced, an improvement compared to our earlier data 
(see chapter 2), which could be due to higher titre (2.4-1.5 x 1013 gc/ml vs 6.39 x 1012 gc/ml) as 
well as greater injection volume (8 µl vs 5 µl) . 
To test whether GluCl was functional, membrane conductance of transduced neurons was 
assessed following treatment with ivermectin (IVM), the ligand for this modified GluCl channel. 
IVM-treated neurons with both GluCl subunits showed increased conductance, indicating that 
GluCl channel was functional and responded to IVM ligand. This increase in conductance was 
absent in non-transduced IVM-treated neurons and in transduced vehicle-treated neurons, 
suggesting that the GluCl channel is closed in the absence of IVM. Furthermore, we see that 
activated GluCl channel is capable of silencing transduced DRG neurons.  
It is important to note that the silencing effect of GluCl activation in DRG neurons is different 
from that in CNS neurons. In the CNS, neurons maintain low intracellular chloride ion 
concentration. Opening of the GluCl channel allows an influx of chloride ions from the 
extracellular space, hyperpolarising the neurons (Slimko et al., 2002; Lerchner et al., 2007; 
Frazier, Cohen and Lester, 2013). DRG neurons, however, maintain high intracellular chloride 
ion concentration, so GluCl channel activation does not trigger an influx of chloride ions and 
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hyperpolarisation. The silencing that is evident in our study is likely due to a general increase in 
membrane conductance, however the precise mechanism of action is not clear (Weir et al., 
2017). 
Administration of IVM to animals injected with AAV9-GluCl produced a profound increase in 
the mechanical and thermal sensory thresholds. This finding is important as it shows that 
transduction levels in DRG neurons after a single AAV infusion are sufficient to influence 
behaviour. This opens a wide range of possible applications for AAV-mediated delivery of other 
chemogenetic tools. For example, virally-administered DREADDs have been previously used to 
control neuronal activity in the brain, both to inhibit neuronal activity in nucleus accumbens 
neurons using the hM4Di DREADD (T. Zhang et al., 2018), and to activate hypothalamic 
neurons using the hM3D (N. Zhang et al., 2018). Intrathecal administration of AAV9 carrying 
these tools could make it possible to express them in a large number of DRG neurons, and to 
study their role in the pain circuit by influencing their activity both in health and in a range of 
pathological conditions, such as neuropathic pain (Weir et al., 2017). 
4.4.4 Conclusion 
In this chapter we have shown that the intrathecal delivery of AAV vectors developed in 
chapter 2 can be used to express a number of functional transgenes in the L4 DRG neurons. 
This includes GECI such as GCaMP6s to study the neuronal activity patterns in the DRGs, Cre 
recombinase to allow control of the gene expression in floxed-STOP-cassette transgenic lines 
and chemogenetic tools, such as the GluCl channel, to control neuronal activity. Importantly, 
these examples show that the level of neuronal transduction after AAV9 delivery using this 




Chapter 5: Project conclusions and future directions 
5.1 Project outcomes 
Viral vectors are invaluable tools that can be used to study multiple aspects of the physiology 
of the nervous system in health and in pathological conditions. Further, they can be used as 
potential treatments for a multitude of nervous system disorders, including chronic pain 
(Glorioso, Mata and Fink, 2003; Mata, Hao and Fink, 2008; Srinivasan, Fink and Glorioso, 2008; 
Lentz, Gray and Samulski, 2012; Kantor et al., 2014; Guedon et al., 2015). In the case of pain 
research and therapy, primary afferent neurons in the dorsal root ganglia are of a particular 
interest as they play a critical role in nociception and physiological, as well as pathological, 
sensitization (Basbaum et al., 2009; Ringkamp et al., 2013; Liem et al., 2016). Targeting these 
neurons with viral vectors is a very powerful experimental approach that can be used to 
express a wide array of transgenes for research and therapy (Lentz, Gray and Samulski, 2012; 
Guedon et al., 2015; Liem et al., 2016; Chen et al., 2018). There are many types of viral vectors 
available, each with its own advantages, however AAV vectors are the most popular type used 
for transgene delivery in the nervous system (Lentz, Gray and Samulski, 2012; Kantor et al., 
2014). AAV vectors have been used to target DRG neurons, however variables such as delivery 
route and AAV serotype have been shown to greatly impact transduction levels in these 
neurons (see chapter 2.1).  
The aim of this project was two-fold. The first aim was to characterise the transduction pattern 
of AAV9 vectors in adult mouse DRG neurons following intrathecal delivery, and to explore the 
impact of various experimental variables, such intrathecal delivery method, post injection time, 
viral titre, transgene and AAV serotype. This also included assessment of any unintended 
effects of IT delivery and AAV transduction, such as a change in nocifensive behaviour and the 
triggering of an immune response following transduction. Also, we aimed to restrict transgene 
expression to DRG neurons that send projections to distinct anatomical structures by the 
means of peripheral injections of AAV9. The second aim of this study was to explore the 
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applications for AAV transduction of DRG neurons following intrathecal delivery using several 
functional transgenes in vitro and in vivo, including GECI GCaMP6s for visualising neuronal 
activity, Cre recombinase for control of gene expression and mutated GluCl channel for 
neuronal activity modulation. 
5.1.1 Characterisation of DRG transduction following in vivo delivery of AAV9 
Initially, we used lumbar puncture to deliver AAV9 into the intrathecal space. We observed 
transduction in the majority of L4 and cervical DRGs after intrathecal injection of 5 µl of AAV9-
eGFP. However, this method suffered from low reliability, as many injected animals showed 
very low or absent expression. This is likely due to the variability in uptake and administration 
volumes of AAV vector due to syringe dead space. Furthermore, it is possible that the lack of 
visual confirmation of needle placement meant that some injections were not intrathecal. The 
issues caused by the syringe dead space can be overcome by using specialised syringes with 
zero dead space, however this does not address the problem of visual confirmation of the 
needle placement. We designed a method of intrathecal delivery that eliminates dead space 
by using a thin polytetrafluoroethylene (PTFE) catheter connected to a syringe pump to deliver 
AAV intrathecally. By inserting the catheter into an opening in the dura it is possible to visually 
confirm intrathecal placement of the catheter. A similar AAV intrathecal delivery method has 
been used in rats (Xu et al., 2012), however it involved catheter implantation for 72 hours, 
while our method only requires the catheter to be in the animal for 7 to 9 minutes. DRG 
transduction observed using this technique was as good as lumbar puncture delivery, however 
the reliability was much greater, with only few animals (8%) showing low transduction in their 
L4 DRGs. Importantly, the proportions of CGRP, IB4 and NF200-positive neurons both in 
transduced neuronal population and in all L4 DRG neurons were not significantly different, 
suggesting that our IT delivery does not target a particular DRG neuronal subtype. However, 
assessment of transduced neuronal sub-populations was performed only at L4 DGR level, and 
future experiments are needed to assess neuronal distribution at other DRG levels. 
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Although this technique is more reliable, it is also more invasive and more complex compared 
to lumbar puncture. The intrathecal space in the mice is extremely limited, and introduction of 
foreign objects such as a catheter may cause damage to the spinal cord and nerve roots 
(Fairbanks, 2003). Mechanical hyperalgesia has been reported following spinal cord injury 
(Brewer and Yezierski, 1998; Yezierski et al., 1998). Therefore, we used the Von Frey test to 
assess mechanical sensitivity in animals following intrathecal saline administration using the 
catheter approach. We observed no significant change in mechanical sensitivity, suggesting 
that the catheter does not cause spinal cord damage. However, further confirmation with 
other behavioural tests, such as the Hargreaves test for thermal sensitivity (Hargreaves et al., 
1988) or the Basso, Beattie, Bresnahan (BBB) Locomotor Rating Scale for motor function is 
required (Basso, Beattie and Bresnahan, 1995; Ma et al., 2001). 
In addition to the delivery method, AAV9 transduction itself may cause behavioural alterations 
and a local immune response (Samaranch et al., 2014). However, when we tested this we 
found no significant difference in the mechanical sensitivity or the immune cell composition of 
lumbar DRGs between saline and AAV9-eGFP injected mice. This suggests that AAV9 
transduction following intrathecal delivery does not cause a local immune response and does 
not change the mechanical sensory phenotype. However, it is important to note that other 
assessments are required to fully explore the effect AAV9 transduction might have on the 
animal behaviour, as well as its immunogenicity.  
As part of this project, we assessed the impact of several experimental factors, such as virus 
titre and post injection time, on DRG transduction efficiency following IT delivery of AAV9. 
Reducing the post injection time period from 30 days to 7 days resulted in comparable 
numbers of transduced neurons in the L4 DRG. Interestingly, our data for 14-day post injection 
time period show reduced transduction in the cervical DRGs compared to 30-day post injection. 
However, this difference is not likely to be due to the reduced time available for vector spread 
in the CSF, as the 7-day post injection time period results in cervical transduction comparable 
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to 30 days. It is rather caused by the methodological variability, and further experiments with 
14 days post injection time periodare required to assess reproducibility of these results. 
Furthermore, we found that decreasing the virus titre had a tendency to reduce the number of 
transduced neurons in the L4 DRG, albeit this did not reach statistical significance. Further 
investigation with a larger experimental group is needed to determine the precise impact of 
viral titre on transduction in DRG neurons. Importantly, this trend was more pronounced in 
cervical ganglia, with a statistically significant reduction in transduction at lower titres. This 
could be explained by the progressive fall in the number of viral particles with increasing 
distance from the injection epicentre, with fewer viral particles spreading to the cervical level 
at lower titres.  
We also assessed whether changing the AAV serotype or the packaged transgene has an 
impact on neuronal transduction. We found no significant difference in L4 DRG neuronal 
transduction between AAV9-eGFP and AAV9-mCherry, suggesting that the transgene itself 
does not impact transduction. However, when we examined IT injection AAV serotype 8 we 
observed a reduction in the percentage of transduced neurons in L4 DRG. This data is in 
agreement with the literature, where AAV transduction has been shown to be influenced by 
the serotype, and AAV9 has been shown to have superior transduction rates in DRG neurons 
compared to AAV8 (Vulchanova et al., 2010; Snyder et al., 2011; Schuster et al., 2014). 
In our attempt to target sensory neurons innervating distinct anatomical structures, we 
injected AAV9 into the sciatic nerve, the knee joint and the plantar surface of the hind paw. 
We observed that intra-sciatic injection produced moderate labelling in the ipsilateral L4 DRG, 
while no labelling was present in the contralateral L4 DRG. This suggests that intra-sciatic 
injections can be used to selectively deliver transgenes to a sub-population of sensory neurons 
on the ipsilateral side of the animal. However, in experiments with intraarticular and 
intraplanar injections we observed labelling on both ipsilateral and contralateral sides in L3 
and L4 DRGs, respectively. This is likely due to the AAV9 leaking into the bloodstream. In the 
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future, it may be beneficial to assess whether changing the injection volume or the viral titre 
can restrict transduction only to the ipsilateral DRG neurons. In addition, future experiments 
investigating whether injections into other peripheral targets, such as tibial bone (Kushida et 
al., 2001; Liu et al., 2012), bladder wall (Fu et al., 2011) and parts of the digestive system 
(Benskey et al., 2015) could be used to specifically target primary afferent neurons that send 
projections to these structures. 
Overall, we achieved the first aim of this project by characterising AAV9 transduction after 
intrathecal delivery. We set up a new intrathecal delivery method for AAV9 using a catheter 
that achieved high transduction in the L4 DRG neurons, and assessed the impact several 
experimental variables, such as titre and post injection time, have on the transduction. We 
also investigated the potential for peripheral administration of AAV9 into anatomically distinct 
structures as a way to target only sensory neurons that project to these structures. 
5.1.2 Setting up an in vitro sensitisation model 
The second aim of my project was to explore the applications of intrathecal delivery to express 
different transgenes that can be used to study several aspects of primary sensory neurons 
physiology. Before assessing whether AAV9-delivered transgenic tools could be used for in vivo 
experiments, such as in vivo calcium imaging, we first confirmed that GCaMP6s was functional 
in vitro, and tested whether it could be used to study acute sensitisation in DRG cultures. To do 
this, we set up a neuronal sensitisation model that uses electrical field stimulation as a trigger 
for neuronal activity. We opted to use electrical stimuli instead of the more commonly used 
chemical triggers like capsaicin, as electrical stimulation circumvents the caveat of neuronal 
tachyphylaxis, often observed with chemical stimuli (Koplas, Rosenberg and Oxford, 1997; 
Mohapatra and Nau, 2003). We observed that virally-delivered GCaMP6s could be used to 
image neuronal activity in dissociated adult mixed DRG cultures. GCaMP6s performance was 
comparable to that of a commonly used chemical calcium dye Fura-2 AM. Although GCaMP6s 
has been shown to have superior signal-to-noise ratio and brightness compared to synthetic 
182 
 
calcium dye Oregon Green Bapta-1-AM (T. W. Chen et al., 2013), future experiments 
comparing various aspects of GCaMP6s and Fura-2 AM performance, such as deactivation 
kinetics, are needed to quantitatively compare these two dyes. 
By comparing the trigger-elicited neuronal activity before and after addition of a potential 
sensitizer, we hoped to quantify the neuronal sensitisation. We analysed the difference in 
neuronal responses after application of several compounds that are known neuronal 
sensitizers, including PGE2 and bradykinin. Overall, we detected only mild sensitisation of 
neuronal responses that was mostly elicited by stronger stimuli and was only present after 
addition of PGE2 or inflammatory soup. The lack of potentiation of neuronal responses 
observed in this study compared to that reported in the literature could be attributed to the 
way these compounds elicit neuronal sensitisation. The sensitizers trigger intracellular 
signalling pathways that alter activity of several membrane proteins, such as TRPV1 (Lopshire 
and Nicol, 1997; Geppetti and Trevisani, 2004; Huang, Zhang and McNaughton, 2006). This 
causes stimulation with capsaicin, a TRPV1 activator, to produce greater neuronal responses. 
However, electrical stimulation may not elicit neuronal activity via the targets of these 
intracellular pathways, and therefore would not show an increased neuronal response. 
Alternatively, these sensitizers may exert their action on a particular subset of DRG neurons, 
such as small-diameter unmyelinated C-fibres that express Nav1.8 (Gold et al., 2002; Meves, 
2006). In this study DRG cultures contained a mix of neurons from different sub-populations, 
so it is possible that an effect on a small proportion of the neurons in culture was diluted by 
the rest of the neurons. 
In future experiments, it may be beneficial to explore other stimulation paradigms, possibly 
ones that deliver stronger stimuli, as most of the significant increases in neuronal responses in 
this study were found following the strongest trigger stimuli. Furthermore, prolonged 
application of the sensitizers may increase the sensitivity to electrical stimuli. Future 
experiments could also be carried out to explore the use of other sensitizer compounds, such 
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as cytokines and chemokines, to sensitize neurons to electrical stimuli (Dawes et al., 2013). 
Lastly, although a large number of neurons was used to assess the effect of each sensitizer, the 
number of biological repeats used for cultures was low. Therefore, it is important to repeat 
these experiments with an increased number of animals, to control for animal differences.  
Overall, we showed that virally-delivered GCaMP6s remains functional and can be used to 
visualise neuronal activity in vitro. We used GCaMP6s and Fura-2 AM to attempt to set up an in 
vitro sensitisation model, however we did not manage to elicit robust neuronal sensitisation. 
Further work is required to develop and optimise this model. 
5.1.3 Confirmation of transgene functionality in vivo  
Although we did not succeed in setting up an in vitro sensitisation model, our cell culture 
experiments showed that virally-delivered GCaMP6s is functional and can be used to image 
neuronal activity in DRG neurons. When AAV9-GCaMP6s was administered intrathecally using 
a catheter, we observed transduction in the majority of L4 DRG neurons following 
immunohistochemical assessment. My colleague Dr Chisholm designed and optimised an in 
vivo calcium imaging set up that could be used to image activity in L4 neurons of mice 
previously injected with AAV9-GCaMP6s. We observed a strong increase in GCaMP6s signal in 
L4 DRG neurons post-mortem, coinciding with the increase in intracellular calcium. This 
showed that virally-delivered GCaMP6s retains its functionality in vivo and can be used as a 
proxy for neuronal activity. Furthermore, we were able to use AAV9-delivered GCaMP6s to 
study neuronal responses to electrical stimulation of the sciatic nerve. We showed that 
GCaMP6s could report single action potentials at low frequencies of stimulation, and at higher 
frequencies the strength of GCaMP6s fluorescence was proportional to the stimulus frequency. 
In addition, we showed that it is possible to recruit only A-fibres or A- and C-fibres by varying 
the strength of the electrical stimuli. These experiments show that virally-delivered GCaMP6s 
can be used to study neuronal activity of DRG neurons in vivo. Although not shown here, the 
use of this technique has allowed us to study the responses of sensory neurons to natural 
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stimuli, such as heat, cooling, stroking and pinching in healthy mice and those with a plantar 
UV burn, as well as neuronal activity in animals that received an intraplantar injection of 
formalin (Chisholm et al., 2018). 
We also explored the use of virally-delivered Cre recombinase to modulate expression of 
genes in transgenic mouse lines. We found that intrathecal delivery of AAV9-Cre into 
TdTomato-floxed-STOP-cassette mice produced strong expression of TdTomato in a majority of 
L4 DRG neurons. Similar results were observed in GCaMP6s-floxed-STOP-cassette mice, 
although the percentage of transduced neurons was lower. This could be attributed to 
methodological variability. Repeating these experiments with an increased number of animals 
would help to establish whether the difference in transduction is due to differences between 
these two transgenic lines or the result of methodological variability. However, we have shown 
that despite reduced transduction, levels of Cre-dependent GCaMP6s expression were 
sufficient for the use in in vivo calcium imaging experiments.  
Finally, through collaboration with Dr Weir at Oxford University, we explored the use of 
intrathecal AAV delivery for expression of chemogenetic tools. In these experiments, we used 
our IT delivery method to express an engineered glutamate-gated chloride channel GluCl in 
primary afferent neurons. We found that intrathecal catheter co-administration of two AAV9 
vectors carrying α and β subunits of the GluCl, respectively, results in expression of a 
functional GluCl channel in the majority of the L4 DRG neurons. Furthermore, activation of 
GluCl by ivermectin fully silenced over 90% of the transduced neurons in vitro. Finally, 
administration of ivermectin to AAV9-GluCl injected animals resulted in changes in animal 
behaviour, increasing the mechanical and thermal threshold, assessed by Von Frey and 
Hargreaves tests, respectively. This suggests that the GluCl channel was functional in vivo, and 
that the number of transduced neurons was high enough to elicit a change in behaviour. Dr 
Weir and colleagues went on to show that in a model of neuropathic pain, activation of AAV9-
delivered GluCl can alleviate injury-induced hypersensitivity (Weir et al., 2017). 
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These experiments show that intrathecal delivery of AAV9 can be used to express a number of 
functional transgenes in DRG neurons that can be used to interrogate various aspects of the 
primary afferent neurons physiology in health and disease.  
5.2 Future directions 
The results in this project, and other studies, show that intrathecal administration of AAV9 
results in potent transduction in DRG neurons. It is not known which part of the DRG neurons 
the AAV9 particles initially transduce. One possibility is that after intrathecal injection AAV9 
particles transduce DRG neuronal projections in the posterior root, which are then 
retrogradely transported to the neuronal soma in the DRG. This could explain the superior 
transduction seen with AAV9 compared to other serotypes after intrathecal injection (Snyder 
et al., 2011; Schuster et al., 2014), as AAV9 exhibits strong retrograde transport (Castle, 
Gershenson, et al., 2014; Castle, Perlson, et al., 2014). Recently, a new designer AAV, rAAV2-
retro, has been developed, and it has shown superior retrograde transport compared to all 
other commonly used AAV vectors, including AAV9 (Tervo et al., 2016). Therefore, it could be 
beneficial to assess the DRG neuronal transduction efficiency of rAAV2-retro using intrathecal 
delivery, as the superior retrograde transport capabilities may result in a higher percentage of 
neurons transduced compared to 60% observed in this project with AAV9. 
The majority of our experiments focused on transducing sensory neurons in the lumbar DRGs. 
However, there are many areas of research that focus on sensory and motor function at higher 
levels. For instance, in stroke research the forelimb pellet reaching and grip strength tests are 
common behavioural assessments of the pathology severity and is used to test the effects of 
various interventions (Kathe et al., 2016). Another example is migraine research, where there 
is  great interest in the trigeminal ganglia and the role the trigeminal sensory neurons play in 
the development of migraine (Edvinsson et al., 2018; Messlinger, 2018). Therefore, a viral 
delivery technique that is capable of transducing sensory neurons in the higher ganglia would 
have many applications both within the pain research field and beyond. There are several 
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experimental approaches that may produce better labelling in the higher ganglia. First, we 
showed that delivering a high-titre AAV9 with a lumbar catheter results in transduction of 
around 60% DRG neurons in the cervical ganglia. Therefore, further experiments that focus on 
transduction in the cervical and trigeminal ganglia after intrathecal lumbar catheter delivery of 
a high-titre AAV9 may help us to determine factors that are important for high ganglia 
transduction. Second, changing the catheter orientation so that it points rostrally may boost 
the spread of the virus to the higher ganglia. However, it is likely that the spinal level and the 
technique of catheter will have to be altered to avoid damaging the spinal cord as the 
intrathecal space around the thoracic level is very restricted. Alternatively, switching to 
cisterna magna (CM) delivery of the AAV vectors could result in higher transduction in higher 
ganglia, as the injection epicentre would be much closer to the cervical and trigeminal ganglia. 
CM injections are often performed in larger laboratory animals such as rats, rabbits and 
primates (Kikkawa, Kurogi and Sasaki, 2014; Samaranch et al., 2016; Hinderer et al., 2017; Lee 
et al., 2018). However, CM injections in mice are more difficult due to the small size of the 
injection target (Yili Chen et al., 2013). There are several methods for CM injection in mice, 
from direct injection through the atlanto-occipital membrane using a standard Hamilton 
syringe (Fu et al., 2003, 2007; Sinnett et al., 2017), to the use of modified needles with 
stoppers to regulate penetration depth (Lee et al., 2011, 2013), and the use of curved needles 
to allow easier access (Yili Chen et al., 2013). All these methods may be applicable to AAV9 CM 
delivery, however loading of small volumes of viral suspension may be problematic as 
observed with lumbar puncture delivery in this project. Finally, a recently developed O’Buckley 
intrathecal delivery method relies on insertion of a thin catheter through the condylar canal in 
the mouse skull (Oladosu et al., 2016). This method may be effective for the transduction of 
cervical and trigeminal ganglia, as it allows visual verification of the injection site and uses pre-
loaded catheters instead of syringes, which makes it easier to observe correct loading and 
delivery volumes. Future experiments should focus on exploring the use of these methods to 
deliver AAV9 into the CM. This would include an assessment of transduction in the trigeminal, 
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cervical, thoracic and lumbar ganglia, a head-to-head comparison of these delivery methods, a 
characterisation of the transduction pattern and an assessment of the impact of viral titre and 
post injection time on the transduction efficiency.  
Our results show that AAV9 does not target a specific sub-population of DRG sensory neurons. 
This feature is beneficial, as it reduces the population bias in the results. However, it can also 
cause a dilution effect if only a particular sub-population of the transduced neurons responds 
to a specific treatment. In that case, analysis of all transduced neurons together is likely to 
result in a statistically insignificant effect. Therefore, it may be beneficial to target viral 
transduction, or the expression of the transgene, to specific neuronal sub-populations. This 
could be achieved by using AAV serotypes that have a preference for a particular sub-group of 
sensory neurons, for instance AAV8 has been reported to preferentially target large-diameter 
neurons in the DRG (Vulchanova et al., 2010; Jacques et al., 2012). However, this approach 
may not produce the desired level of specificity, as other neuronal sub-types are also 
transduced. A better approach may be restricting transgene expression by using sub-
population-specific promoters. For instance, in vitro transduction with an adenovirus that 
packages a lacZ reporter gene under the control of a CGRP promoter resulted in a 91% co-
expression of the LacZ gene with the endogenous CGRP neurons (Durham et al., 2004). 
Alternatively, it is possible to use Cre-dependent AAV vectors (Saunders and Sabatini, 2015; 
Haenraets et al., 2018). For instance, reversing the transgene sequence and flanking it with 
LoxP sites in the expression plasmid will make the transgene expression impossible. However, 
when cells expressing the Cre recombinase are transduced, Cre will cause recombination and 
inversion of the transgene, making its expression possible (Saunders and Sabatini, 2015). These 
viral vectors can be used in conjunction with transgenic mouse lines that express a Cre 
recombinase in a particular subset of DRG neurons, for instance in the Nav1.8-positive 
nociceptors (Stirling et al., 2005), to restrict expression of the transgene to a particular sub-
population of neurons.  
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We have shown that GCaMP6s delivered using IT injection of AAV9 is functional in animals and 
can be used for in vitro and in vivo calcium imaging. Using this technique, we have explored 
the responses of DRG neurons to different modalities of stimuli, and showed that there is a 
degree of polymodality in the L4 DRG neurons (Chisholm et al., 2018). In the future, it would 
be beneficial to explore how the pattern and the magnitude of neuronal responses change in 
animal models of chronic pain, such as the chronic constriction injury model of neuropathic 
pain, or the intraplantar CFA injection model of chronic inflammatory pain, as there is evidence 
that the activity of DRG neurons as well as their modality is altered in chronic pain (Basbaum et 
al., 2009; Gangadharan and Kuner, 2013). For instance, we found that relatively few primary 
afferent neurons responded to cold stimuli compared to the number of neurons responding to 
hot stimuli (Chisholm et al., 2018). Neuropathic pain is known to induce cold hypersensitivity, 
and that effect is partially mediated by primary afferents (Allchorne, Broom and Woolf, 2005; 
Basbaum et al., 2009; Draxler et al., 2014). It would be interesting to investigate whether 
neuropathic pain results in an increased number of cold-responsive DRG neurons, as well as 
augmentation of the intensity of their responses to cold stimuli. In addition, central terminals 
of the DRG neurons also express the transgene after AAV9 transduction. Therefore, it is 
possible to image the activity in the central terminals of the primary afferents in animals after 
AAV9-GCaMP6s IT administration, which can be used to study the dorsal horn pain circuitry. 
Moreover, it may be possible to further interrogate the interactions between neurons in the 
spinal circuitry involved in nociception by using a second GECI of a different colour, such as 
red-shifted RCaMP or R-GECO (Zhao et al., 2011; Akerboom et al., 2013). These GECI use 
excitation and emission frequencies that are different from those of GCaMP6s, so their signal 
would not interfere with that of GCaMP6s, and therefore this allows expression of two GECI in 
the same animal. For example, by expressing the GCaMP6s in the sensory neuron terminals 
and the red-shifted GECI in the other parts of the nociceptive circuitry in the spinal cord, we 
may be able to image how these two parts interact. For instance, it is possible to transduce 
neurokinin-1 receptor positive projection neurons that receive input from the sensory neurons 
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and project from the dorsal horn to the higher centres by injecting AAV9 into the parabrachial 
nucleus (Cameron et al., 2015). By expressing a red-shifted GECI in these neurons and a 
GCaMP6s in the primary afferents, it could be possible to image how activity in the afferent 
neurons influences that in the projection neurons. This could then be expanded to 
investigating the changes in signal processing in various chronic pain models, such as the 
chronic constriction injury neuropathic pain model, in the targeted area of the pain circuitry.  
Transgenic mouse lines are being developed for targeted GCaMP6s expression, such as ones 
where GCaMP6s expression is under the control of Cre recombinase, which in turn is only 
expressed in primary afferent neurons by expressing it from the Advillin gene locus (Zurborg et 
al., 2011). In this study we started breeding of GCaMP6s-floxed-STOP-cassette mice with an 
Advillin-Cre-ERT2 mice. By using a Cre fused to a mutated oestrogen receptor this allows 
temporal control over the GCaMP6s expression by activating the Cre with tamoxifen 
administration (Lau et al., 2011). This way, we eliminate the need for the intrathecal injection 
of the AAV9-GCaMP6s to image activity in the sensory neurons. However, we were unable to 
breed a cohort of mice of sufficient size due to time constraints. In addition, viral delivery of 
GCaMP allows greater flexibility, for example for targeted administration to an anatomical 
subset of neurons, or for co-expression of several transgenes in the animal. 
Viral vectors have been used extensively as a method for modulation of gene expression, for 
instance as delivery vehicles for Cre recombinase. Virally-delivered Cre has been used in pain 
research to study the effects of knockout of certain genes, for instance the Nav1.6 knockout in 
neuropathic pain (Chen et al., 2018), or the signal transducers and transcription activator 3 
(STAT3) in both oxaliplatin-induced chronic pain and pain caused by lumbar disk herniation (Y. 
Y. Li et al., 2017; Zhang et al., 2017). The usefulness of the Cre-LoxP system for modulation of 
gene expression is limited by the availability of transgenic lines with LoxP site insertions at the 
relevant paint in the genome. It is also possible to interfere with the expression of genes at the 
RNA level by using miRNAs and shRNAs. Viral vectors have been used to deliver these  tools in 
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a wide variety of fields (Herrera-Carrillo, Liu and Berkhout, 2017). In the field of pain research, 
AAV-administered shRNAs have been used to knock down many genes to study their roles in 
more detail, such as ion channels Nav1.3 and Cav2.2, as well as TRPV1, in neuropathic pain 
(Samad et al., 2013; Hirai et al., 2014; Yang et al., 2018). Therefore, it would be beneficial to 
explore the use of virally-delivered RNAi tools in conjunction with intrathecal administration of 
AAV9 carrier. If successful, this would be a powerful model for studying the importance of 
many genes in the DRGs, both in healthy animals and in pathological pain models.  
Despite extensive use of RNAi approaches, it has some disadvantages. These tools act at the 
mRNA level, therefore they are not suitable for studying non-coding genome regions (Schmidt 
and Grimm, 2015). Furthermore, virally-delivered shRNA has been shown to cause cell damage 
and death (Grimm et al., 2006; Grimm, 2011). Therefore, alternative methods of influencing 
gene expression may be necessary to overcome these limitations. One such tool is the 
CRIPSR/Cas9 system. Briefly, this system uses guide RNA (gRNA), comprised of CRISPR-
associated RNA (crRNA) and trans-activating CRISPR RNA (tracrRNA), to target the Cas9 
nuclease to specific sections of the host genome. Once in place,Cas9 nuclease can then create 
a double-strand break at the target site (Doudna and Charpentier, 2014; Hsu, Lander and 
Zhang, 2014; Sander and Joung, 2014). Both the Cas9 and the gRNA can be delivered in a single 
AAV vector (Senís et al., 2014), and this delivery system has been successfully used in several 
studies. For instance, for deleting the mutant exons of the dystrophin  gene to correct 
Duchenne muscular dystrophy (Tabebordbar et al., 2016; Wang et al., 2017). Therefore, the 
use of this technique to study the contribution of various gene to pain states is another avenue 
that is worth exploring in the future through viral delivery of CRISPR/Cas9 system to neurons in 
the pain circuit. 
Another powerful experimental approach is using AAV vectors to deliver chemogenetic and 
optogenetic tools to modulate neuronal activity. Targeted expression of optogenetic tools that 
influence activity of neurons can be used to interrogate specific parts of the neuronal circuit 
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(Yamawaki et al., 2016). This approach has been extensively used for interrogating neuronal 
circuitry in several research fields, including sleep (Fuller, Yamanaka and Lazarus, 2015), stress 
(Sparta et al., 2013) and hearing (Shimano et al., 2013). It has also been used in the pain field. 
For example, AAV vectors have been used to target expression of optogenetic tools to neurons 
in the anterior cingulate cortex, where inhibition of these neurons by the optogenetic tools 
delivered resulted in a reduction in nocifensive behaviour in animals with trigeminal neuralgia 
(Moon et al., 2017). Another example is the attenuation of mechanical and thermal 
hypersensitivity in a mouse model of neuropathic pain by silencing primary sensory neurons 
after intrathecal AAV-mediated delivery of GluCl channel (Weir et al., 2017). Furthermore, as 
with other transgenic tools, it is possible to restrict their expression to particular neuronal 
population by using cell-specific promoters, or Cre-dependent AAV vectors (Koh et al., 2015). 
In the future, targeted expression of optogenetic and chemogenetic tools in the DRG neuronal 
sub-population will be of tremendous help in untangling their contributions to nociception.  
Overall, viral vectors are a very useful tool in expressing a wide range of tools that can be used 
in research. Although most of these tools can be expressed in the animals by generating 
transgenic lines, viral vectors offer a much greater degree of flexibility. Different delivery 
routes, as well as viral serotypes and promoters can be used to select the cell type transduced 
by these vectors. In addition, levels of transgene expression that are useful for research are 
achieved in a very short period of time, often within a week (see chapter 2). Furthermore, it is 
possible to administer multiple vectors to express several products at the same time, as well as 
using multiple injections of the vectors to achieve expression in the intersection neurons that 
project to these areas. 
Finally, AAV vectors are not only capable of delivering transgenic tools but can also be used to 
express pathology-correcting proteins. These are largely restricted to diseases that are caused 
by a mutation in a single gene, such as Duchenne muscular dystrophy that caused by a 
mutation in the gene that encodes dystrophin (Lai and Duan, 2012; Lostal et al., 2014). These 
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diseases can be effectively countered by administration of the correct gene using AAV vectors, 
which often results in partial correction of the pathology (Passini et al., 2005; Thöny, 2010; 
Elmallah et al., 2014; Lostal et al., 2014; Gray-Edwards et al., 2015; Nichols et al., 2015). 
Currently, there are 153 clinical trials that are testing the therapeutic potential of AAV vectors 
in humans for a wide range of diseases ((ClinicalTrials.gov), accessed 28/08/2018). Of these, 3 
studies are using intrathecal delivery of AAV vectors, and all three of them are using AAV9 
((ClinicalTrials.gov) accessed 28/08/2018). There are, however, some drawbacks to using AAV 
vectors for therapy. The small size of the encoding region (~4.7 kb) means that some whole 
genes cannot be packaged in a single AAV vector, such as the dystrophin gene (Lostal et al., 
2014). This means that truncated gene sequences have to be used instead of full gene 
sequence, often resulting in an incomplete rescue (Lostal et al., 2014). This in part can be 
circumvented by simultaneous administration of several AAV vectors each carrying a part of 
the full gene sequence (Lostal et al., 2014). In addition, pre-existing AAV neutralizing 
antibodies (Nabs) in humans are known to significantly reduce transduction efficiency of AAV 
vectors (Lykken et al., 2018). Interestingly, the prevalence of neutralizing antibodies in the 
population varies between serotype-specific Nabs, with anti-AAV2 and anti-AAV1 being most 
prevalent (72% and 67%, respectively), while anti-AAV9 Nabs were only detected in 47% of the 
population (Boutin et al., 2010). This suggests that certain AAV serotypes may be more 
applicable to gene therapy in humans (Boutin et al., 2010; Lykken et al., 2018). Despite these 
drawbacks, AAVs are becoming the vector of choice for therapy, and progress is being made 
towards circumventing these problems (Deverman et al., 2018; Lykken et al., 2018).  
5.3 Conclusion 
AAV vectors are powerful tools that have a wide range of research and therapeutic 
applications. In this project, we investigated the use of AAV9 for transduction of sensory 
neurons and explored functionality of AAV9-delivered transgenic tool in several experimental 
settings. We developed a new intrathecal delivery method for AAV9 that resulted in 
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transduction of the majority of lumbar and cervical DRG neurons. We characterised the impact 
various experimental factors such as viral titre and post injection time have on the 
transduction efficiency. Furthermore, we assessed the feasibility of peripheral delivery of AAV9 
into distinct anatomical structures in order to target specific populations of DRG neurons. 
Finally, we explored the use of AAV9 for delivery of several transgenic tools, including 
GCaMP6s for neuronal activity imaging in vitro and in vivo, Cre recombinase for control of gene 
expression and GluCl for modulation of neuronal activity. Future experiments will be aimed at 
exploring alternative intrathecal administration routes, restriction of expression to sub-
populations of DRG neurons and further exploration of the use of AAV9-delivered transgenic 
tools in the pain research. Beyond that, our work may also be able to inform a number of other 
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